var title_f5_31_5616="RUL RML atelectasis-I";
var content_f5_31_5616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frontal chest radiograph reveals combined atelectasis of the right upper and right middle lobes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A suprahilar opacity obscures the right upper mediastinal contour and fades laterally. A juxtaphrenic peak is present (arrow) as well as rightward shift of the mediastinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5616=[""].join("\n");
var outline_f5_31_5616=null;
var title_f5_31_5617="Inflamed pinguecula";
var content_f5_31_5617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflamed pinguecula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pinguecula arises from and remains confined to the conjunctiva. There is usually space between the pinguecula and the edge of the cornea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe JD. The Eyes Have It: An interactive teaching and assessment program on vision care. WK Kellog Eye Center, University of Michigan. Copyright &copy; Jonathan D Trobe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5617=[""].join("\n");
var outline_f5_31_5617=null;
var title_f5_31_5618="Doppler transmitral inflow pattern";
var content_f5_31_5618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal Doppler echocardiographic transmitral diastolic inflow pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 329px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFJAYEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1n4ZeAfB158NvCd1eeE/D89zPpNpJLLLp0LvI7QoSzErkkkkkmum/4Vx4H/6E3w3/AOCuD/4mj4T/APJLPBv/AGBbL/0QldVQByv/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNdVjnPeg5xx1oA5X/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/ia6qigDlf8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+JrqqKAOV/wCFceB/+hN8N/8Agrg/+Jo/4Vx4H/6E3w3/AOCuD/4muqooA5X/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/ia6eSWOIoJHRC52ruOMn0HvT6AOV/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+JrqqB70Acr/AMK48D/9Cb4b/wDBXB/8TR/wrjwP/wBCb4b/APBXB/8AE11VGaAOV/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+JrqqKAOV/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+Jrqqa7hFLNwoGSx6AUAcsfhz4HUEt4O8NADkk6XBx/47VbTvA3gLULbz7fwb4d2bivzaTADx/wGvFvjh4/vPFEE+jaNeLptjBIm+F2ZbjUO/wAm37qDHcgn9K83+GfjrWfBvj7Zp0suuWtyfLkt/tEhUL/s7z1HvQB9N+MvD/w+8MaYlzN4J8OzzTOI4IE0y3BkY+5XAHvWN4ZT4eaxqMVlP4D8P2ssrFY2Om27KT2HC9Tz+Vdn4g0Cy8e+GdPeUzWb/LcQupUtEepU9iOMev0ql4W+GthomoQX8l1Ndzw/NGrqEVW/vYHOaANL/hXPgcZ/4o3w3x/1C4P/AIml/wCFceB/+hN8N/8Agrg/+JrqjwKQZJzngjpigDlv+FceB/8AoTfDf/grg/8AiaT/AIVz4I/6E3w3/wCCuD/4mur70c59qAOV/wCFceB/+hN8N/8Agrg/+Jo/4Vx4H/6E3w3/AOCuD/4muqoJwMnpQByv/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TXVUUAcr/wrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E10t1cwWcLTXc8UEK9XlcKo/E0+KRJY1kidXjYZVlOQR6g0Acv/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TXVUUAcr/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TXVUUAcr/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TXVUUAcr/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TXVUUAcr/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TXVUUAcr/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TXVUUAcr/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TXVUUAflXRRRQB+lXwn/AOSWeDf+wLZf+iErqq5X4T/8ks8G/wDYFsv/AEQldVQAUUUUAFFFFABRRRQAUUUUAfPvx80HxT408Tvb6Fo95Ja+HrEXVtc7zCDeu4cNHlcTbUi27R0L9j19t8KalPrHhrTNQvbOexurm3SSa1njaN4ZCPmUqwBGDmtWigAooooAx9Y8QWukmU3MV28cQUySRRFljyQBk/jms3WfHWi6LCLi/mkFmZEj+0omUDvjav5EUniXS/EOoazZGwu7OLRYcvcWzlhJdNjgFgOFHp3xXO6v8PtQ1DxDqF819B/Z95FCI9Pct5drKm3LqoG1iQrdR39qAOqufFun29zJBFFd3PkukcjQQFwhcZUcVT1H4ieG9NN6t9fG3lsp0tpYXU+Zvf7mF6kH1pLHQ9b0e5vRpt5YyW85jYNcht6bQA3AGPxqhqngFNSj1S6ufscmqzzrNbXjpkxqpBCnjoACO/WgDvXYLyx4UZJz0rx/4rfEG50/wzNfaZtijW4Fv5cigySg9SAeg4FehXrR3dxBYSm4O9FLGMY3j+9n2I/WjUdF03VluYL+zgkEq4eUrhlI4BB/h/CgD518S+CdU8aeG4NXsAq6vbuT9pEITZF7r3JyOFzUvwn+Dus2t3PceIraWyWQedDMgjLKMcblByufTHavpGxs1ttKW3gJk8knGVVWJH6Z96zNNjhfX47r+zr+DUbi3DyyTO3lqBgbSoYruHTpQBnaF4f8QeHre5aHUY9SKEJBBKgjBjHqRj5/fpXX2txBcxvJG8TkHZJtYNtI6qSKLuQ28QdonlTo/ljLfXHf+deTX2mX/hP4kwa3ZaxDHYatOIDpOwIsq45K443qcdeT70AewE7U5JJA6gdaU8sODx3zxTIZI5F/cspUdQO1OUDd8oH4evegDAi8QT3VxGLTRtQnsZJDH9sRoggA43gF9+M57Z46VBH4wtZb2BVtLsabcS+RFqWVELS9lxu3jnjJXHBph8N3AubUQ6nNbWNtOLlI4xhyCeY2P8Sn86rr4Bs2ht/PvLt7iG8F5vEzhCwOceVnYBx2FAGtpms3l7q1xaS6JeW0cDlWuJJoih4BHAcsc59Kh0jxHPqciBdImjiZmVma4hZlAOMlA2fw61ftdLS21jUNR812a5VQUIAChR2P9fesjRfCJ0m/W4gu7XhyxK6fEkjKf4WkAyfr1NAHV0UUUAeQ/GLS5ZvG/hLVNW0C88ReFLRLhLmxtbY3RjnYAJK0A++MZHQ459efQvBKWUfhiyXS9In0ayw5isJ4vKeEF2OCmTtznOOwPbpW5RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAflXRRRQB+lXwn/5JZ4N/wCwLZf+iErqq5X4T/8AJLPBv/YFsv8A0QldVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAYGc4GemaTOR6H+VABBPOcn8qTGSvU49qAIbS9trwSfZbiKby2KOEYEow6gjsfY064Gbd8x+bkY2E9c9q5/wALeDNN8N6trep2TTNd6xctdXJdzs3Ek/KvQdevWuk3Nuxt7Eg54oArZb7L+5XbJHwAcE+n4VLDvC5cKJTww4G49j37CqF7ZXDzpJZSNC2/c7Fjzjtt6YqObQ861HqNvfXcLA5kh37o5PbB6fhQBqwKyxgSEF8kkgYzVDUotSbU9Pks7yCGxViLmKRMtJ/dCnt3qxawmC4lxLuV8MYt2fLPOSPYntWR40tNbu4NP/4R+WyV47tJLiK6jDCSIddpPRhwaANy53qheIAyAHA4G89lyfWub8V+HNL1jR3XVbecxxP9sWRdolicHPykcg/SuqIyMHpTZAuxt+3GDkt0xQBwfhPxXo2p3UbaXaX4utwgeOcFXUZ+8wPUe/Nd6xwPc9K5vUbvTdI1+a+1GWCCV4FVJJMDKgngdyfYVf8ADWrNrlh9vWCS3t3dhCsgw7KOjEdu/FAGqRkj25pRTeQeM4pNx3cc56D27n9aAF4+6QcdOeaXkNwoweSaRjwTtOc4+v8A9ahfvEgKWGAT0/z1oAdRRRQBwGp+INdt28aajbz2JsfD1xgWckBzNEtnBcOPMDfKx81gDggYGQavJ43DXaMdOddMlupbCO5Mo3meON3YGPHC/u3UHJO4fdA5rRufB+i3Wo3d7cW87yXcyXFxEbubyJpEREVnh3+W2FjQcr/CO9Pn8K6U9/PfJC6XkhdwfOkMayMhQyCLdsDlSQWABIJGeTQBz0XxDcWME9xo7xyXcNjcWcSXAYyJdTpCu44ARlaRSRyMHgnkCrqXxCksL9HvrdreOyjvkv7WEiXfLF5Bj8tyBkMJhjIX73IGKvR/DfT4vCttpEd1cidP7PE1600rySLazJKFQmTMQJRsBGAUvkZxW0PB2gm3WGSwE0YjnjPnyvKXE23zd5ZiXLbV5bJ44NAGHD4/uJI7aJNBuZb+4vvsMUUcm2NybeScOskqplQImDfLkHpnjPRa54ht9EuNOGpIYba680NclvkhdIzJtb6qknP+zjuKLXwxpltLaShbuaW0n+0wPc3s87RyeU8WQZHJxslcY6fNnGeas+INE03xDpj6frVol3Zu6u0TkgEqwYdCD1HI7jIOQSKAOUm+IPkXGkrPphRL02iTRiVnmtHuXVIxIqoUXl1zudTzwG4y6DxxLcyabM9g9jYXOpT2SzTyxkSiKG6d24b92oNuOT69O9buoeEtG1DUjf3VtKbgywTsEuZY0eSFlaJ2jVgrMpVeSCcKAeBinv4W0aSytbSSxR7a2nmuIo3dmUPKsqyE5PzBlnlGDkfN04GADjJ/iFe3sLQ6fZJDfw3endGcxTwXM7INryRqefLcFlUjpgk9JL74hvZalBJeW7wwQWmoLd2cZEha5huLSKMI+BlT55wcDhxkAjA6EeA9AEUyG3vGMotw0j6jctIBA7PDhzJuXazsRgjrz2qwfBugm3SGTTxLGsFxb/vZXcsk7pJLuLMSzM8aNuOWBHBHNAHM3HxLe3t0a40j7ORLIklxczvBZgKsbDEzxDlvMwAyqMxvyMAnvLe4uJL66iktHjt4whiuDIpE2QdwAByNuB1xnPFY1x4M0e5tTb3P9pzQtuDrJqt03mKwAZGJkyyEKPlOV68cnOxa6da2t5c3UEbJNcKiSfOxXCAhQFJ2rwT0Az3oAt0UUUAFFFFAH5V0UUUAfpV8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAB9qRRjPuc0tFABRRRQAd80UUUAZKaW48TPqbTLsNuIViA5POST60nilbo6PI9lrEWjvGwdruWJZFVQeQQxA56ZrWIBIyM4PHtXIfFrR7vXvAOq6dp+m22pXU8W1IJ5Agz/AHgSD8w7Dj60AdTZXMF5bJNazxXETDiSNgyn8RU9cN8HfD154a8G2mn6jo+naZcxRqr/AGOXf5zY5dxtADHvgnNdpdzrbWss8jKqRqXZmOAAPegDwT4o+H5vEnxJ8KaP/bNxHe2kpuWlCgRxoMEEZPMnHb1HNe920KwxKoyWAGWblmOByT3PFeFeAje+N/jVqviaRI9R0DSnez0+4JHlREAbvLHVj05wK93IbLFeDjAB6UAPoGcc9aB70mc4wQc89e1ADceYoOVzg4I5x9DTsc+1BzjjGfeloAKKKKACivN7vxjqlv4u1i1QpNZ6fqMVvJbJZSErbG0hmkmaYHapUyMcEcgBerA1Y074jC9064uTpn2Y+VDNbfaJJEjlEj7QjN5fEoyDsQPnI2lqAPQKK8um+J23UdCY2syfbodQtl07btknvYbm2iRFLhSB88pywX5eWAIwOo8eaxqOkaRp0mnIBd3V7DbMqx+cQHznaCVyeO5FAHU0VgRanfWXhK51G7tbm7u7eKSY2/lLDLJtydoUMwyQOOefasXUviJZwsV0+2N4sk8VtbzbmEUrvAZySVVmCrHsOQrcuBjgkAHc0V51D49uZNUjK2MyrdWdr9nsZh5TC5kuJozuYjITEec4+6MgEnB0rXxnc392NP07SBLq0PnG7gkugiQiJwh2vtO8sSCvA4+8VPFAHZ0V59D4y1ebxHDYWOnQ3sLLqjMC/lSZtbiGJQpyRjEp69SQflwQeg8L+KbXxJNJ/ZsbtbR20E7TkjAeVS3lEdQ6rtLA9N6+9AHQ0Vi+JNal0mTSbe1sxd3Wp3Zs4VaXykVhDLNuZsEhcQnoCeehrB0rx/HcRx3Gpae1jZy6bc6lHJ5wkbZbtGkwYAADBkXaQTuGSdp4oA7iiuHt/Ft7Yapo+j63bQx3t3FE80883kIZJWb91B8pWRkxgjcpwVI3E13FABRRRQB+VdFFFAH6VfCf/klng3/sC2X/AKISuqrlfhP/AMks8G/9gWy/9EJXVUAFFFBIHUgd6ACigHIyOlAIPTmgAoozzjvRQAUUUE/rQAUUUUAFFFFAAabJkIxUgEDIz0p1BGRg9KAMnStbhvZJLeRfIvY2KNCx6n1U9wfWtIzRgfM6D1O4YHGa5zxLpkJs2urUw2t6iMsZC8OwPC498H868D8NeI0m8cXOjeOrvVtIvriREt44nPk7s45xjHcZ96APqFHWRA0bKynoVOQadVfT7OKxtUggUhF9Tkk+uasUAc749tr658NXI0jWI9H1FcPDdSkBNw6K+f4TmvF/B3xo8SnUp7HWNOtNYkt7hraQaa37xj2dRjaVODUP7UFnKJknuNfurfTTGC1j520S84Owdz0+ma8d0LWZLTSXXSJ3tdLkDrd28ke2aQkjGDzu2468de9AH0Tqvxz0Lwzby2up6drNjqgYstnqIO9we4bLcHtXhPxX+Nep+Od+mWytZaQ7AeSnO9f+mnrnHTtXFeLNQ1fUHFrc6j9rs7EGOBlTBVP4j7HIWqnhzw1rmsajCNJt72VjKFjljQ5Y88Z7GgDu/gH4l1fR/G9tpFteGxtLyUrIZcMqH1APUdeOM19O+KfiZoPhWwuXuNVGp6hETGbW1T5nfHAwOn1ya8N8N/A7W5tQ0rWPEVu0ViAv2i1LATcdAQOpNe/R/Dnw3bNZ3VhoFjJPFgIk7Fo4v9vaQcsKAKHw98bal4gQS6jbc3L8RwqVitkPQeaeXPr8or0dWbzWUqcAZ3Y4rD0Lw79g2y395Jf3S8BmXZGg7BIwSFFb9ABRRRQAUUUUAU7XTLS1m1CWGEB9QmE9zklhI4jSLODwPkjQYGBx6k5x08E6GloLVYLsW6FDFH9vuMW+w5Xyvn/dYwB8m3jjpxXSUUAc0fA3h1rU28mnmWIx3ER82eV2InkSSUlixO4vFG27OQV4IrR1TQrDVdPt7K+W4eG3dJImW6lSRXT7reYrByfcnnvWpRQBW0+yisLVbeBrh41JIM87zPyc8u5LH8TWPB4M0C20W30q1sBb2VtMbiAQTSRvFIS2WSRWDqcMw4P3Tt6cV0NFAGBL4R0aaNlmt55GaKOIyvdzNLiOQyIRIW3Bg7FgwO734FNfwbojRW6Lb3EbQCQLLFeTxysJGDSB5FcO4ZgCdxOSM10NFAGKnhfSY723u4raSO5gmmnSSOeRDumcPKDhvmVmVSUOV+UccCs7TfBsFjoR05LgqZtSOp3csMflefIZ/OK4B+VchUxk/KuDmurooAqXmn2t7c2E9zFvlsZjcW7biNkhjeMng8/JI4wcjnPUA1j3Pg3SZIdPjgiaAWWUj2uzfummjmkjOTyHaGPOcnAIGATXR0UAZOo+HtO1HUIb28jnllieORU+0yiHdG25GMQbYzK2CCVJBAPYY1qKKACiiigD8q6KKKAP0q+E/wDySzwb/wBgWy/9EJXUcbiTjPTrXL/Cf/klng3/ALAtl/6ISupx13YOeOnagBoATAyBgAAAcCl4KnoSRnGcikYhxgEYIBP0NJjLqWGXXoRx19s0AOzjcxxgD7w/GgNxksuOo+lAzzxg55OOtBDYODznI/woAQgkMAfmPvwDSk7WJLZHHHpSEZU5+RiPyJ4p3Q5zwT3oADjjNJtO4ksTnGB6UpOFJwTjtijGC2MDPOfegBaMjGcjHXNIuec9aGIUEnoKAFopFwQGHcdaRWBJAycNg9/egBw96KBRQAyaPzIymQAeuRnIrwv4q/D/AFq21a31/wAKWcepXiNveOUgscHOEH8PTjGele70hAOMgEjke1AHk+jfHXwk9ko1+7fStRjOye3uIyNj+gPf6+1VvFnxw8HmxubLSNcDXMsDFLmBdyxHoMnsa63xn8MvC/i6TztT06MXY/5bxfKx/wB7HWs+x+Dngu0kd00WDzG6MCcAemPT2oA+PfG/iXV/EdzaNqd3d6glr8gSVt6oc/d3d++eK9L+F+meKtR1Oe90bTNOifaEhj1Ab2VSOq5xxjrX0WPh94ZsbOUWXh3T5pDyElUEsew3HpVKGTUfDlgqT+Gku08wiFNK+bZyMZGBge/PSgBmjeEVn0VdI17w/oklrOoaeW1UR4PXBXBOegyDXV6RodppUaw6fa2tpar92OKLDfi3fPpiuZ0OXxDc+JYdS1y2vbOCZfLt7OBvMiQdzNjoehB+td2M45xn2oAjuoftEDxb3j3grvjO1gD6HsaW3hS3hSKJdsaDAFSUUAFFFFABRQeBQTQAUUUUAeb3fjHVLfxdrFqhSaz0/UYreS2SykJW2NpDNJM0wO1SpkY4I5AC9WBqxp3xGF7p1xcnTPsx8qGa2+0SSJHKJH2hGby+JRkHYgfORtLV2lrplpazahLDCA+oTCe5ySwkcRpFnB4HyRoMDA49Sc46eCdDS0FqsF2LdChij+33GLfYcr5Xz/usYA+Tbxx04oA5Kb4nbdR0JjazJ9uh1C2XTtu2Se9hubaJEUuFIHzynLBfl5YAjA6/xzr7eHfCdxfmS2gu2MdvCZ3/AHSTSsEUsTjKqzZPT5VPSmHwN4da1NvJp5liMdxEfNnldiJ5EklJYsTuLxRtuzkFeCK15tKtJ/7O8+N5TYSCW3MkrMVcIyBmJPzna7fezyc9QDQBkeEvEUmueB7fWIY4ru88lxJFbONkk8ZZHVG5GC6sAfTBrIuviTYi0jnsbWW5jmjtfJfJVTLOrOI2wpYFUXe2FJAYAAniuysNPtbBrprSLy/tUxuJQGJDSEAEgE8Z2jgYGcnqSTlR+D9Bi065sYdPWK3uLs37iKR0YTkg+Yrg7kYYGNpGAABgcUAcu3xAnF9YzvZTxwTWsqfY3Xaz3P2yC2i2uwB2M0vDED5WBIB4rUi8ZXVxqZ0a20lH16OWZJ7drvbDGsSQOziXYSQRcwYGwHL84wTWrJ4R0aWPZcW8858l4N893NJJsZ1kPzsxbO5EIbOV2jBFMPg7RTFEoguVkikeVbhL2dZ9zgBiZg/mHIVQQWIwq+gwAYI8Yas/ie3020sIJke+ntpllfy2iEcEMgCsMg8yNk45xj3ra8L+LbfxFcRRWltKhFmtzc72H+jSM7J5DY/jDRyA+m33FWR4T0YTxzJbSRzR3P2tZI7iVGEmxYychskFVUFfunHINULbwbBDpOsWi3BSXVtQa9u5oY/LLhpASgAPH7tQhOeSS3U4oA0/E2stottaPFam6nurqO0ij8wIN75wWbBwBjngn2PSsPR/HDXd1bLqGnLY20zXkPnm5DhJbVykwI2j5Mq+185O3lVyK6q/0+11D7N9si8z7PMtxF8xG2Rc4PB56ng8Vjal4N0m8sBarE0KCaeXKuxP+kSF7gcnpJuce27jGBQBiReNbux/sWLVLWNH1NRc+ddS/ZkjWWXEcCnaVeZVZQVJXOOCc4rvqydX8PadrFxHLqEc8uzb+7FzKkT7W3LvjVgj4PPzA1rUAFFFFAH5V0UUUAfpV8J/+SWeDf8AsC2X/ohK6d8jJXAOO/T865j4T/8AJLPBv/YFsv8A0QldQfmypxjof89qAFIyegwRg8daTcFUA8YGcAZ6UuPmzxSLje2GHuo7UAOJwOhP0qNpNsqpgksCRgcDHqaeowAMk47mgAfNjIJ70ABPUk4A65oH3s84IFNYnJ7gHPB56U7+I8/hQAhbKZX0BHbNLgHGMfL0x2oz1yO/HvSZOCQO+MdKAFOTngH0zScNkUuOCMDH86Q424wcAjgCgBRxgYx6Yoz60dDweT2NLQA1DkEdDk8Z96UZI5GD6U0Nk8OuCflx39aVSTg4wPegB1ANIM7vb0pPvbTjPP5daAHUUikFQQQfcU3ccHlSckDH8qAH0UhIBoy2Og796AGyeZhfKK/eG7d6d8e9PrlfiJqN/p2kWUulaSurTS3sMLQlSwRGJzJgen9a6dyRkHGD2xk4+lAD6Ackjnj2pFzjnqOtDMFGT0oAWmMxDgh0CL94Ec+3OeKeBgYHSmoQQD8u4jkjvQBHNPAk0dtLNGk04by42cBnwOdo74HWpqKAcjI6UAFFFFABRXm934x1S38XaxaoUms9P1GK3ktkspCVtjaQzSTNMDtUqZGOCOQAvVgasad8Rhe6dcXJ0z7MfKhmtvtEkiRyiR9oRm8viUZB2IHzkbS1AHoFFeXTfE7bqOhMbWZPt0OoWy6dt2yT3sNzbRIilwpA+eU5YL8vLAEYHUePNY1HSNI06TTkAu7q9htmVY/OID5ztBK5PHcigDqaK5W21TUnk0OwdpFvbqWWa4M0CxstvF947QzAZZ4l6nhyeMVleAvHY8S+KNa083FhJAgaawW3kDSCJJXhfzBk4JKo44HyygdjQB39Fctqvi1rHWtSsl0/MGnWi3dxezXKRQoGWQopzzyY8ZxgZz7HCi+IGoXt7plrY6RELmTVzp11HM8iKV+xyXKtGzojc7V5ZOxAzkNQB6NRXnsfxCdNOvrn7CbmLTIJr7UJN4iMVus88YKLzvbFvIcZXheuSBXoVABRRRQAUUUUAFFFFAH5V0UUUAfpV8J/+SWeDf8AsC2X/ohK6liQDgZOK5b4T/8AJLPBv/YFsv8A0QldVzn2oAidkiYb3Rd3GSQCx/rThwQcEg98d6SWGObYZUDbTuXcOhqRuATkD3NACdz1o6Etk9OlLRQAmMt3yKja4iDRr5se+T7i7hlvXHrUtMaON5FdlVnTO1iMlcjnHpQA7p1o69P1FLn9KKAEP4jmkYc8nj2zmnUj7sfLjOR19M8/pQBC1zEt0lu0sazMCyxkjcw9RUzcDOMntSGNDIJCimQDAbHIH1p1AESbW+dGBAJAIbgnPP6049V5BIPf6V8cfHqz1PQfi3fPFNf2+nX7xT28MdwQkmdvmEDt85b86+vtGG3SLFeeIIxycn7o796ALRB7HJx0Peq63Vs141osym6jAZowfmAPc1apAqhmYKAzdSByaAG5+QnfwBkkClBwRjgH/ZpxAIwelFAEKTRsm8TIyqCWZSCuPc9qSK7tZCoiuIXL8qFcHP0rifiB4t074fadul06eS0uRLI5hXIDnrn65/Svmf8AZ12an8a4J5d0cf725jj8xioO04AGeQM0AfZVtf2txdy28NzE9zCP3sKuCUPuPxqyMKQqgDvjpSgAZwAM81UkEaagsk2xXK+XG5cA89gO/SgCaKeN3aNZUd1OGCnJX646VJyyHYduQeccg+tV4bK3hu5LmOBUnk4Z1zlvrU4jA39SG6gmgBWH7sgDIxjHSoLe8gnuZ4ImJlhIEgKkYP49as03LeYR8uzH45oAUDp3I70tFFABRRRQBTtdMtLWbUJYYQH1CYT3OSWEjiNIs4PA+SNBgYHHqTnHTwToaWgtVguxboUMUf2+4xb7DlfK+f8AdYwB8m3jjpxXSUUAc0fA3h1rU28mnmWIx3ER82eV2InkSSUlixO4vFG27OQV4IrR1TQrDVdPt7K+W4eG3dJImW6lSRXT7reYrByfcnnvWpRQBjab4ft7C9uLiOe7l82BLdRPcSStGoZ2OHdi2SX5Of4V9KmtNB0yzGlC1tRENLgNtZ7WYeVEVVSnXkYVeufug9RWnRQBlX3h/S746kbu1Eh1GFILnLsN6Ju2gYPykb2IIwc854FUU8F6GitiC6MhuVvPPa+nM3nLH5YcSF94OwleuCCR3ro6KAOcl8FaBIqK1k4Vd4KpcyqsgaQyMsgDYkXezHa2QNxwMGujoooAKKKKACiiigAooooA/KuiiigD9KvhP/ySzwb/ANgWy/8ARCV1OefauW+E/wDySzwb/wBgWy/9EJXQ21/a3Qk8ieNzG5jcZwVYdQR2NAFmjvULXMCSCNp4lkI3BS4Bx64qFdUsWulthd2/nuSETzFy5HUAZ5xQBcooPtRQAUd6KOc+1ABQKKr3l3DaWtzcTSKI7dC8hLAbQBnn04oAsE4GT0oIyMHpWLpN/a6po9tql2IYVnQgbpQV2knAznByOa14WVowyMroehXpigByAKoABAHqaUdO/wCNQi7tyqsJ4irNtU7xgn0HvSRXltNcyW8VxC88YBeNXBZQfUdqAKuqaJpmqzW82pWNvcywHMTSoGKfStAAKAFAAHAA7VDc3dvabDdTxQiRtiGRguTjoM9TwamZgqlmICgZJPAAoAWiud1zXLgMsHh5Le9ukT7RKC2V8oHkAg/ePYVe0TXbHWLa3ktpQss0Im+zyfLKoOM5U88E4PvQBqGikJAxkgZ4qDULuKwsZ7u4bEUKF298dh7npQB49+0x4c1bWfD9ve6fqFvBaaerzS20zbftDcYA9TjdxXlX7JunTXPxAudTWP8A0WKCTLBeFdsDg/Q/hnFdz8edcTxJ8M9F1oaddrBbampu9Pl3JKowwycY44zzxzVr9li9tBp3iaC2/cWyXfmxRSkeYI8Hk/TufegD3uqWoaZbahLavdR7zbSebHyRhux4rltH8Q6r9pjvr8RXegajKws5bKF3e3GcIJNuchufmHA7nmthPFWktfvZz3EllMmGU3cLQLKPVGcAMPoaANvDiQEMCnOQRz+FPrn9T8YaPpsH2i5mnNmGCvdx27vAgP8AE0gG0KO5zxTbbxnoN5rqaPaanBJfMCyqMlX243KrfdZhkcAnGaAOiphjUyhyvzKMA/Ws+fxBo1vJPHPq+nxSW/8Arle5RTH/ALwJ4/Gp7HVNPv0jexvrW5WTJQwzK4bHXGDzQBcooooAKKKKAOHv/E+oQard6IggGqvqlvBaEoSGtZE8xpCM9VSK5A7Exj1qumpeI1fxaJNVs3GjLiLFjjeTbrKCfn7FsY9q62XQdMl8RQa7JaI2rQW7Wsdxk5WNjkrjOOuecZGTjqcpcaDp1xHqqSQuBqmPtZSZ0aTCBOqkFflUD5cUAZ+m68/9iWH2zz5dSuLAXRkjspfIyULYLgFF6Hgtnp6jNH4bavrGtaTaXusCYfabSKcbrRYU3MoJ2kSMSOe4FdNZabbWWlRabAj/AGSKLyVV5Wc7MYxuYljx6msRfBen2+krp2nT6jb2oMC7Hvp5wIonVvLUSOQoIXaSOcE0AXvEusyaQunJBafari/uxaRIZPLUMUd8s2DhcIc4BPoD0rkbj4oQxgLFpFzNc28Ty30EZZ2i2TywMke1G8xt9vNjOwEKORnFdX4p8PR+IRpaTXM0EdleLdnyXeN3xG6bQ6MrL9/OQe2O9Qv4M0No7dY7a4tzBGYVe2vJoXZCxYq7o4ZwWJb5ieWJ6k0AZsvjaf7Xc29voszlb86XbySXCKk845PTJVAoZixGflIAJxmG/wDHslhq66dPo8r3MIi+2LA7ymPzGIXy9qYfAG47inykYycgdFceGtJuLS4tpbVvLnuvtrlJnRxNkHzFcMGQ8fwkVAfCOkefHOqXqTqgjaRL+4VpVDFgJSHzKAWb7+77xHQmgDm734hXS6ZqFxb6UkZFlqFxZPLPuEj2jbGDqANoJIIwxJAOdvGekn1+Ww8Ipq+p2ey4KJ/o0Mgbc7sERQxwOSy8npn2qRfC2iiKOL7CrRxpcxqrOzDbcNumBBPIY+vTtirC6HYf2EdGeKSbTyhjKTzySsVJzjezFuOxzxgYxgUAcbq3irWrrVNN0aytlsNQbUmtL4xTpJtUW3nqY2dCCCCMlkB+VhgZDVseIfFF1o3imO0e0hk0lNLuNRuZt5EkYiZAdo6EYbp3yORjnTsfDGk2UtvLBbytNBO1yks1xJLIZWj8sszuxLnZ8vzE4AGMYFWNR0PT9Rv7e9u4Ge5gjeJGWV0BjfG5GCkB1O1flYEcUAcfqvjnVbZIII9Ggi1KSaxYQyXO9Gt7mUxg7gBtkBUgjBAyCCwzVq88cmHX10k2iHzmlt47iCR5RHOkDzFH/dhBxG4wHLZAyoGcasfgrQo7Ka1W1nMcphJZ7uZpE8lt0QSQvuQISSoUgDJx1NKngzQ11CO8FtOZo5nuFBvJjGsrxtG7hC+3cyyPk4ySxJ55oAt+EL2fUvCWiX12we5urGCeVgAAXaNSTgdOSa16r6dZwadYW1lZx+Xa20SwxJknaigBRk8ngDrVigD8q6KKKAP0q+E//JLPBv8A2BbL/wBEJW9JpllJM8r2sRkcgswXBYj19awfhP8A8ks8G/8AYFsv/RCV1VAFAaPp4z/okRJYNkjJz9f6VgTfDrwzLLfyNYEPeffZZXBjOOTGQcofp6V11FAHNr4N04aouotPqD3ioI/Ma6flfQjOKbqnhG2vkgY3+pwz2u4200dy26IkY6dGx6HNdNRQBgSQ+IbPT5TBdW2o3McZMayxiIzPzwSOF7Utj/wkbwrLd/2dHI4BaD5iI+BxuHXnNb1FAGDLoVy8q3K6xeR3m3Yzrt2FfTYRj6HrUU/g3SLmTzLtJ55GUpMzzN+/Ho4zg10dFAHP6X4T0qwZXW1UlTlULFo0/wB1T04xUn/CM2Sl1gkuoIHyXgimIQ568dR1PQ96oeCPFL+IbrW7O4hjjudKu/szmN8h+NwPtwRmuoeaJHCPIiueQpYAmgDnofBHh6G5M8enKGPbzH2g4xkDOAfepG8HaGYRGll5RDFhJHIyvk5zls5PU8HIreR1kQMjBlPQinUAc3beE7dkhTVrmbVI7fcLdbkDEYOfTqQDgN1qyfDls1k9lLc3s1i+AbeSXK7Qfu5xux+NbdFAFewsbawgWCygjhiUABUGOnSsfxXpzOlvq1hbebqunMZYQmA0qkEPHn0IJ/ECugooA5ea48UT2iXum29nGspVhZXgZZETBzlgcBuhwenIq5baJNLNa3Gs30l7NBhlj2hIlf8AvAAc98ZrcooA8x1yxvNHk8e3ulSWbXc0cNzCt1yiEIwYnPHvXC+Grix8G3c1rLEZ9Q1HQvtMssAAWaSQpgKTwAPm616n49sdTuL/AE6PRrGGRNQ3WV/cSciKAjdnb3PykZ96y7r4fxalY6OLOV7CSwvUeQtGD50KZwgyOhBX8jQB2HhaO107R9N0iJo1mtbOIGJew24z+JBrSvLS3vbd4LyGOaFxhkdcgipgqhiwUbjwTjmloArvY2j2DWL20LWbJ5RgKAoUxjbt6Yx2qg/hrRn0uDTjp1v9jg5ijC42H1BHIPvmteg8CgChBo2mwKFjsbYYGNxjDMfqTyfxqg3hDQS87ppsUMk0glZ4S0Z3joQVIx+HXvW9RQBhto2oecoi8QagltgZQpCz8HjDlM49c5J9ap22h6xfwvb+JtUSa1CtF5NiphE69mkb7wb2RgP5V1BooAqaTYrpmm29mk886QrsWSd97kdsnvjp+FW6KKACiuHv/E+oQard6IggGqvqlvBaEoSGtZE8xpCM9VSK5A7Exj1qumpeI1fxaJNVs3GjLiLFjjeTbrKCfn7FsY9qAPQKKwdB1oy2GkR6gZ5L+7tEuHljs5RAMqWOZACidDwWz09Rnn/hh45/4S651WOSewl2Fby0Fq4Yi0kZ1jEnJxIPLJYcY3qMeoB31FZHifWDolhDOlsbmSa5htY4w4TLyuEUknoAWGfauSvfiWLYm2GkSyapCZ/tVskjOEEThSEZUO8tkFQQoP8AEVPFAHolFcRP48YT6klvot1JFaXNvYpK8qR+bcTxwPGm0/Mv/Hwu4kcYONx4qLXPH0+i3hsrzRXkvoLYXl1DayPNiJndU8orHl3by3IVgnTrk0Ad5RXEnxvM95JDHpYWFp7yzt5mnBLz24cnKAcIRG2DnOR071c0rxRMPhzD4m1y0WFxp63skNs+7cPLD4XOMZ7Anjue9AHVUV5z4j8W635ttpFpZJY6zJfQQTeXcLIFhkjlkVo3ZCNx8llO5DjB68Gt/Xddv9M8UaFpsFvBPaXcFxLczSPseMRGL5lxweHYkY54xigDp6K841L4hX0eixXVrpEUVzdw215YpNPvEtvLPFGd+ANjgSrwNw+YcnBFatz42Np4kstKuLKNhPNHayyW8zym3nePeFfEexR0HLhjkELigDsqKwfAWpXOr+DNG1C/cPdXNskkjBQoLEc8DpW9QB+VdFFFAH6VfCf/AJJZ4N/7Atl/6ISuqrlfhP8A8ks8G/8AYFsv/RCV1VABRRRQAUUUUAFFFFABRRRQBz3hLwlpvhf7c2nq5nvpjPcSu2S7En8utQ+KoQda0S4c26W0Ur/aZZJAu1dvyjGectgfjXOfDOK8g8Z+M11bUZnuPtY+z2bP8kcJAO5QfVj1/wAa4zxJqOj6r8QvHWmeLQ8NvBpubTMxRZdqEkpyPnGP0oA9X8MeINL1PV9RttPuPMkyJTHkYXHyHGPUrn8a6avlT4beJdItNS8EtZ3n2XVkgaz1MBRt8ktvjkYnq20hT6FvavqpWDKGUgqRkEcgigBaKKKACiiigAooooAKAaKKACiiigAoopAMMTzk+9AC0UUUAB6elFFB6etABRRRQBmS6DpkviKDXZLRG1aC3a1juMnKxsclcZx1zzjIycdTlLjQdOuI9VSSFwNUx9rKTOjSYQJ1Ugr8qgfLitSigDPi0ezi0L+x0SX7B5BttjTuz+WRtxvJ39O+cj1qjrXhex1KzEMYa0cWjWCywMylbd2QvGACByEAB6r26nO9RQBi+LNATxFptvZSXElvHHdwXJaIsrERyK+0MrKVJ243A5HWoD4N0TybdI7e5he38zZPBeTxTHzG3SbpVcO25sMdzHJAPUV0NFAGNJ4Y0iS0v7Z7QmK+mjuJ/wB6+5pY0jRHDZyrKIYsFSCCoPXJqvN4O0eUxMyXwmjQx+euo3CyuhO7a8gk3OuScBiQMnGK6GigDJj8OaVHLDItoN0VzNdpl2IEswYSNgnByHbg8DPAFLZeH9Ns9AbRIrdn0tojbm3nleYeWV2lMuSduOMZwBWrRQBh2nhXSLVoXS3mkliuBdLLPdSzSeYEKAl3YsQFZgASQM9Ku6hpFlqF7Y3dzHJ9psnLwSRzPGy5xkHaRuU4GVOQcDINX6KAOch8E6BDZXFolk/2eaNIdjXMreWiNuRIiWzEqkAgJtAIGOgpy+DdEW/ivPs9yZ45UuBuvZ2UyooRZGQvtZ9qgFiCT3JroaKAKulafa6TpttYafF5VpboI4o9xbao6DJJJ/GrVFFAH5V0UUUAfpV8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXVUAFFFV7K1Fojqss8u92kJmkLkZ7AnoPQdqALFfJ3xO1/U7H4z+K2tdWuxJY32kta6fBfzpcTo0SebHbwrmN85BbeOO3U5+saDyKACiiigAooooA8203wRq0PxT1fxbqWpWxs5VWK3gVSDHEuDlj68V4h8dfCE99aa18Rrm/lTT7e9ijtdPkj2s6FkRiGzxkliPYV9Ba/pniu71fUpLLUYotL+zj7PblATJJjkE+h6fjXy58VotQ1PTvD2o65qslzqF7NPZXOkRZ2W3l52gqO/Q5I7+1AG3cap4f0r4d3Gp6LZql015a3OnGbBe4JKLNbnPbb5jV9XaBfrqmjWl4ltLarLGGEMgAKcdOK+P8Aw/4V0TSrGFtf1hNQ0m/srhbORwyGwvkRiAccE4HHvgfX3X9mfxNdeIfh5DFqTzyXlmwiZ5VIJGBjk9eh/OgD1p2CDLHAyB+ZxS0UUAFFFFACMNwwc/gcUo4FFFABSDPOcnnvS1HHIXeRSuChx9aAJKKhaFjdJKJpAgUgxDG1j69M1NQAUUUUAFFFFABRRRQAYooooA4e/wDE+oQard6IggGqvqlvBaEoSGtZE8xpCM9VSK5A7Exj1qumpeI1fxaJNVs3GjLiLFjjeTbrKCfn7FsY9q62XQdMl8RQa7JaI2rQW7Wsdxk5WNjkrjOOuecZGTjqcpcaDp1xHqqSQuBqmPtZSZ0aTCBOqkFflUD5cUAZ+m68/wDYlh9s8+XUriwF0ZI7KXyMlC2C4BReh4LZ6eozz3hrxVrL+DTreqxyyTS2MU0ETWqwJLPIBsjRhIxO52VRkDqK7my022stKi02BH+yRReSqvKznZjGNzEsePU1jWngzTbFdOispL9LSzkR1t5b6aeNgikIu2R2ChWKsMY5Re1AHPa343m0LxnoGg3N9p8ihII9SeVgk0sk5aOJolyP+WiZYAHAcdO/VeKdek0Q6VFbadLqF1qN2bSGKORY8MIZZdxLEDGIjnvzwD0M9z4e0y6h1SKe13pqbrJdfvGBdlRUUg5yuAi424wRkckmrV5p9re3NhPcxb5bGY3Fu24jZIY3jJ4PPySOMHI5z1ANAHCa38RpbN9WgtrCCWWC0vJrWdJXliaW3QsySNsVAcg5CuxGCDtNXJPGl3a3kFtd2Cfbri1tXitUkG0yzSyIMy9lwm4/LkAHG48Vrr4K0BbmSc2TsX88eU9zK0SibPmhYy2xQ2TkADrTj4O0Q2/lPbTv+6jgEj3czSKschkjxIX3Aq7EhgcjgA4AAALnhzV/7YsppHgNtc29xJazw794SRGwcNxkHgg4BwRkA5A1ap6TptrpNktrYxskIZn+Z2kZmZizMzMSzEkkkkkmrlABRRRQAUUUUAFFFFAH5V0UUUAfpV8J/wDklng3/sC2X/ohK6quV+E//JLPBv8A2BbL/wBEJXVUAFFFFABRRRQAUUUUAFFFFAHk/jjx5pvwvhvrq5/tXUBM5UCRi6JLjIG7sDkVf0i40OfwtH4j8TeH7Cy1G4jF1LCkavIQ3AcdyTnr1rF+M9ubkSab4v1G10/wfqcixJNBHmeOfjaSceorqtD8EW6a1pusTanNePYWCafBHtATywQQzDuSMfnQB51rGov4EvfDa3+maPeeCdZvAHmuINz2bOchmyPfqfeu7+G+sare+J/E2n3Vro0el2Uq/ZZtOIxKr/MhOOCdpGT61peI9B0/X9K1fw9fmEi6Rmhtmx8pI+8ue2fy5ryj4T+H9G8AfFqPSNO1a6lGoaV5gtpHDYlWXaykAnGACw+lAH0G0IaTfvkGRjAY4/KpaKKACiiigBpQEk5bn3NOoooAKq2tmluxKtIeTjc5OAe3Xn8atUUAFFFNL4BLKwxntnP5UAOopkMomQSJyjcg8gn8DT6ACiiigAooooAKKKKACiuA1PxBrtu3jTUbeexNj4euMCzkgOZols4Lhx5gb5WPmsAcEDAyDSt8SrRdSuUbT7r+zbd5opblUctG0UbO5Zdu0INhTO/O7Hy4OaAO+orhdQ8cXunw2AvdFSK71EGW1i+1M48sKGYyFI2KsNyjAVhlh82MkZ7/ABFeC/keS0n2XkNiLKznjMbxyzJcSOJCqswwsJJwG+7wOaAPSqK4mw8dPez2cUejXMZkt5Lq4kuJVhS2SOVomY78ErlSynHK4JxWTL8R72eN4tP0qA30d1p6kPJJ5MsF1K8asjtGhJzGwyAV6EFuRQB6ZRXEw+MLyXWLvSrPT1vNSSefbC0ohRYoY7dn+fDbjuuEA4Gc84AzUVv8RIrz7Nc2WnPJpcp08PcPMFcC9KLDtTBzgyLuyRgcjPSgDu6K5zxDrWoaf4l8PafYWkFxBqDTidpJCjRhFBBXt3P5dq5u2+I039lQ3I0x7tItOs9Qu5RKsRCXEssYCJzlgYicFgMd88EA9Horgbz4hNaTS2E+mKusxXj2rQLO7xDbDFMX8xYy2Nk8Y+59446DdXY6HqA1bR7LUFgnthcwrL5M6bJI8jO1h2I6GgC7RXGaj40uLfWLuyttI8+K31GPSzM1yE3TyW8cyELtPyfvFDHOR1AboKifEMGfTopdOjtvPmlt5Zbm68uISx3LW7xxPsxI+5GIB2ZBXucAA76iiigD8q6KKKAP0q+E/wDySzwb/wBgWy/9EJXVVyvwn/5JZ4N/7Atl/wCiErqqACiiigAooooAKKKKACiiigDyX45WrPoUsk+mNcRfaItqIocPhgc/7LcY/CvT9KYSadbS+T5DSxI7RnqpKjg/Tp+FeTfF/wAay23jbwx4XtVf7HcXAl1KURkhEXBUZ+vP4V63YXDXMJkaPYpZghz95cnB/EUAY/i7wnZeJoY/tEtxbXUSsIbm3fY6Ej9R3xXzdD4Q1L4danoHiaae4n8RHWTZX8cjBxLbsSI5FA5AI2jPqa+sq+fviFpF9J8RdduotVP+gWsOpQ27oCOGQMpPpgMQPpQB9A0VW027W/061u4+EuIklX6MAf61ZoAKKKKACiivEfij4u8aaD8TdD8PeFrq1uIdXTcsdxCGMDA85brtI5yaAPbqK5L4caprGp6df/8ACRtbDUba8kt2igHChTgH3z1rq1VhI5L5U42rjp680AOoqF5pFu44hA7ROCTKCMKR2I681NQAUUUUAFFFFABRRQc4460AFFFFAHP3Pg/RbrUbu9uLed5LuZLi4iN3N5E0iIiKzw7/AC2wsaDlf4R3qY+F9JOoz3ggmWSdi80S3MqwSsV2lnhDeWxI6kqc4B6itqigDm08E6GkEMSxXoEBBgf+0LjzIMKV2xv5m5FwSNqkAjtUs3hDRZ1bzbWVpGWEecbmXzQYt3lsJN28MN7/ADAhjuOSa36KAMeDw1pUQYG3effbPZubmeScvEzFmVi7Etkk8nJ7dKox+BtAjiuE+zXTmdbdHkkvrh5AIHZ4drs5ZdrOxBUg8101FAHP3Pg/RbjeXt51keVpmlju5o5CzIqN86uGwVRARnB2gkZ5qY+F9G2OgsVVHktZCqOyjdbMrQ4APAUovA4OMHIraooAoanpFlqc9lPdxyGezk82CSOZ4mRiMHlSCQRwVOQe4NZ0Xg7QorSW1jscQSWsFmy+dJzDC7vGud2eGkc56nPJOBXQUUAYd54U0e7uJ7iW2kS5muftbTw3EsUol8pIdyujBlBjjRSAQDjkE5qbTNEi0/Up7uOeeQPbQ2scckjP5aRlznLElmYucseTgZ6VrUUAZT+HtLe5mna1zLNepqDt5jczpGkav17JGgx04zjOTVOXwdokgCtbT+V5z3DQi7mEUjvM07F4w+18yOzYYEDOBxxXQ0UAFFFFAH5V0UUUAfpV8J/+SWeDf+wLZf8AohK6quV+E/8AySzwb/2BbL/0QldVQAUUUUAFFFFABRRRQAUUUUAeS+ObDUZPi14fub+7tY/CkimBiGCyJc7SVRj1w3y4+tej+HGvG0mP+0oxHcq7oVBzwHIX9AK8H+MWi6bf/E7UD4jtdXudLh0gXyrYSlREyEhpCB3wv6V7t4TmtbnwxpM2nNI9m9rG0LSfeZNowTnvigC6L60aXyhdQGXO3YJBnPpivP8A4zaZBrVlpui/a10u41aZoF1FMK8ZVGdVz1wxAGM1yvwd8Mtc3Vxqz+H/AArNCmt37f2hNBuv1K3EmCrbMZBAx83St79pC2vbn4cudNgSSaO6iJnLYa1y23zQfbd+VAG98Htbk1rwRbC7mjlvrCWXT7koABvicp+oAP4121eIfBC+bwv4m1L4f3qSz6hGo1B79myt0HUMXU9xyB9T9a9voAKKKKAGyZ8ttpAODgnoK+LP+Ez8SaD408ZeK5NPbVGjZ9Pk1SIb4bJyQEMfboOnvX2D4qfy/DOrOJvIItJSJc/cOw818oeHfBXjX/hSGtWVjHZS6dqkhvTKJczyhcZG0jnOM9e1AHVeA7nxxYeIfBuqHU7fWNL8RgT3V1CqxqXAwY3wPvAsecdQfQ19KxiUTSbyhiONmOCPXNfBPgmbxtqVlKnhi9u47XwyRfNYGXLxrn5zGO45OVz+tfc/hnUo9X8PabqEUyzLdW6SiRRgNkDJAoA06KKKACiiigAooooAKKKKACiiigDgNT8Qa7bt401G3nsTY+HrjAs5IDmaJbOC4ceYG+Vj5rAHBAwMg0rfEq0XUrlG0+6/s23eaKW5VHLRtFGzuWXbtCDYUzvzux8uDmt658H6Ldajd3txbzvJdzJcXERu5vImkRERWeHf5bYWNByv8I71MfC+knUZ7wQTLJOxeaJbmVYJWK7SzwhvLYkdSVOcA9RQBz+oeOL3T4bAXuipFd6iDLaxfamceWFDMZCkbFWG5RgKwyw+bGSM9/iK8F/I8lpPsvIbEWVnPGY3jlmS4kcSFVZhhYSTgN93gc10yeCdDSCGJYr0CAgwP/aFx5kGFK7Y38zci4JG1SAR2qWbwhos6t5trK0jLCPONzL5oMW7y2Em7eGG9/mBDHcck0AZFh46e9ns4o9GuYzJbyXVxJcSrClskcrRMx34JXKllOOVwTismX4j3s8bxafpUBvo7rT1IeSTyZYLqV41ZHaNCTmNhkAr0ILciu0g8NaVEGBt3n32z2bm5nknLxMxZlYuxLZJPJye3SqMfgbQI4rhPs105nW3R5JL64eQCB2eHa7OWXazsQVIPNAGfD4wvJdYu9Ks9PW81JJ59sLSiFFihjt2f58NuO64QDgZzzgDNRW/xEivPs1zZac8mlynTw9w8wVwL0osO1MHODIu7JGByM9K27nwfotxvL286yPK0zSx3c0chZkVG+dXDYKogIzg7QSM81MfC+jbHQWKqjyWshVHZRutmVocAHgKUXgcHGDkUAbVebJ8S7htDGrNoJW1Ojrr3N4NwtNpZsjb/rAOQvQg8sp4rudE00aZbzoZ5J5J7ma5eR+uXcsFHoFBCj2UVn/8IdoX9lf2b9h/0L+zP7G8vzpP+PTbt8vO7PTjdnd70AUNc8T3OnXesXMFu91Y6aILZo0HW4kILM7AMypHG8TEhTgMxwcVs6NqTa74civrKa0jluI28uWGQXMStkgEEbd4BHT5T2ODTIfD9sNKmsZ5bmQTXElzJLHM8MhdpC/DoQwAyFGD90AdKevh7TE8PTaGkDrpsySJIizSB38wkyEybt+5izEtnJJJzQBn+BtTvdTh1Rrm4S9sobsw2d8sYj+0xhE3NgHBAk8xQwwDt/E9NWdoejWeiWv2bT/tIgAAVJrqWcIAMAL5jNtGOwwK0aACiiigD8q6KKKAP0q+E/8AySzwb/2BbL/0QldVXK/Cf/klng3/ALAtl/6ISuqoAKKKKACiiigAooooAKKKR2VFLOwVR1JOBQB8s/GXxnq1j8QPE134VtPt2nR6aulanPjctuzHqPf5gK+jPBEpm8HaJIe9nFz64QCvlXx14mh8PfFHxXou2A6Hrt1BLPNH85RkZDj6HGCP9qvrzTZIJdPtmtNotzGvlgDAC44GO3FAHPR/DvwfHq66qnhrSl1JZxci5FuvmCXdu359d3OfWpviRZS6j4D120t7SW8mltXCQRMFd2xxtPr3H0rpKKAPBfhf4YsvD2oeG/Euv+JZtT13UrYWNuj8bQowYRzyV6E4H3TXvVfO8ugT33xPbVZbiV/Cel6sfLhZ9jW90+S20f3CX6e9fRFABRRRQBxHxknsm+H+tWF3fxWU15aukBc43uBkKPckYr5x0Xxvea7d/Dvwz4ZsJbK701BbahDNFt3M20Fgf7pAY89M17R+0bBpd9oGkWd1Iz6sL+KaxtFBP2kqw3IewBHf2FdPpfgq2n8bXHi7VrW3OovFHHbIFw0CqD1OeW560AeN+KvB3/Cq/i5oniTSpJI/DWr3KWV4pbcEeQncHGPuHAOc8Yr6H02PT9NEemafGIEgQIlvGPlRex+nFea/tRW+rXvwsvLXRtNkvtzrJOUXcYo0+Yv+Ht6VwXhrxn4k8Ef2FD4j18XWi6xpq3tteSL5zEkLiIHjH3xQB9NUVgaH4ms73R7W6vJY7OWSMM8Vw4Rx749D61vKwZQykFSMgjkEUALRSEjIBIyegpaACiignAyelABRVT7YRerA0EuxxlJlG5D7E9jVosFxkgZOBnuaAFooooAKK4DU/EGu27eNNRt57E2Ph64wLOSA5miWzguHHmBvlY+awBwQMDINOvvHb2aaiYrZLmaG8khjtnLpKyJDFI21I0kZyPMGTgAZGSOpAO9orgoPiEt5frb2likKzWgubY3s/kyXG6389TGm3DqM7WIbIIbjAzVey+IV6PD0WoX+kRl7bSIdZ1IxXOFit5A5DRgglm/dSnaSMBfvEkAgHotFedXPjqTSNS1c6mzSWdpeXaqkUQLeXFaxShQcjks7deueortNLudSmtJX1LTobS5XlI47nzVYYyPm2rg54PGPQmgDRorx7SPG2vv4X068vpgL3ULOx1JRsjZESe4hQquAMLtdsBgzDP3jxWva+PbmzguZdQja78p9UYRxoqllg1I20YDZAyFKjpzjJNAHpVFcZB4yu59Qk0mLSYjrkV1JbvAbvEIVIYpi/m7MkbZ4hjZ94kdBmnap4uuD8MLfxVpFojTXVpbXcVvcNwBKUOGI7gOencUAdjRXE3PjC7tdWlsG08S3j3NvaRwCUKiPJC8h3SYOVHlnkLn0Bqi3xLW1so7vUtJkgt5oZzD5c4kd5oZkhePbgYBkcBWzyBkhelAHolFYPhHX31+1unmspLSa2m8lh85jk+VWDRs6IWHzYOVHII9Ca/izxPNol7BaWmnfbZ5LG6vzunESrHbmIOM4OWPnDAx1HJA5AB01FcDcfEKSCK4Mmjssix2lzGTOTGtvcGUJJMyoTHgwuGwHAJXk5yOx0S/XVNIs76MwlbiJZAYZRKnI/hccMPQ0AflxRRRQB+lXwn/5JZ4N/wCwLZf+iErqq5X4T/8AJLPBv/YFsv8A0QldVQAUDPOSK57xvrUXh3SV1S4vobSCCQeYJcbZQf4ee/pXER+IZ/iA5s/D2twW1sW8+KeL5ZQR/B1Pv2oA9Yorm/BGtT6nZTW2phI9Wsn8m4iHX2f6Ec1vG5iF2ttuzKV34HYe9AE2ecd6Ka5AKkg5zgYpWbbjgnJxxQAtct8SJ1TwrdWwuIYLm6HlQeccKzkjAJrqa+bP2xPFEVlY6Ro9uZ11Es1yrx/dVMEEE0AeS6V4P0TUPCemLqFyYPFM3iD7FdTLNkxxkDDe4yetfaPg7w3b+FtHj0+1uLm4RAPnuH3MSBivkbwJpmieFbP4d+LZ2OoNqTXA1O3OZNiqzhZAPUFR+VfZun3MV5ZQ3FvnyZFDIT3U9DQBYooooA8l8a+AtY1TX9Yh0DxFBp1hqqRXF3aOpLCRHX94uPu52jJr0+GVLKwt1vbhd6xqGkkYfMQACc/WvIvj54k8Y+FNS8N3HhG1hu0uZ2hZGXMjuRkR9ehGSPcVzvij48aFLok2k61o18NajjzJBEm5YZhxg88DrQB9B/a7fKgzRgt0BbBP0qevl3TfDfiPXNK0jxTqN1GL5JBNZSC6DQFfveU4AG08Y5J54r27wZ8R9A8TwOkV7BBqMDGO5tJJBvjcZyPccHmgDy/x94gg0342Ta54is7ifwvo2nG3WZYjJGl0xyAR2PXmoPht8YtS1D4f+Jda12CeOC0Vlt5l53SNgKin2J/SvMfGHxD06bQfifZSTMdU1bVI1gjKjHkKTyD7Y5/CsrwF4V8UaxFpngqEvbadqU66hLeIN6RKoOD7nnpmgD2bwLrnjq6tPEHhDxXJBqPiC3tE1G2tpWUC/tpFOYS+MDkgcj9BmvD9d1LxPeaJdva6ZqMfge0vDB9nuAHFhID80KN2AJH6V7r450Hxr4T8f+HPHAuT4ma3T+zbmCysTFJ9m+YliNzZ65JHevItS8c683gzxvoOjeGZYNKku/tN1OfvQBmyxkBHO7aPTFAHtHgj4d6f4t8PWsmo6g15p4UeRtkPnWxHOwPwP0r1rSBZeHNANq94kkenREyfNlkQZPI618x6bJo9z4GtvFHgPxFD4V12EEz2dzchYrhlH3Qp7muf0u/8R+ONN8R+MLx78+JNOiVoxbLttpoE+8rIAQw57Ed6APpTwx480D4hXc8fhS9vIrmDIe4EGF47MD1HSu70uC6t7RY766F1OCcyhNgP4ZOPzr4c0L44XuheKpNQ8OaTbaTpt4qG/wBMtwGidxnMkecFWOfevpL4YfF7RvFviGfTbe4ukkkTzUivU2MjfxKG6EegoA9cqG8uEtLWW4l3bIxuO0ZNUr26/sx5by/ukSyO1ApX7h9c07VtRg0/TJ9SuLqCOwhiMjuwyMeuc0AU9N17Tdf8yDT7p0ukXfgoVdOcZwf5VqWMRhiCSStNMoAd26n/ADzXl/wq+IFx4hbVjrLomqR75LWyeMRPLbgkhk/vD3rK1r426fp1tez+G7DUNakSc+fAYiphPQnPZeP0oA9uorB8Da1deIfC2n6rf2DafPdRiQ27HJQHpzW9QBz9z4P0W61G7vbi3neS7mS4uIjdzeRNIiIis8O/y2wsaDlf4R3ovfB2iXlzJcS2sq3Ekkkryw3UsTMZFRXBKMDtYRR5T7p2A4yM10FFAGBbeENFt57SWO2mYWiKkEUl1NJDHtj8pSImYpu2fLuxnk88moF8C+H1t7eAWlx5MEQgVDezkGIHIiYF/njHZGyoycDk101FAGHc+E9EupriS5sEla4eV5Q7syuZY1ikypOMFFUYxjj1q9pGlW2kwNFaNdMrHJNxdS3DdMYDSMxA9s4q9RQBz6eDtCSzs7VbHEFpbQ2cK+dJ8kMLq8a53ZOGRTk8nHJNEng7QpFdXscq/n7h50nPnT/aJP4u8o3e3QYHFdBRQByviLwfFfyPc6XJBY38t19rluXWd2L+SsPymOaMr8kcYIztO3lSeav2XhrT7fwdZ+Gpke5023s47LEjEMyIgUElcEN8oORjB5GK26KAMWLwvpMd3FdfZ5HuY5Y5llkuJHYvHG0asSzEkhXYc5znJyeajl8IaFNbR282npJDGtwio7uQBO4eXqe7AHPbHGK3qKAMGPwxbQ3GnvBc33lWtwbopPdy3Blfy2jUFpHY7QGJ29M4PWr1/o1hqF2tzdweZMtrNZht7DEUxQyLgHHJiTnqMcEZOdCigDDl8K6TI29YbiGTyILbzLe7mhcRw+Z5a7kcHjzZO/O7nOBjS0vT7XS9PgsbCIQ2sChI0BJwPcnkn1J5J5NWqKAPyrooooA/Sr4T/wDJLPBv/YFsv/RCV1Vcr8J/+SWeDf8AsC2X/ohK6qgDyL9piG7XwPZalpiTS39jfxPFCg3LLk8q47jivkVb2Xw743xrOn3VnatN5l5pqSMvDdxX31418OReKtAm0q4up7WKUgmSAgOMehNeUa7+zd4e1qc3N9q+qSXpUK07MCWx60AePfD/AOJiW/xKudR1LUL+y0i9UxW91KQSqL0VuMEV9CeH/GVtrfimeXRfElhPYPGPNE4CvGR0284Ncvo37M3hewuoJbnUL+9ihk8xYJcBM/QV2OsfBnwfq3iNNWudOVCqBDBCTGjY7naRQB0+j397Pr93BIkdxYrErRXkZG08/d479fyqrceNrGHxO/h5oZ01PG5N6/u2XsxbsK6LTbC20yxhs7CFYbaFdqRr0A/Gnta27z+c8ETTYx5hQFsemaAOQ8I+JNYvfEWq6RrGnKv2P5lu4fuSA9AB9K+f/wBom01K6urPxjb/ALhm8y0axvQCAig8qeAc4/M19aKqr91QPoK8v+OHwvg8f+HLa3t7gWVxZSmdHwSCMHIx6+lAHytrmkW/grR/AfiTSL0zyarHJJLbu++KPa+CB7HJH4Gvq3w746u9dFrBoem+VLCiGe3bHllTjmNx6ZNeWaT+zNZ3d3arceIbm40ZIt4Re0hPzKPQd/Wvofw54a0zw7oUGk6XbiK0hTYuTlj7k0AW7e/M1z5QtbhQOrsuFH41erntN8R6S3i288KWrSjU7O2W7lVlO3YxABDdzyK6GgDifir4ak8QaJDPb3T29xpcq6hCUHJkjIcD8QpH414deeNNYki1m68P+C49O1vVE8y41G4hyfLK4Oc9epx/Wvp7U7KLUdOubKcuIbiNonKHDbWGDg1heF9V0e8u9S8O2CyPLoIhtJxMmeCgK/N/FwP0oA+adH8H3Wv/AA3W30a11rQ4bfe17cCUiG5x827aR2wOhHFV7Lxes2iSCTwhbW/iSSHyrHWtPTi5RPlLMgJJbaGJ9a+wfKj8oxbF8ojbsxxj0xWLo3hHQNFnWbS9KtraVSSrIv3Sc5x6dTQB8afGPwhodp4M8NeIvDOoR6rcXTPFqcyHa7ykA/NHklDwwINemfsi6m+n+FtREkd1eeZdBBHEm9oAAePX8K665+CNtqXiq28WWdwdF1C4cy31osfmIxPUAE4Ge/H/ANf17Q9HsNDsEs9LtYreBeSI1A3HuT6mgBbG/F80nlwTRooIWSRcZPtXkHifwV4d+HGleJ/FFxdXN7carbvbXVtckGK5LEEKFAG0/Ke/rXt1cl4i8D2fiLxVpWsarczyxaY3mW9mMeVv5yzD+I80AfBvjCzbU73+09L0CPSrB1CNZW028KVHLd9vrzWTo+q3lqZI445pbRYyksKuUwD16fT0r9FLLwf4agju/smjWKx3obzgsQxIG68f4V43qH7L/h+W01MWepXMNzcT+ZAxX5YUz/qyM8jnrQB80aXZaKmixa5CUke1k2XNi5O9gf4lOelS+HfFeo2fjmDX7K2S+myQsci52p0CkrgAgV9XaH+zd4E06W3muYLy+kjzuSeb92+fUAA/rWrqHwC+Hl7MZDonkAjASCVkUfSgDxzXfjY+qQWv/CPXj6PqcyeTqMc+JLTHT5e4brzkVP8AE7xZrkVhoPhbWNas7HSr+2E7X4XzA2OitgjAya9XX9n34eKhX+x3J7MZ2yK3tM+EfgXTrJbWHw5ZyRg7gZ8ysD7FiSPwoA8S/wCFi+EvEnw/03QfG3hjVbq+gUR262kJ8yVVHEkRGDgjtyPXNVPBFp488M+ENUt7LStQj0y8b5EuIN1xbxnoW4znFfUkej6dHcW88djarLbJ5cLiIbo19Aewq/QBxvwk1RNT8EWW24mnmtv9HmaaPY4cAEgj6MK7KmxxpGCI0VQTkhRjn1p1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAflXRRRQB+lXwn/5JZ4N/7Atl/wCiEqzqlx4mj1GRdNstPlsvl2PLIQ/TnIz61W+E/wDySzwb/wBgWy/9EJXVUAcFrutePNPtfOsfDdhqLBgDFFc7Wx3Iyf0rJHjH4ikkH4fLwM5+3rz7CvU6KAPKP+Ew+JTMdvgGEDOBuvF/PrSyeLfiaAAngK237sHN8uMfXNeqhg2cEHBwcdjS0AeSt4u+KAIz4DtB9L0Nx+dMbxh8UvN+XwFZmPGcfbBn+deu0UAeRL4t+KsitjwHYxsBxvvAcn86jfxT8XJQyw+B9LiLDAeS8ztPrjPIr1hL+0kvpLNLmJruNdzwhxuUepFWFYNnaQcHBx60AeGafrnxb07UDbW3gmwNvgtJ/pQ8vee6nPTp39a1pPE3xeMvlR+CNJU4z5hvht9v4q6TxZ8T/C/hHXTpmv6k0F20YkWMx/Lt7c1mH45eAQu860BHnaX8psKfQ0AeRaNrnxHk+PevXln4W09dcXTY4bvT5bsBDDuXbIsmcHnHfvXqD+Ifi8sakeDNEdm7C/A2/X5qdovjf4Z3HifUPFVprVsmpy2gtppJXKgxKdwAB+grrtW+IHhnStHsNVvdUiTTr7P2e4AJRyBnGR34P5UAcXJr3xjZQE8IaEuSMN9uGevcbq858Eax8UZviV43vdL0LSmvjJDDqNlJcAJG4XCMjZGflHv1r6G0jxfoOsaa1/pup289uoyxVuR7EHv7VmW9z4Y8PalqWuS3Isp9ZMck8lwdiv5Y2LjI9KAOPfWPjRt2r4Z8PBifvm8BA/DdVe8vvjXd6fPajQ9DtZZVKrcx3Y3RHPUDPpXslrcQ3dvHcWsqSwSKGSRDlWB7g1LQB43b3XxqtLOISaZ4cvZYwEb98VMmBjdnIwT1pP7T+NrsW/sHw5EDghDc52+xO7mvRfGOq6jplranR7L7ZcyTANH38sD5iPU+31qDS/HfhzUsrFqcEcyP5ckUx2NG/Ta2ehzQBwi33xsADnSfDLH+55pH67u1N1Sb43QmCOztfC90Dy8qFo9nbBDNz68V7JXIeM/iN4Y8G3tvaeINRW2nnXci7S3Ge+OlAHnel2fxx0yyjtY5PDlysbHDy5LMPTr/APXq65+OMcBlUeFpXyP3O1gff5t2OK9Z0XVLPWtMg1DTZRNaTrujcDGR+NWpJY44mld1EajJbPAFAHjMf/C9njJZvCMbE8Ao5IH/AH1j/wDVUnkfHEoT9t8KKf7vkN/8VXpuneKNC1KVorDWLC4lVtjIk6lg3oRnOfatYOpDEMpCnBwelAHjn2X44kE/2l4UB7L5DVJ9g+NrKf8AiceFEJ9LZyRXsCsGUMpBB6EUtAHja6f8buc634YGCMf6KeeeaQ6P8aug8R+HAOT/AMejf/rr2WigDmfh9Z+J7LRZo/Guo2moak05eOS1i8tVi2rhcdyGDHPuK6amq6sWCnJU4PsadQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH5V0UUUAfpV8J/+SWeDf+wLZf8AohK6quV+E/8AySzwb/2BbL/0QldVQBR1vJ02VUmmhlYYjeL7wbt2PH1qC0S8g0lnMst7cbcruARm9ugA/KtWmCQ+eY9jY27t2OPpQBVsIpPMkuJAEMwBKY5B96u0Ugzjkgn2oAWooGlYy+coXDkLg9V7H9f0qWigDKvNA0+5u5bwQCK9kUK1xHw5A7E1dhgSztDHaxA7QSFzjcfc+9WKKAPjf9pTwL4lv7u48dXsUSWLFYGtgSZIAOATxyM8V4FpM0MF6j3kBuLds74lxlv8K/SXxF4XttdhvYrq4uFjuojGUDZQHGA209SK87i+AfhKXwiNIazNteLJl76MZkfBzwTxgjt2oA+e/CvgzQ9GstO1vxlY+ZoOolpLWbJHTOY2564BxnuKp/EfwH4h0TwW+qv50XhSS732do8nmeQG+6x5ON3A4r7Pk8FaNdeE7Pw9qFrHdafbKqorKByM4PseTVnWPDdhqHhOfQJLWOWweDyRDKSVIHTJ69QKAPz3u7fS9N8F2tzYazeprU8v722iJELR465HcHjn0pPDVr4n8e6jZ6DaXF3qRVt6QSzEhVzyck10+rfD/wAbwtquh2fg7UHsRcl4StszlNpxlX7qce/WvUf2WPh54l0LxXc6trmjXOnWslsYUaYFHDcZODzzigD6W8JaND4f8M6bpVuhSO1gSPbuJwQOefrWvTY1CIqDOFAAycmnUAeH/tFeIfGOjabNFpUEdvo1yghS/hZjNHKT6DkcZGenNeGfC34WX/i3XLie7ubiwntZA10LwMPtEnUlGGBnOTyTX2R410CLxP4Xv9InYxi4TCuByjA5B/MUnhbRn07Q7K11B4rq5gQKZQhXd7kHv9aAOJv9H8VWkVtaW/iiD7LaKJoopFIu5FC/cYj7wH0r4z+J2u6j4k8eXl9qVwt7OkywIV+UFV6DB6flX6HxLa312Lg27rc2xaNWliKsvuCRyPSvjvW/h14xl+M9zrlt4eu7jTxqfmrcLblFkTd98KRgflj+dAH1B8OrvUJfBOlQ3OlPp862qBBtwmQOOByAa07XXIb/AErVFmt3FxZh47i1j+dhgHhccHI9K3WLiIlQDJt4BPeoBZx28Un2GKKOYg4YjqT69zQB4Z8K/Dfh/TNAttW8U6Lb2Oox3DpGWjkimZSfleQMQCevQV03xI1C01G0ih0rfLBY3CHVEtZwkiQ+vX5h1yRmuqsPDX2jUZ5vEVxLqc4ctEskSiFFboFwOcY7mtvTtC0vTllWysYIhL/rPlyW+pPb2oAzI9X03SfClvfRTzTaWFRY3iAdwp4wfp+lblvP9rhjuIX/ANHdNy/Lhv1p8drbxRGKOCJIj/AqAL+VTAYGB0oAihuYZpJEilR3iO11VslT6EVV0/Tmtbia4mu57iWXg7yAqjPACjpVxIYo3d0jRXflmCgFvrT6ADH60UCigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPyrooooA/Sr4T/8AJLPBv/YFsv8A0QldVX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAfqpRX5V0UAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The recording of the transmitral diastolic inflow (panel B) is obtained by placing the Doppler sample volume between the tips of the open mitral valve leaflets, as shown in panel A. The most commonly measured values are given in tabular format (panel C) and the site of the pulsed wave Doppler sample volume is shown un the upper left panel.",
"    <div class=\"footnotes\">",
"     m/s: meters per second; VTI: velocity time integral; ms: milliseconds.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5618=[""].join("\n");
var outline_f5_31_5618=null;
var title_f5_31_5619="Continuous renal replacement therapy solution: Drug information";
var content_f5_31_5619=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Continuous renal replacement therapy solution: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5929284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Normocarb HF&reg; 25;",
"     </li>",
"     <li>",
"      Normocarb HF&reg; 35;",
"     </li>",
"     <li>",
"      PrismaSol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5929287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkalinizing Agent;",
"     </li>",
"     <li>",
"      Electrolyte Supplement",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5929368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If using PrismaSol&trade;, ensure that compartment A and B are mixed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Continuous renal replacement circuit:",
"     </b>",
"     Pre- or post-filter: Volume of solution administered depends upon the patient&rsquo;s fluid balance, target fluid balance, body weight, and amount of fluid removed during hemofiltration process.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Post-filter replacement:",
"     </i>",
"     Volume infused/hour should not be greater than",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of blood flow rate (eg, blood flow rate 100 mL/minute [6000 mL/hour], post-filter replacement rate &le;2000 mL/hour)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5929367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5929369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ability to convert lactate to bicarbonate may be impaired; use solutions containing lactate cautiously.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5929374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [concentrate; preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Normocarb HF&reg; 25: Bicarbonate 25 mEq/L, chloride 116.5 mEq/L, magnesium 1.5 mEq/L, sodium 140 mEq/L (240 mL) [strength represents final solution after mixing; when diluted as directed, makes 3240 mL of infusate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Normocarb HF&reg; 35: Bicarbonate 35 mEq/L, chloride 106.5 mEq/L, magnesium 1.5 mEq/L, sodium 140 mEq/L (240 mL) [strength represents final solution after mixing; when diluted as directed, makes 3240 mL of infusate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PrismaSol B22GK 2/0: Bicarbonate 22 mEq/L, chloride  118.5 mEq/L, dextrose 100 mg/dL, lactate 3 mEq/L, magnesium 1.5 mEq/L, potassium 2 mEq/L, sodium 140 mEq/L (5000 mL) [strength represents final solution after mixing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PrismaSol BGK 2/0: Bicarbonate 32 mEq/L, chloride 108 mEq/L, dextrose 100 mg/dL, lactate 3 mEq/L, magnesium 1 mEq/L, potassium 2 mEq/L, sodium 140 mEq/L (5000 mL) [strength represents final solution after mixing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PrismaSol BGK 2/3.5: Bicarbonate 32 mEq/L, calcium 3.5 mEq/L, chloride 111.5 mEq/L, dextrose 100 mg/dL, lactate 3 mEq/L, magnesium 1 mEq/L, potassium 2 mEq/L, sodium 140 mEq/L (5000 mL) [strength represents final solution after mixing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PrismaSol BGK 4/0/1.2: Bicarbonate 32 mEq/L, chloride 110.2 mEq/L, dextrose 100 mg/dL, lactate 3 mEq/L, magnesium 1.2 mEq/L, potassium 4 mEq/L, sodium 140 mEq/L (5000 mL) [strength represents final solution after mixing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PrismaSol BGK 4/2.5: Bicarbonate 32 mEq/L, calcium 2.5 mEq/L, chloride 113 mEq/L, dextrose 100 mg/dL, lactate 3 mEq/L, magnesium 1.5 mEq/L, potassium 4 mEq/L, sodium 140 mEq/L (5000 mL) [strength represents final solution after mixing]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PrismaSol BK 0/0/1.2: Bicarbonate 32 mEq/L, chloride 106.2 mEq/L, lactate 3 mEq/L, magnesium 1.2 mEq/L, sodium 140 mEq/L (5000 mL) [strength represents final solution after mixing]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5929370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May heat to &le;40&deg;C (104&deg;F) before administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5929288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used as a replacement solution to replenish water, correct electrolytes, and adjust acid-base balance depleted by hemofiltration or hemodiafiltration (continuous renal replacement therapy [CRRT]); drug poisoning when CRRT is used to remove filterable substances",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5929344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Endocrine &amp; metabolic: Acid/base abnormalities; electrolyte (potassium, calcium, phosphorous) abnormalities; fluid imbalances; glucose abnormalities",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5929289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5929290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Continuous renal replacement therapy: Can cause hypokalemia, hypocalcemia, hypophosphatemia, and hypoglycemia. Monitor closely and correct with appropriate replacement solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes mellitus or glucose intolerance: May require insulin adjustment when using the PrismaSol&trade; solutions as some contain dextrose. Adjusting solutions or rates of administration may cause changes in dextrose delivery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticoagulants: Citrate, when used as an anticoagulant, can contribute to the base load and cause hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Normocarb HF&reg;: Dilute prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; PrismaSol&trade;: Mix compartment A and B prior to use. If not mixed, patient may experience severe reductions in electrolytes (magnesium, calcium)/glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Only for use as replacement fluid in patients receiving continuous renal replacement therapy under direct supervision of an intensivist. Use only with continuous extracorporeal blood purification equipment in CRRT.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5929372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemodynamic status, electrolyte and acid-base balance, serum glucose. Fluid balance record extremely important as this system requires hourly calculations of replacement fluids to be given.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5929363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement fluids achieve fluid and electrolyte balance by substituting for the ultrafiltrate removed during some forms of continuous renal replacement therapies. Replacement solutions may vary in composition and may include a buffer and electrolytes to manage acid-base disorders and electrolyte imbalances.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Culley CM, Bernardo JF, Gross PR, et al, &ldquo;Implementing a Standardized Safety Procedure for Continuous Renal Replacement Therapy Solutions,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(8):756-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/31/5619/abstract-text/16595818/pubmed\" id=\"16595818\" target=\"_blank\">",
"        16595818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mehta RL, &ldquo;Continuous Renal Replacement Therapy in the Critically Ill Patient,&rdquo;",
"      <i>",
"       Kidney Int",
"      </i>",
"      , 2005, 67(2):781-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/31/5619/abstract-text/15673337/pubmed\" id=\"15673337\" target=\"_blank\">",
"        15673337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8851 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5619=[""].join("\n");
var outline_f5_31_5619=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929284\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929287\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929368\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929367\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929369\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929374\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929370\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929288\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977832\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929344\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929289\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929290\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929372\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5929363\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8851\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8851|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_31_5620="Vasopressin: Patient drug information";
var content_f5_31_5620=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vasopressin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     see \"Vasopressin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"     see \"Vasopressin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9559967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pitressin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pressyn&reg;;",
"     </li>",
"     <li>",
"      Pressyn&reg; AR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691811",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat diabetes insipidus.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat bleeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703123",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vasopressin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin or a muscle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12150 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-8C22B84DCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5620=[""].join("\n");
var outline_f5_31_5620=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559967\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015209\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015208\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015213\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015214\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015216\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015211\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015212\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015217\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015218\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=related_link\">",
"      Vasopressin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=related_link\">",
"      Vasopressin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_31_5621="Pindolol: Patient drug information";
var content_f5_31_5621=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pindolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     see \"Pindolol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pindol&reg;;",
"     </li>",
"     <li>",
"      Dom-Pindolol;",
"     </li>",
"     <li>",
"      Mylan-Pindolol;",
"     </li>",
"     <li>",
"      Novo-Pindol;",
"     </li>",
"     <li>",
"      Nu-Pindol;",
"     </li>",
"     <li>",
"      PMS-Pindolol;",
"     </li>",
"     <li>",
"      Sandoz-Pindolol;",
"     </li>",
"     <li>",
"      Teva-Pindolol;",
"     </li>",
"     <li>",
"      Visken&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop performance anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bold or forceful actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by drugs that are used for mood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702744",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pindolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, Raynaud's disease, very bad lung disease, very weak heart, or slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10976 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5621=[""].join("\n");
var outline_f5_31_5621=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210141\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013021\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013023\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013022\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013027\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013028\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013030\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013025\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013026\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013031\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013032\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=related_link\">",
"      Pindolol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_31_5622="Sitagliptin: Drug information";
var content_f5_31_5622=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sitagliptin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/13/13525?source=see_link\">",
"    see \"Sitagliptin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16339640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Investigating Unpublished Reports of Pancreatic Toxicity With Incretin Mimetic Drugs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is evaluating unpublished new findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with type 2 diabetes treated with incretin mimetics. These findings are based on pancreatic tissue samples taken from patients who died from unspecified causes. The FDA has requested these samples, as well as information on the methodology used to collect them, and will communicate its final conclusions and recommendations. Healthcare providers should continue to prescribe incretin mimetics according to the drug label recommendations and patients receiving incretin mimetics are advised to continue therapy as directed and to discuss any concerns with their healthcare provider.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3415811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Januvia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9748132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Januvia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3415815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3415869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <i>",
"      Concomitant use with insulin and/or insulin secretagogues (eg, sulfonylureas):",
"     </i>",
"     Reduced dose of insulin and/or insulin secretagogues may be needed.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3415870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 to &lt;50 mL/minute (approximate S",
"     <sub>",
"      cr",
"     </sub>",
"     of  &gt;1.7 to &le;3.0 mg/dL [males] or  &gt;1.5 to &le;2.5 mg/dL [females]): 50 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (approximate S",
"     <sub>",
"      cr",
"     </sub>",
"     of  &gt;3.0 mg/dL [males] or &gt;2.5 mg/dL [females]): 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ESRD requiring hemodialysis or peritoneal dialysis: 25 mg once daily; administered without regard to timing of hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3415871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Child-Pugh score 7-9): No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh score &gt;9): Not studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3415876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Januvia&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3415813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10107832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM204269.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM204269.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3415872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3415816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise as monotherapy or in combination therapy with other antidiabetic agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3415807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Januvia&reg; may be confused with Enjuvia&trade;, Janumet&reg;, Jantoven&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SitaGLIPtin may be confused with saxagliptin, SUMAtriptan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3415846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported with monotherapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (4%), constipation (3%), nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Osteoarthritis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (5%), pharyngitis (1%), upper respiratory tract infection (viral; 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure (possibly requiring dialysis), anaphylaxis, anemia, angioedema, bundle branch block, depression, erectile dysfunction, exfoliative dermatitis, gastritis (",
"     <i>",
"      Helicobacter",
"     </i>",
"     ), GERD, hepatic steatosis, hyper-/hypotension, hypersensitivity, liver enzymes increased, migraine, orthostasis, pancreatitis (acute cases including hemorrhagic or necrotizing forms with some fatalities), peripheral neuropathy, renal function decreased, rosacea, Stevens-Johnson syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3415841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious hypersensitivity (eg, anaphylaxis, angioedema) to sitagliptan or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3415842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Rare hypersensitivity reactions, including anaphylaxis, angioedema, and/or severe dermatologic reactions such as Stevens-Johnson syndrome, have been reported in postmarketing surveillance; discontinue if signs/symptoms of hypersensitivity reactions occur. Events have generally been noted within the first 3 months of therapy, and may occur with the initial dose. Use with caution if patient has experienced angioedema with other DPP-IV inhibitor use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pancreatitis: Cases of acute pancreatitis (including hemorrhagic and necrotizing with some fatalities) have been reported with use. Monitor for signs/symptoms of pancreatitis; discontinue use immediately if pancreatitis is suspected and initiate appropriate management. Use with caution in patients with a history of pancreatitis as it is not known if this population is at greater risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetic ketoacidosis (DKA): Sitagliptin should not be used in patients with DKA due to lack of efficacy in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Clinical trials included only a limited number of patients with heart failure (HF). No specific recommendations regarding this population are provided in the approved US labeling (Canadian labeling recommends against use in this population).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established in severe hepatic dysfunction. Dosage adjustments are not required in mild or moderate hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate-to-severe renal dysfunction and end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis; dosing adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Type 1 diabetes mellitus: Sitagliptin should not be used in patients with type 1 diabetes mellitus (insulin dependent, IDDM) due to lack of efficacy in this patient population",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin: Concomitant use of insulin may increase the risk of hypoglycemia.  Monitor blood glucose closely; dosage reduction of insulin may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin secretagogues: Concomitant use of an insulin secretagogue (eg, sulfonylurea) may increase the risk of hypoglycemia.  Monitor blood glucose closely; dosage reduction of secretagogues may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3415852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3415851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: DPP-IV Inhibitors may enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: SitaGLIPtin may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3415817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3415818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies; therefore, sitagliptan is classified as pregnancy category B. There are no adequate and well controlled studies in pregnant women. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. Health professionals are encouraged to report any prenatal exposure to sitagliptin by contacting Merck&rsquo;s pregnancy registry (1-800-986-8999).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3415820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6207904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if sitagliptin is excreted in breast milk. The manufacturer recommends that caution be used if administered to breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6296744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Januvia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (90): $885.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (90): $885.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $295.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3415874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , serum glucose; renal function prior to initiation and periodically during treatment",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3415857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Januvia (AR, AT, AU, BB, BE, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IN, IT, JM, KP, MX, MY, NI, NL, NO, NZ, PE, PH, PL, PR, PT, RU, SE, SG, SR, SV, TH, TR, TT, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3415855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sitagliptin inhibits dipeptidyl peptidase IV (DPP-IV) enzyme resulting in prolonged active incretin levels. Incretin hormones (eg, glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells. Decreased glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by the DPP-IV enzyme.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3415858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: ~198 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 38%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Not extensively metabolized; minor metabolism via CYP3A4 and 2C8 to metabolites (inactive) suggested by",
"     <i>",
"      in vitro",
"     </i>",
"     studies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~87%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine 87% (79% as unchanged drug, 16% as metabolites); feces 13%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/31/5622/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/31/5622/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/31/5622/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/31/5622/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/31/5622/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9482 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-72FD83CAD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5622=[""].join("\n");
var outline_f5_31_5622=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339640\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415811\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9748132\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415815\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415869\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415870\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415871\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415876\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415813\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10107832\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415872\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415816\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415807\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415846\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415841\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415842\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415852\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415851\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415817\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415818\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415820\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6207904\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6296744\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370392\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415874\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415857\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539981\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415855\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415858\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9482\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9482|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/13/13525?source=related_link\">",
"      Sitagliptin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_31_5623="Peritoneal equilibration test";
var content_f5_31_5623=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peritoneal equilibration test",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5623/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5623/contributors\">",
"     Madhukar Misra, MD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5623/contributors\">",
"     Ramesh Khanna, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5623/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5623/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5623/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5623/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/31/5623/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peritoneal equilibration test (PET) is a semiquantitative assessment of peritoneal membrane transport function in patients on peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The solute transport rates are assessed by the rates of their equilibration between the peritoneal capillary blood and dialysate. The ratio of solute concentrations in dialysate and plasma",
"    <span class=\"nowrap\">",
"     (D/P",
"    </span>",
"    ratio) at specific times (t) during the dwell signifies the extent of solute equilibration. This ratio can be determined for any solute that is transported from the capillary blood to the dialysate. Creatinine, urea, electrolytes, phosphate, and proteins are the commonly tested solutes for clinical use.",
"   </p>",
"   <p>",
"    Since glucose is absorbed from the dialysate to blood and very quickly metabolized, a conventional",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    ratio for glucose is meaningless. Instead, the fraction of glucose absorbed from the dialysate at specific times can be determined by the ratio of dialysate glucose concentrations at specific times (t) to the initial level in the dialysis solution",
"    <span class=\"nowrap\">",
"     (Dt/D0).",
"    </span>",
"    The PET also helps measure ultrafiltration and residual volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the peritoneal equilibration test is presented here. A detailed analysis of the utility of this examination in evaluating patients with less than adequate clearances or ultrafiltration is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELEMENTS OF THE PERITONEAL EQUILIBRATION TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PET is a highly reproducible procedure consisting of a standardized four-hour dialysis exchange with a dialysis solution [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/5\">",
"     5",
"    </a>",
"    ]. The test permits the comparison of multiple results in a patient over a long period of therapy; in addition, the results between patients within a center and between populations from different geographic locations may be compared.",
"   </p>",
"   <p>",
"    The PET is standardized for the following elements [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of preceding exchange prior to the test",
"     </li>",
"     <li>",
"      Inflow volume",
"     </li>",
"     <li>",
"      Positions during inflow, drain, and dwell",
"     </li>",
"     <li>",
"      Durations of inflow and drain",
"     </li>",
"     <li>",
"      Sampling method and processing",
"     </li>",
"     <li>",
"      Laboratory assays",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is extremely important to adhere to the standard test regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In one study, variations in the performance of the preceding exchange prior to the test, such as utilizing a dry, tidal, or standard exchange, resulted in significantly different results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/6\">",
"     6",
"    </a>",
"    ]. There are data, however, to suggest that it is not mandatory to have a preceding dwell time of 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standardized four-hour PET procedure consists of the following sequential steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An overnight 8 to 12 hour pre-exchange is performed.",
"     </li>",
"     <li>",
"      While the patient is in an upright position, the overnight exchange is drained (drain time not to exceed 25 minutes).",
"     </li>",
"     <li>",
"      Two liters of dialysis solution are infused over 10 minutes with the patient in the supine position. The patient is rolled from side to side after every 400 mL infusion.",
"     </li>",
"     <li>",
"      After the completion of infusion (0 time) and at 120 minutes dwell time, 200 mL of dialysate is drained. A 10 mL sample is taken and the remaining 190 mL is infused back into the peritoneal cavity.",
"     </li>",
"     <li>",
"      During the four-hour dwell time, the patient is upright and allowed to freely ambulate.",
"     </li>",
"     <li>",
"      A serum sample is obtained at 120 minutes.",
"     </li>",
"     <li>",
"      At the end of the dwell (240 minutes), the dialysate is drained in the upright position (drain time not to exceed 20 minutes).",
"     </li>",
"     <li>",
"      The drain volume is measured and a 10 mL sample is taken from the drain.",
"     </li>",
"     <li>",
"      All the samples are sent for solute measurement (creatinine, urea, and glucose).",
"     </li>",
"     <li>",
"      The serum and dialysate creatinine concentrations are corrected for a high glucose level, which contributes to non-creatinine chromogens during the creatinine assay, however a single glucose correction factor cannot be applied to both conventional and low GDP solutions [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       Dt/D0",
"      </span>",
"      glucose, and the",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      ratios for creatinine, urea, and others, are calculated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The standardized test for clinical utility measures dialysate creatinine and glucose levels at 0, 2 and 4 hours of dwell, and serum levels of creatinine and glucose at any time during the test. The extensive unabridged test, which was originally proposed by Twardowski et al, has become a very important research tool [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/3\">",
"     3",
"    </a>",
"    ]. A simpler and less time consuming version, called the \"fast PET\" exists, but this version is less popular due to several flaws [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneal transport characteristics obtained within the first month of initiating PD may be relatively inaccurate. This was shown in a prospective study of 50 consecutive patients in whom the results of PETs obtained one and four weeks as well as one year after PD commencement were compared [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/11\">",
"     11",
"    </a>",
"    ]. Significant differences were observed between the one and four week tests in the measurement of",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    urea,",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine and",
"    <span class=\"nowrap\">",
"     D/Do",
"    </span>",
"    glucose; by comparison, there was general agreement between the four week and one year PET measurements.",
"   </p>",
"   <p>",
"    In our program, we perform a PET test approximately one to two weeks after initiation of PD therapy (which is three to four weeks after catheter insertion) to use as a baseline value. The test is repeated when clinical problems arise and when clinical suspicion of an alteration in membrane transport occurs (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PET has several clinical applications, particularly the classification of peritoneal membrane function and the assessment of inadequate dialysis (",
"    <a class=\"graphic graphic_table graphicRef77628 \" href=\"UTD.htm?9/36/9803\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Another approach to assessing peritoneal membrane status is the Peritoneal Dialysis Capacity (PDC) test, which utilizes the following three parameters:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An area parameter",
"      <span class=\"nowrap\">",
"       (A0/dX),",
"      </span>",
"      which is equivalent to the",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      for PET",
"     </li>",
"     <li>",
"      JvR, which is the fluid reabsorption rate after glucose equilibrium is achieved",
"     </li>",
"     <li>",
"      JvL, which is the large pore fluid flux",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although limited data suggests that the PDC test may help categorize the underlying cause of low ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/12\">",
"     12",
"    </a>",
"    ], further study is required to understand the possible role for this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peritoneal membrane function classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transport classifications for creatinine",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    and glucose",
"    <span class=\"nowrap\">",
"     D/D0",
"    </span>",
"    based upon averages, standard deviations, and minimal and maximum values over four hours are shown in this figure (",
"    <a class=\"graphic graphic_figure graphicRef65815 \" href=\"UTD.htm?1/63/2047\">",
"     figure 1",
"    </a>",
"    ). Drain volumes correlate positively with dialysate glucose and negatively with",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine at four-hour dwell times.",
"   </p>",
"   <p>",
"    Peritoneal dialysis patients are classified as having one of the following peritoneal membrane function characteristics based upon the results of the PET:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High transporter &mdash; defined as a creatinine",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      greater than +1 SD from the mean, or a glucose",
"      <span class=\"nowrap\">",
"       D/Do",
"      </span>",
"      of less than -1 SD from the mean",
"     </li>",
"     <li>",
"      Low transporter &mdash; defined as a creatinine",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      of less than -1 SD from the mean or a glucose",
"      <span class=\"nowrap\">",
"       D/Do",
"      </span>",
"      of greater than +1 SD from the mean",
"     </li>",
"     <li>",
"      Average transporter &mdash; defined as a creatinine",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      and a glucose",
"      <span class=\"nowrap\">",
"       D/Do",
"      </span>",
"      of between +1 SD and -1 SD around the mean",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the original series, approximately two-thirds of patients had average transport rates on the baseline PET [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/10\">",
"     10",
"    </a>",
"    ]. The remaining one-third consisted almost equally of high and low transporters. This distribution, however, may not be observed in all patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be an association between initial peritoneal transport status and certain clinical features, particularly age. This was best studied in a report of 3,188 patients from Australia and New Zealand who initiated PD between 1991 and 2002 and underwent a baseline PET within the first six months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/15\">",
"     15",
"    </a>",
"    ]. Upon multivariate analysis, a high transporter was associated with increased age (OR of 1.08 for each 10 years, 95% CI 1.03-1.13) and ethnicity (OR 1.48 for Maori and Pacific Islander racial origin, 95% CI 1.13-1.94). By comparison, this finding was not associated with gender, diabetes and other comorbid conditions, smoking, previous hemodialysis therapy or transplantation, or residual renal function. A similar association between increasing age and high transporter status at dialysis initiation was noted in a second smaller study from Spain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Almost 90 percent of properly conducted PETs show consistency in both ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/17\">",
"     17",
"    </a>",
"    ]. If there is discrepancy between the creatinine",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    and glucose",
"    <span class=\"nowrap\">",
"     D/D0",
"    </span>",
"    the test should be repeated. This discrepancy is often the result of elevated serum glucose levels. If serum glucose is elevated (&gt;235",
"    <span class=\"nowrap\">",
"     mg/dl),",
"    </span>",
"    the classification should be based on",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine only [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prediction of dialysis dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effective peritoneal dialysis dose is customarily measured by calculating the clearance of creatinine, which is the product of the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine and the drain volume:",
"   </p>",
"   <p>",
"    Ccr &nbsp;= &nbsp;",
"    <span class=\"nowrap\">",
"     (D/P)",
"    </span>",
"    &nbsp;x &nbsp;V",
"   </p>",
"   <p>",
"    Solute clearance and ultrafiltration vary with peritoneal membrane function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low transporter &mdash; The solute",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      ratio increases almost linearly during a long-dwell exchange in a low transporter. In addition, the ultrafiltrate (UF) continues to be generated late during the dwell. Clearance per exchange therefore increases almost linearly throughout the long-dwell exchange (",
"      <a class=\"graphic graphic_figure graphicRef62604 \" href=\"UTD.htm?6/26/6574\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      High transporter &mdash; In high transporters, intraperitoneal volume begins to diminish after three to four hours since UF and solute equilibration peas early. The clearance per exchange begins to diminish beyond this time.",
"     </li>",
"     <li>",
"      Average transporter &mdash; Peak clearances for average transporters are attained for approximately between eight to ten hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Selection of peritoneal dialysis regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the features of clearance and filtration vary significantly with membrane function, the optimal peritoneal dialysis regimen will differ according to transporter type (",
"    <a class=\"graphic graphic_algorithm graphicRef82415 \" href=\"UTD.htm?31/15/31998\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=see_link\">",
"     \"Choosing a modality for chronic peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low transporter &mdash; Because clearances continue to increase with time, low transporters are treated with long-dwell exchanges via continuous ambulatory peritoneal dialysis (CAPD) or continuous cyclic peritoneal dialysis (CCPD). Due to the slow rate of increase in the",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      ratio, clearance per unit time is augmented relatively little by rapid exchange techniques such as nightly intermittent PD (NIPD).",
"     </li>",
"     <li>",
"      High transporter &mdash; The clearance per exchange over long dwell is less in patients with high transport rates. During the shorter dwell, high transporters capture maximum UF and completely equilibrate small solutes. These patients are therefore best treated with techniques using short-dwell exchanges, such as NIPD or day time ambulatory PD (DAPD). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=see_link\">",
"       \"Rapid transporters on maintenance peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Average transporter &mdash; Patients with average transport rates can be effectively treated with either short- or long-dwell exchange techniques.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Long-term monitoring of membrane function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    ratio have been used by a number of researchers to monitor peritoneal membrane function over time. Since PET results and clearances are highly reproducible, a change over time of a transport rate as assessed by an alteration in the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    ratio should indicate a transport rate change. However, long-term studies on peritoneal membrane function in PD patients have reported variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis of membrane injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many patients with acute peritonitis display altered peritoneal membrane function, it is not customary to perform a PET during or after an episode of peritonitis since acute changes are usually reversible after recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, many patients with acute peritonitis require a change in their dialysis prescriptions due to the increased transport of both large and small solutes, and reduced drain volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The change in prescription usually involves increasing the glucose tonicity or shortening the dwell time to obtain improved UF. A discussion concerning the effect of peritonitis on the dialysis prescription can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=see_link\">",
"     \"Rapid transporters on maintenance peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some severe peritonitis episodes result in irreversible membrane changes due to extensive intraabdominal adhesions; these adhesions compromise solute and water transport due to reduced membrane fluid contact [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/25\">",
"     25",
"    </a>",
"    ]. In this setting, the PET will show a low",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine ratio and drain volume [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/25\">",
"     25",
"    </a>",
"    ]. The diagnosis is confirmed by CT scan with intraperitoneal contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/26\">",
"     26",
"    </a>",
"    ] or by infusion of an intraperitoneal radioisotope and peritoneal scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis of causes of inadequate ultrafiltration and solute clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is an overview of the use of PET in assessing the causes of inadequate ultrafiltration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    solute clearance. A detailed discussion of this subject is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any patient who requires three or more 4.25 percent glucose dialysis solution exchanges to maintain dry weight is considered to have inadequate ultrafiltration capacity. The diagnostic importance of the PET in determining the causes of inadequate ultrafiltration is shown in Figure 4 (",
"    <a class=\"graphic graphic_algorithm graphicRef78657 \" href=\"UTD.htm?43/34/44590\">",
"     algorithm 2",
"    </a>",
"    ). In this algorithm, it is assumed that every PD patient has had a baseline PET performed at the time of training.",
"   </p>",
"   <p>",
"    When a patient complains of fluid retention, the clinician should first ascertain that the drain volume is indeed reduced before performing another PET. Unchanged drain volume with fluid retention is seen with the loss of residual renal function, excessive fluid intake, or noncompliance with the dialysis prescription.",
"   </p>",
"   <p>",
"    If the drain volume is verifiably reduced, the clinician should repeat a PET, preferably with 4.25 percent dextrose [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/28\">",
"     28",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_algorithm graphicRef78657 \" href=\"UTD.htm?43/34/44590\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When PET results are unaltered from the baseline values, UF failure is due to either loss of dialysate outside the peritoneal cavity (excessive lymph absorption or dialysis solution leak into the abdominal wall or thoracic cavities) or failure to drain the dialysate because of catheter malfunction.",
"     </li>",
"     <li>",
"      When PET results suggest that membrane transport (solute clearance) has increased, bacterial or chemical peritonitis should be suspected. If peritonitis is absent, the constellation of inadequate UF and increased solute clearance is termed",
"      <strong>",
"       type I membrane failure",
"      </strong>",
"      ; this condition occurs in some patients in whom PD has been continuous for prolonged periods and, as reported by some studies but not others, in some patients with frequent prior peritonitis episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In type I membrane failure, the inability to generate sufficient UF is gradual and permanent. Patients report using an increasing percentage of hypertonic solutions to maintain dry body weight. Cycler dialysis with short-dwell exchanges may occasionally restore fluid balance. In some, temporary cessation of PD may transiently restore UF capacity and allow remesotheliazation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/30\">",
"     30",
"    </a>",
"    ]. In others, however, sclerosing peritonitis (see below) develops after the switch to hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=see_link\">",
"     \"Rapid transporters on maintenance peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased solute and fluid removal with repeat PET is termed",
"      <strong>",
"       type II membrane failure",
"      </strong>",
"      . This condition may be due to severe, recurrent, or smoldering peritonitis, extensive adhesions resulting from previously severe peritonitis, or an extremely rare disorder, sclerosing encapsulated peritonitis (SEP). SEP is a progressive condition, which continues to evolve even after cessation of PD. Progressive intraabdominal adhesions may eventually lead to intestinal obstruction and death [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serial PET studies in proven cases of sclerosing peritonitis suggest that SEP goes through several phases. The initial phase is similar to type I membrane failure (high-transport rates) which then progresses to type II membrane failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/32\">",
"     32",
"    </a>",
"    ]. If PD is discontinued in a timely manner, the initial phase is reversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis of early ultrafiltration failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the unabridged PET in normal patients, the sodium",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    curve typically exhibits an initial drop due to the high rate of ultrafiltration. Because of sodium sieving, the ultrafiltrate is initially low in sodium. As a result, the dialysate sodium concentration is diminished, thereby resulting in a fall in the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    sodium ratio. With the cessation of ultrafiltration later during the dwell, dialysate sodium tends to equilibrate with that of capillary blood, thereby returning the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    sodium to baseline. Absence of the initial drop of",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    sodium is therefore an indication of ultrafiltration failure, a finding typically observed in the early phase of sclerosing encapsulating peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To best assess ultrafiltration failure, some recommend that a modified PET be performed, rather than the standard PET [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/34\">",
"     34",
"    </a>",
"    ]. The modified test replaces the 2.5 percent dextrose solution with a 4.25 percent dextrose solution, resulting in a maximal osmotic drive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5623/abstract/35\">",
"     35",
"    </a>",
"    ]. With this test, failure is defined as an ultrafiltration volume of less than 400 mL after a four hour dwell with two liters of 4.25 percent dextrose (3.86 percent glucose). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15991?source=see_link\">",
"     \"Evaluation of hypervolemia in peritoneal dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Assessing the influence of systemic disease on peritoneal membrane function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous reports have indicated conflicting peritoneal membrane patterns for certain systemic diseases, such as diabetes mellitus, systemic sclerosis, systemic lupus erythematosus, and amyloidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1106732020\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The peritoneal equilibration test (PET) is a semi-quantitative assessment of peritoneal membrane transport function in patients on peritoneal dialysis. The ratio of solute concentrations in dialysate and plasma",
"      <span class=\"nowrap\">",
"       (D/P",
"      </span>",
"      ratio) at specific times (t) during the dwell signifies the extent of solute equilibration. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The PET is a highly reproducible procedure consisting of a standardized four-hour dialysis exchange with a dialysis solution. It is standardized for key elements of the procedure. The standardized test for clinical utility measures dialysate creatinine and glucose levels at 0, 2 and 4 hours of dwell, and serum levels of creatinine and glucose at any time during the test. We perform a PET approximately one to two weeks after initiation of peritoneal dialysis therapy to use as a baseline value. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Elements of the peritoneal equilibration test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The PET has a number of clinical applications. It is principally used to classify peritoneal membrane function and assess the reasons possibly underlying inadequate dialysis or ultrafiltration. To best assess ultrafiltration failure, some recommend that a modified PET be performed rather than the standard PET. It is not customary to perform a PET during or after an episode of peritonitis since acute changes are usually reversible after recovery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical applications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/1\">",
"      Pannekeet MM, Imholz AL, Struijk DG, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/2\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/3\">",
"      Twardowski, ZJ, Nolph, KD, Khanna, R, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/4\">",
"      Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 1997; 17:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/5\">",
"      Trivedi H, Khanna R, Lo WK, et al. Reproducibility of the peritoneal equilibration test in CAPD patients. ASAIO J 1994; 40:M892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/6\">",
"      Lilaj T, Vychytil A, Schneider B, et al. Influence of the preceding exchange on peritoneal equilibration test results: a prospective study. Am J Kidney Dis 1999; 34:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/7\">",
"      Lilaj T, Dittrich E, Puttinger H, et al. A preceding exchange with polyglucose versus glucose solution modifies peritoneal equilibration test results. Am J Kidney Dis 2001; 38:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/8\">",
"      Twardowski ZJ, Prowant BF, Moore HL, et al. Short peritoneal equilibration test: impact of preceding dwell time. Adv Perit Dial 2003; 19:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/9\">",
"      Perl J, Bargman JM, Kulasingam V, Yip PM. Modification of the glucose correction factor by peritoneal dialysis solution type in the peritoneal equilibration test. Perit Dial Int 2010; 30:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/10\">",
"      Twardowski, ZJ. The fast peritoneal equilibration test. Semin Dial 1990; 3:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/11\">",
"      Johnson DW, Mudge DW, Blizzard S, et al. A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement. Perit Dial Int 2004; 24:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/12\">",
"      Van Biesen, W, van der Tol, A, Veys, N, et al. The personal dialysis capacity test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast transport status in peritoneal dialysis patients. Clin J Am Soc Nephrol 2006; 2:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/13\">",
"      Khanna R. Peritoneal inflammation and high transport status. Clin J Am Soc Nephrol 2006; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/14\">",
"      Rodby RA, Firanek CA, Sarpolis AL. Re-evaluation of solute transport groups using the peritoneal equilibration test. Perit Dial Int 1999; 19:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/15\">",
"      Rumpsfeld M, McDonald SP, Purdie DM, et al. Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. Am J Kidney Dis 2004; 43:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/16\">",
"      Selgas R, Bajo MA, Cirugeda A, et al. Ultrafiltration and small solute transport at initiation of PD: questioning the paradigm of peritoneal function. Perit Dial Int 2005; 25:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/17\">",
"      Prowant BF, Moore HL, Twardowski ZJ, Khanna R. Understanding discrepancies in peritoneal equilibration test results. Perit Dial Int 2010; 30:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/18\">",
"      Krediet, RT, Boeschoten, EW, Zuyderhoudt, FM, et al. Peritoneal transport characteristics of water, low-molecular weight solutes and proteins during long-term continuous ambulatory peritoneal dialysis. Perit Dial Bull 1986; 6:61.",
"     </a>",
"    </li>",
"    <li>",
"     Hallet, MD, Kush, RD, Lysaght, MJ, et al. The stability and kinetics of peritoneal mass transfer. In: Peritoneal Dialysis, Nolph, KD (Ed), Kluwer, Dordrecht, 1989, p. 380.",
"    </li>",
"    <li>",
"     Passlick-Deetjen, J, Chlebowski, H, Koch, M, et al. Evaluation of long-term changes in peritoneal membrane function. In: Peritoneal Dialysis, La Greca, G, Ronco, C, Feriani, M, et al (Eds), Wichtig, Milano, 1991, p. 109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/21\">",
"      Raja, RM, Kramer, MS, Barber, K. Solute transport and ultrafiltration during peritonitis in CAPD patients. ASAIO J 1984; 7:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/22\">",
"      Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L. Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 1987; 17:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/23\">",
"      Rubin J, McFarland S, Hellems EW, Bower JD. Peritoneal dialysis during peritonitis. Kidney Int 1981; 19:460.",
"     </a>",
"    </li>",
"    <li>",
"     Prowant, BF, Nolph, KD. Clinical criteria for diagnosis of peritonitis. In: Peritoneal Dialysis, Atkins, RC, Thomson, NM, Farrell, PC (Eds), Churchill Livingstone, Edinburgh, 1981, p. 257.",
"    </li>",
"    <li>",
"     Twardowski, ZJ. Dialysis adequacy and new cycler techniques. In: Contemporary Issues in Nephrology, vol 22: Peritoneal Dialysis, Twardowski, ZJ, Nolph, KD, Khanna, R (Eds), Churchill Livingstone, New York, 1990, pp. 67-100.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/26\">",
"      Twardowski, ZJ, Tully, RJ, Nichols, WK. Computerized tomography CT in the diagnosis of subcutaneous leak sites during continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Bull 1984; 4:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/27\">",
"      Wankowicz, Z, Pietrzak, B, Przedlacki, J. Colloid peritoneoscintigraphy in complications of CAPD. Adv Perit Dial 1988; 4:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/28\">",
"      Pride ET, Gustafson J, Graham A, et al. Comparison of a 2.5% and a 4.25% dextrose peritoneal equilibration test. Perit Dial Int 2002; 22:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/29\">",
"      Heimb&uuml;rger O, Waniewski J, Werynski A, et al. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/30\">",
"      Miranda B, Selgas R, Celadilla O, et al. Peritoneal resting and heparinization as an effective treatment for ultrafiltration failure in patients on CAPD. Contrib Nephrol 1991; 89:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/31\">",
"      Huarte-Loza E, Selgas R, Carmona AR, et al. Peritoneal membrane failure as a determinant of the CAPD future. An epidemiological, functional and pathological study. Contrib Nephrol 1987; 57:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/32\">",
"      Verger C, Celicout B. Peritoneal permeability and encapsulating peritonitis. Lancet 1985; 1:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/33\">",
"      Dobbie JW, Krediet RT, Twardowski ZJ, Nichols WK. A 39-year-old man with loss of ultrafiltration. Perit Dial Int 1994; 14:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/34\">",
"      Mujais S, Nolph K, Gokal R, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20 Suppl 4:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5623/abstract/35\">",
"      La Milia V, Pozzoni P, Virga G, et al. Peritoneal transport assessment by peritoneal equilibration test with 3.86% glucose: a long-term prospective evaluation. Kidney Int 2006; 69:927.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1972 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-DF5911362B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5623=[""].join("\n");
var outline_f5_31_5623=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1106732020\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELEMENTS OF THE PERITONEAL EQUILIBRATION TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peritoneal membrane function classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prediction of dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Selection of peritoneal dialysis regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Long-term monitoring of membrane function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis of membrane injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis of causes of inadequate ultrafiltration and solute clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis of early ultrafiltration failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Assessing the influence of systemic disease on peritoneal membrane function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1106732020\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1972|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/15/31998\" title=\"algorithm 1\">",
"      Optimal PD regimen and PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?43/34/44590\" title=\"algorithm 2\">",
"      PET and ultrafiltration failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1972|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/63/2047\" title=\"figure 1\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/26/6574\" title=\"figure 2\">",
"      PET rapid vs slow transporters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/36/9803\" title=\"table 1\">",
"      Applications of PET",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=related_link\">",
"      Choosing a modality for chronic peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15991?source=related_link\">",
"      Evaluation of hypervolemia in peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=related_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=related_link\">",
"      Rapid transporters on maintenance peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_31_5624="Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum";
var content_f5_31_5624=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5624/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5624/contributors\">",
"     Lee-may Chen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5624/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5624/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5624/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5624/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5624/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5624/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/31/5624/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6099371\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of ovarian malignancies (95 percent) are epithelial; the remainder arise from other ovarian cell types (germ cell tumors, sex cord-stromal tumors) (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serous carcinoma, the most common histologic subtype of epithelial ovarian carcinoma, is regarded as closely related to fallopian tube and peritoneal serous carcinoma, based upon similarities in histology and clinical behavior. Some experts have proposed that these carcinomas all originate in the fallopian tubes. Based upon their common features, these carcinomas will be discussed as one clinical entity in this topic review. Distinctions between these conditions will also be addressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=see_link\">",
"     \"Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum is presented here. Related topics are discussed in detail separately, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pathogenesis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=see_link\">",
"       \"Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Histopathology (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"       \"Epithelial ovarian cancer: Pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidemiology and risk factors (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link\">",
"       \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical features and diagnosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"       \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"       \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Staging and surgical treatment (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adjuvant therapy (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link\">",
"       \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099395\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of primary ovarian malignancies (95 percent) are derived from epithelial cells; the remainder arise from other ovarian cell types (germ cell tumors, sex cord-stromal tumors) (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/2\">",
"     2",
"    </a>",
"    ]. For epithelial carcinomas, serous is the most common subtype (75 percent of epithelial carcinomas) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099403\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer is the second most common gynecologic malignancy. Primary fallopian tube cancer and peritoneal serous carcinoma have been considered rare malignancies. However, as noted above, the incidence of fallopian tube carcinoma may have been substantially underestimated, since presumptive ovarian and peritoneal carcinomas may derive from the fallopian tube.",
"   </p>",
"   <p>",
"    Worldwide, in 2008, approximately 225,000 women were diagnosed with ovarian cancer and 140,000 died from this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/5\">",
"     5",
"    </a>",
"    ]. Ovarian cancer is the second most common gynecologic malignancy in developed countries and the third most common gynecologic malignancy in developing countries (cervical cancer is the most common). In the United States (US), there are approximately 22,000 new cases and 14,000 cancer-related deaths expected from ovarian cancer in 2013, making it the second most common gynecologic malignancy, the most common cause of gynecologic cancer death, and the fifth leading cause of cancer death in women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average age at diagnosis of ovarian cancer in the US is 63 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/6\">",
"     6",
"    </a>",
"    ]. The age at diagnosis of ovarian cancer is younger among women with a hereditary ovarian cancer syndrome. The lifetime risk of developing ovarian cancer is 1.4 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092214#H6092214\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Genetic factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=see_link&amp;anchor=H2754911#H2754911\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\", section on 'Timing of surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link&amp;anchor=H8#H8\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of ovarian cancers are diagnosed at an advanced stage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/6\">",
"     6",
"    </a>",
"    ]: confined to primary site (15 percent); spread to regional lymph nodes (17 percent); distant metastases (61 percent); and unstaged (7 percent) (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fallopian tube carcinoma comprises 0.2 percent of cancers among women in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/7\">",
"     7",
"    </a>",
"    ]. The annual incidence in the US from 1998 to 2003 was 0.41 per 100,000 women. Stage at diagnosis of primary fallopian tube carcinoma is fairly evenly distributed: localized (36 percent), regional (30 percent), and distant (32 percent) (",
"    <a class=\"graphic graphic_table graphicRef60565 \" href=\"UTD.htm?14/11/14526\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The annual incidence of peritoneal cancer (also referred to as serous carcinoma of the peritoneum) in US from 1995 to 2004 was per 0.46 per 100,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/8\">",
"     8",
"    </a>",
"    ]. Peritoneal carcinoma is defined by the presence of intraabdominal disease, so all cases present at an advanced stage (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A detailed discussion of the epidemiology of epithelial ovarian cancer can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092134#H6092134\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099411\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of epithelial ovarian (EOC), fallopian tube, and peritoneal carcinoma is associated with: increasing age, infertility, endometriosis, polycystic ovarian syndrome, use of an intrauterine device, and cigarette smoking (for mucinous carcinomas) (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"     table 3",
"    </a>",
"    ). Factors that are associated with a decreased risk include: previous pregnancy, history of breastfeeding, oral contraceptives, and tubal ligation.",
"   </p>",
"   <p>",
"    Several ovarian cancer susceptibility genes have been identified, primarily",
"    <em>",
"     BRCA1",
"    </em>",
"    and",
"    <em>",
"     2",
"    </em>",
"    and the mismatch repair genes (associated with Lynch syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/9\">",
"     9",
"    </a>",
"    ]. It is estimated that",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutations and Lynch syndrome account for 10 to 15 percent of ovarian cancer cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. A personal or family history of breast cancer had been thought of as a risk factor for ovarian cancer; however,",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutations appear to account for a significant amount of this increased risk.",
"   </p>",
"   <p>",
"    A detailed discussion of the risk factors for EOC can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092142#H6092142\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099419\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial ovarian carcinoma (EOC), fallopian tube carcinoma, and peritoneal carcinoma are histologic diagnoses. This evaluation is performed following surgical removal of an ovary or fallopian tube or biopsies of the peritoneum. Less frequently (approximately 20 percent of women with advanced disease will be managed this way), the diagnosis is based upon tissue or fluid obtained via image-guided biopsy, paracentesis, or thoracentesis.",
"   </p>",
"   <p>",
"    The evaluation and diagnosis of EOC is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099427\">",
"    <span class=\"h1\">",
"     STAGING AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical staging and cytoreduction followed by chemotherapy is the management approach used for most women with epithelial ovarian carcinoma (EOC), fallopian tube carcinoma, and peritoneal carcinoma. Some women are treated with neoadjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24472?source=see_link\">",
"     \"Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1103846\">",
"    <span class=\"h2\">",
"     Staging and surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;EOC is surgically staged according to the joint 2010 International Federation of Gynecology and Obstetrics",
"    <span class=\"nowrap\">",
"     (FIGO)/TNM",
"    </span>",
"    classification system (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Total extrafascial hysterectomy and bilateral salpingo-oophorectomy with pelvic and paraaortic lymph node dissection is the standard staging procedure for EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/14\">",
"     14",
"    </a>",
"    ]. Cytology is performed of pelvic washings and the surface of the diaphragm; omentectomy is also performed. Cytoreduction, which may include bowel or partial hepatic resection, is performed when metastases are evident.",
"   </p>",
"   <p>",
"    Staging is typically performed via laparotomy or robot-assisted laparoscopy, but vaginal or conventional or robot-assisted laparoscopic approaches are used for some women.",
"   </p>",
"   <p>",
"    Staging and surgical treatment of EOC is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1105591\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with EOC should undergo adjuvant treatment with the exception of those with grade 1, stage",
"    <span class=\"nowrap\">",
"     IA/IB",
"    </span>",
"    EOC. The preferred regimen is a platinum-based combination. However, treatment options differ based on extent of disease at staging.",
"   </p>",
"   <p>",
"    For women with early-stage disease, we prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    administered every three weeks for six cycles. However, it is reasonable to individualize the number of cycles based upon patient risk factors and the tolerance of therapy. In this case, we prefer a minimum of three cycles be administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link\">",
"     \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with advanced EOC, the options depend on the surgical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with optimally cytoreduced EOC (ie, &lt;1 cm residual disease at the completion of surgery), we prefer a intravenous (IV)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      or a regimen that includes intraperitoneal (IP) carboplatin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , IV paclitaxel, and IP paclitaxel chemotherapy for a total of six cycles.",
"     </li>",
"     <li>",
"      For women with suboptimally cytoreduced EOC (ie, &ge;1 cm residual disease), we administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      for six cycles. These patients are not candidates for IP therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099435\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The one-, two-, and five-year survival rates by stage for ovarian and fallopian tube carcinoma are shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef64569 \" href=\"UTD.htm?27/5/27740\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55344 \" href=\"UTD.htm?11/2/11307\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In an analysis of almost 1900 stage III ovarian cancer patients treated with primary surgery and six cycles of",
"    <span class=\"nowrap\">",
"     platinum/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"      paclitaxel",
"     </a>",
"     ,",
"    </span>",
"    the major prognostic factors associated with improved outcome were younger age, low volume of residual disease, good performance status, and serous histology [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/15\">",
"     15",
"    </a>",
"    ]. Others have reported that patients with residual tumor burden less than 1 cm in diameter without debulking did better than those who required debulking to achieve this residual tumor burden, and among patients who achieve optimal debulking, those with less advanced disease at initial surgery did better than those with more advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The importance of debulking is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H8#H8\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Optimal cytoreduction'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Younger patients are more likely to have a favorable prognosis because they are more likely to have tumors of less aggressive histology and lower grade, and better baseline performance status [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The volume of residual disease is the only major prognostic factor that the surgeon can address. As such, resectability is, in part, influenced by the experience, judgment, and effort of the surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biologic characteristics of ovarian cancer may help predict the patient's prognosis and her response to medical and surgical therapies. Preliminary studies into these characteristics have found an association with relapse or survival with, for example, the decline in CA-125 from pre- to postoperative levels and the expression of nuclear maspin expression in ovarian cancer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition, a 2013 meta-analysis found that high expression of the progesterone receptor (PR) was associated with improvement in overall survival (hazard ratio [HR] 0.88, 95% CI 0.82-0.95) while elevated levels of human epidermal growth factor 2 (HER2) predicted worse survival (HR 1.41, 95% CI 1.05-1.89) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/22\">",
"     22",
"    </a>",
"    ]. However, expression of estrogen receptors was not significantly associated with outcomes.",
"   </p>",
"   <p>",
"    Retrospective studies have suggested that women upstaged to stage IIIC based on nodal involvement alone may have a better prognosis than IIIC patients with gross intraabdominal disease larger than 2 cm, even if optimally cytoreduced [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These results require confirmation.",
"   </p>",
"   <p>",
"    Women with",
"    <em>",
"     BRCA",
"    </em>",
"    gene mutations, particularly",
"    <em>",
"     BRCA2",
"    </em>",
"    , appear to have a somewhat better prognosis than noncarriers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092230#H6092230\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'BRCA gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099443\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following all first-line treatment for epithelial ovarian carcinoma (EOC), fallopian tube carcinoma, and peritoneal carcinoma, we agree with the guidelines for monitoring from the National Comprehensive Cancer Network (NCCN):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Office visits (including physical and pelvic exams) every three to six months up to five years posttreatment, then annually.",
"     </li>",
"     <li>",
"      CA-125 or other tumor markers (eg, HE4) every visit if initially elevated, if indicated. Of note, the Society of Gynecologic Oncologists (SGO) recommendations slightly differ on this; they prefer an individualized approach to monitoring by serum CA-125 based on discussions between women and their physicians on both the pros and cons of CA-125 measurements [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other testing (ie, chemistry profile or complete blood count, CT scan, or transvaginal ultrasound in women who underwent fertility-sparing surgery) only as clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1105882\">",
"    <span class=\"h2\">",
"     Role of CA-125 surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of serial CA-125 measurements in women achieving a clinical complete response following first-line chemotherapy for EOC was directly addressed in the Medical Research Council (MRC) 05 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In this study, 1442 women had their CA-125 levels checked every three months, but both patients and investigators were blinded to the results. Women who remained asymptomatic but whose CA-125 levels exceeded twice the upper limit of normal (n=527) were randomly assigned to immediate treatment or to continued blinding of the CA-125 results with treatment delayed until the time of a clinical or symptomatic recurrence. Women who developed symptoms or signs of a recurrence were removed from the study.",
"   </p>",
"   <p>",
"    Second-line chemotherapy was started a median of five months earlier in the immediate treatment arm. However, at a median follow-up of 57 months from randomization, this did not contribute to improved survival (HR for death with immediate versus delayed treatment 0.98, 95% CI 0.80 to 1.20) or a longer remission duration. Furthermore, immediate treatment had an adverse impact on quality of life.",
"   </p>",
"   <p>",
"    Following patients longitudinally by CA-125 may help identify patients for surgical treatment at recurrence. As an example, 74 women with recurrent EOC who underwent secondary cytoreduction were evaluated to determine what factors were associated with an optimal outcome (ie, to less than one centimeter of residual disease at any site) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/28\">",
"     28",
"    </a>",
"    ]. In this small series, a shorter time to surgery measured from the initial rise in CA-125 was associated with improved surgical outcome; the time from initial CA-125 elevation to surgery was five weeks in those optimally cytoreduced versus 16 weeks for those who were not (HR 1.03, 95% CI 1.01-1.06). However, there is no evidence that early surgical intervention based on a rising CA-125 improves patient outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099451\">",
"    <span class=\"h1\">",
"     FERTILITY PRESERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility preservation options are limited for women with epithelial ovarian carcinoma (EOC), fallopian tube carcinoma, and peritoneal carcinoma, since most cases are diagnosed at an advance stage and are associated with a poor prognosis, and hysterectomy and bilateral salpingo-oophorectomy is part of staging and surgical treatment. Fertility-preserving surgery (ie, unilateral salpingo-oophorectomy) is typically reserved for with stage IA EOC or those with borderline tumors who desire future childbearing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link&amp;anchor=H24#H24\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Preservation of fertility'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=see_link&amp;anchor=H12#H12\">",
"     \"Ovarian tumors of low malignant potential\", section on 'Fertility preserving surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099459\">",
"    <span class=\"h1\">",
"     POSTTREATMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099467\">",
"    <span class=\"h2\">",
"     Postmenopausal estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of epithelial ovarian carcinoma (EOC), fallopian tube carcinoma, and peritoneal carcinoma are diagnosed in postmenopausal women, but EOC may also occur in premenopausal women. Women treated for EOC may experience new or ongoing menopausal symptoms (eg, vasomotor symptoms, vaginal atrophy).",
"   </p>",
"   <p>",
"    Limited data suggest that postmenopausal estrogen or",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    therapy is not associated with an increased risk of recurrence or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. The only randomized trial to evaluated this question included 130 women with EOC and found that women who were treated with estrogen therapy compared with those who were not had no significant differences in median disease free survival (34 versus 27 months) or overall survival (44 versus 34 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, the absolute risk of developing EOC associated with postmenopausal hormone therapy appears to be small. The risk of ovarian cancer associated with postmenopausal hormone therapy is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H256689856#H256689856\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Ovarian cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link&amp;anchor=H6092198#H6092198\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Postmenopausal hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the available data, for women with EOC who have bothersome menopausal symptoms that do not respond to nonhormonal treatments, we suggest estrogen therapy rather than no treatment. Vaginal estrogen therapy may be used for women with symptoms of vaginal atrophy.",
"   </p>",
"   <p>",
"    Options for postmenopausal hormone therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099475\">",
"    <span class=\"h2\">",
"     Sexual health",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of EOC treatment on sexual function likely depends upon disease stage and performance status. Some data suggest that sexual function is maintained in women with early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5624/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of the onset of sexual disorders with menopause appears to depend on the specific type of sexual dysfunction. Vaginal dryness and dyspareunia are consistently increased after menopause, related primarily to the lack of estrogen on vaginal tissue. Postmenopausal women are also more likely to report low desire or arousal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of hysterectomy\", section on 'Psychosexual issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link&amp;anchor=H7#H7\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099379\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States. Fallopian tube serous carcinoma may have been substantially underestimated, since presumptive ovarian and peritoneal carcinomas may derive from the fallopian tube. (See",
"      <a class=\"local\" href=\"#H6099403\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The average age at diagnosis of ovarian cancer in the United States is 63 years old. The age at diagnosis of ovarian cancer is younger among women with a hereditary ovarian cancer syndrome. The lifetime risk of developing ovarian cancer is 1.4 percent. (See",
"      <a class=\"local\" href=\"#H6099403\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of ovarian malignancies (95 percent) are derived from epithelial cells; the remainder arise from other ovarian cell types (germ cell tumors, sex cord-stromal tumors). (See",
"      <a class=\"local\" href=\"#H6099395\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increased risk of epithelial ovarian (EOC), fallopian tube, and peritoneal carcinoma is associated with: increasing age, infertility, endometriosis, polycystic ovarian syndrome, use of an intrauterine device, and cigarette smoking (for mucinous carcinomas) (",
"      <a class=\"graphic graphic_table graphicRef59585 \" href=\"UTD.htm?11/59/12221\">",
"       table 3",
"      </a>",
"      ). Factors that are associated with a decreased risk include: previous pregnancy, history of breastfeeding, oral contraceptives, and tubal ligation. Women with ovarian cancer susceptibility genes are at the highest risk of ovarian cancer, including",
"      <em>",
"       BRCA",
"      </em>",
"      gene mutations and mismatch repair genes (associated with Lynch syndrome). (See",
"      <a class=\"local\" href=\"#H6099411\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EOC, fallopian tube carcinoma, and peritoneal carcinoma are histologic diagnoses. This evaluation is performed following surgical removal of an ovary or fallopian tube or biopsies of the peritoneum. (See",
"      <a class=\"local\" href=\"#H1103846\">",
"       'Staging and surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with EOC who have bothersome menopausal symptoms that do not respond to nonhormonal treatments, we suggest estrogen therapy rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Vaginal estrogen therapy may be used for women with symptoms of vaginal atrophy. (See",
"      <a class=\"local\" href=\"#H6099467\">",
"       'Postmenopausal estrogen therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed., Robboy SL, Mutter GL, Prat J, et al..  (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.601.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/3\">",
"      Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol 1996; 60:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/4\">",
"      Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2012; 119 Suppl 2:S118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/5\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/statfacts/html/ovary.html (Accessed on April 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/7\">",
"      Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 2007; 107:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/8\">",
"      Goodman MT, Shvetsov YB. Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact? Int J Cancer 2009; 124:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/9\">",
"      Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 2012; 124:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/10\">",
"      Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol 2003; 88:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/11\">",
"      Li AJ, Karlan BY. Genetic factors in ovarian carcinoma. Curr Oncol Rep 2001; 3:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/12\">",
"      Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/13\">",
"      Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/14\">",
"      Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/15\">",
"      Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:3621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/16\">",
"      Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/17\">",
"      Crawford SC, Vasey PA, Paul J, et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 2005; 23:8802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/18\">",
"      Berman ML. Future directions in the surgical management of ovarian cancer. Gynecol Oncol 2003; 90:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/19\">",
"      Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006; 100:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/20\">",
"      Solomon LA, Munkarah AR, Schimp VL, et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 2006; 101:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/21\">",
"      Zivanovic O, Sima CS, Iasonos A, et al. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol 2009; 115:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/22\">",
"      Zhao D, Zhang F, Zhang W, et al. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2013; 23:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/23\">",
"      Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 2006; 103:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/24\">",
"      Onda T, Yoshikawa H, Yasugi T, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer 1998; 83:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/25\">",
"      Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/26\">",
"      Rustin G, van der Burg M, Griffin C, et al. Early versus delayed treatment of relapsed ovarian cancer. Lancet 2011; 377:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/27\">",
"      Rustin GJ. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol 2011; 22 Suppl 8:viii45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/28\">",
"      Fleming ND, Cass I, Walsh CS, et al. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 2011; 121:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/29\">",
"      Fruscio R, Corso S, Ceppi L, et al. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol 2013; 24:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/30\">",
"      Eeles RA, Tan S, Wiltshaw E, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991; 302:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/31\">",
"      Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001; 8:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/32\">",
"      Mascarenhas C, Lambe M, Bellocco R, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 2006; 119:2907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/33\">",
"      Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecol Oncol 2004; 92:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/34\">",
"      Biglia N, Gadducci A, Ponzone R, et al. Hormone replacement therapy in cancer survivors. Maturitas 2004; 48:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/35\">",
"      Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999; 86:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5624/abstract/36\">",
"      Campos SM, Berlin S, Matulonis UA, et al. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol 2012; 30:387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83397 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5624=[""].join("\n");
var outline_f5_31_5624=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6099379\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099371\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099395\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099403\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099411\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099419\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099427\">",
"      STAGING AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1103846\">",
"      Staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1105591\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099435\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099443\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1105882\">",
"      Role of CA-125 surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099451\">",
"      FERTILITY PRESERVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099459\">",
"      POSTTREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6099467\">",
"      Postmenopausal estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6099475\">",
"      Sexual health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099379\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/83397\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/83397|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/83397|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/11/14526\" title=\"table 2\">",
"      Staging fallopian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/59/12221\" title=\"table 3\">",
"      Risk factors ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/5/27740\" title=\"table 4\">",
"      Ovarian cancer survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/2/11307\" title=\"table 5\">",
"      Fallop tube cancer FIGO surv",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=related_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=related_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=related_link\">",
"      Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24472?source=related_link\">",
"      Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=related_link\">",
"      Ovarian tumors of low malignant potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=related_link\">",
"      Overview of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=related_link\">",
"      Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_31_5625="Approach to the child with acute diarrhea in developing countries";
var content_f5_31_5625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with acute diarrhea in developing countries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5625/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5625/contributors\">",
"     Jason B Harris, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5625/contributors\">",
"     Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5625/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5625/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5625/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5625/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/31/5625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1159942320\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is the passage of loose or watery stools at least three times in a 24 hour period. Diarrheal illness is the second leading cause of child mortality; among children younger than 5 years, it causes 1.5 to 2 million deaths annually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In developing countries, infants experience a median of six episodes annually; children experience a median of three episodes annually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diarrheal illness may consist of acute watery diarrhea, invasive (bloody) diarrhea, or chronic diarrhea (persistent &ge;14 days). This classification facilitates the approach to management of childhood diarrhea. Issues related to the etiology, clinical assessment, treatment, and prevention of acute watery diarrhea and invasive diarrhea in children in developing countries are reviewed here. Issues related to chronic diarrhea in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"     \"Persistent diarrhea in children in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942355\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of acute diarrhea in developing countries are caused by infectious gastroenteritis. The etiologies of childhood diarrhea differ depending on whether the patient has acute watery diarrhea, invasive diarrhea, or persistent diarrhea (",
"    <a class=\"graphic graphic_table graphicRef50975 \" href=\"UTD.htm?35/51/36668\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17612372\">",
"    <span class=\"h2\">",
"     Infectious gastroenteritis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942362\">",
"    <span class=\"h3\">",
"     Acute watery diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants and young children, acute watery diarrhea is most often due to rotavirus; in older children, it is most often due to Escherichia coli (ETEC) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/4\">",
"     4",
"    </a>",
"    ]. Many etiologic agents of acute watery diarrhea cause symptoms that are clinically indistinguishable. It is usually not necessary to identify a specific microbiologic diagnosis in order to provide supportive care, and antibiotics are not usually indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=see_link\">",
"     \"Clinical presentation and diagnosis of rotavirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=see_link\">",
"     \"Pathogenic Escherichia coli\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Vibrio cholerae is an important bacterial cause of childhood diarrhea in endemic areas, and often occurs in large epidemics. The diagnosis is suggested by a short history (usually less than 24 hours) of vomiting and passage of voluminous watery diarrhea, which may have a characteristic rice-water appearance, associated with severe dehydration (",
"    <a class=\"graphic graphic_picture graphicRef52564 \" href=\"UTD.htm?41/36/42561\">",
"     picture 1",
"    </a>",
"    ). It is important to distinguish cholera from other causes of acute watery diarrhea because patients with severe cholera may have more rapid fluid losses and typically benefit from antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942369\">",
"    <span class=\"h3\">",
"     Invasive (bloody) diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive diarrhea (synonymous with dysentery) is diagnosed by visualizing frank blood in the stool accompanied by fever (",
"    <a class=\"graphic graphic_picture graphicRef64377 \" href=\"UTD.htm?16/47/17137\">",
"     picture 2",
"    </a>",
"    ). It is usually the result of exudative inflammation of the distal small bowel and colonic mucosa in response to bacterial invasion.",
"   </p>",
"   <p>",
"    Shigellosis is the most common etiology of invasive diarrhea among children in developing countries. It is a major cause of mortality and is associated with a high incidence of bacteremia, seizures, and several other life-threatening complications. The four species are S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. S. flexneri is the predominant species in children in the developing world [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/5\">",
"     5",
"    </a>",
"    ]. Children with shigellosis benefit from treatment with antibiotic therapy (",
"    <a class=\"graphic graphic_table graphicRef66147 \" href=\"UTD.htm?0/0/1\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8457?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prevention of Shigella infections in children\", section on 'Antibiotic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Systemic complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other etiologies of invasive diarrhea include Salmonella enterica, Campylobacter spp, enterohemorrhagic Escherichia coli, enteroinvasive E. coli, and the protozoan parasite Entamoeba histolytica. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942376\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic infections associated with diarrhea include influenza, measles, dengue fever, human immunodeficiency virus infection, and malaria. Serious bacterial infections associated with diarrhea include pneumonia, urinary tract infection, meningitis, and sepsis. Surgical emergencies such as intussusception or appendicitis also may present with diarrhea. These concomitant illnesses are major causes of mortality among children brought to medical attention for acute diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent episodes of acute diarrhea may be a presenting feature in children with HIV infection, although HIV disease is more commonly associated with persistent diarrhea (which constitutes an AIDS defining illness). The diagnosis of HIV infection should be considered in children presenting with diarrhea, failure-to-thrive, adenopathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatosplenomegaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35525?source=see_link\">",
"     \"Diagnostic testing for HIV infection in infants and children younger than 18 months\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942383\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of the child with diarrhea can be divided into four components to guide clinical management:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Classification of the type of diarrheal illness",
"     </li>",
"     <li>",
"      Assessment of hydration status",
"     </li>",
"     <li>",
"      Assessment of nutritional status",
"     </li>",
"     <li>",
"      Assessment of co-morbid conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942390\">",
"    <span class=\"h2\">",
"     Classification of diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of a child with diarrhea should include a history of the duration, frequency, and character of the diarrhea, as well as an assessment of the stool (",
"    <a class=\"graphic graphic_picture graphicRef52564 \" href=\"UTD.htm?41/36/42561\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64377 \" href=\"UTD.htm?16/47/17137\">",
"     picture 2",
"    </a>",
"    ). Patients can be classified as having:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute watery diarrhea &mdash; loose or watery stools at least three times in a 24 hour period.",
"     </li>",
"     <li>",
"      Invasive diarrhea &mdash; gross blood (by history or inspection) in the stool of &lt;14 days duration",
"     </li>",
"     <li>",
"      Persistent diarrhea &mdash; loose, watery, or bloody stools of &ge;14 days (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"       \"Persistent diarrhea in children in developing countries\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942397\">",
"    <span class=\"h2\">",
"     Hydration status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death due to dehydration is an important cause of mortality in developing settings. It can occur because the initial dehydration status is underestimated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    because the extent of ongoing fluid loss is underappreciated.",
"   </p>",
"   <p>",
"    The degree of dehydration should be assessed at presentation based on physical signs and symptoms. Several studies have demonstrated that using a combination of three to four physical signs reliably predict dehydration of 3 to 5 percent or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The World Health Organization (WHO) has issued recommendations for assessing dehydration based on four clinical signs that have been associated with dehydration in several studies (",
"    <a class=\"graphic graphic_table graphicRef68271 \" href=\"UTD.htm?36/63/37883\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following the initial assessment, ongoing fluid losses should be estimated based on the volume of emesis and stool. These assessments are essential for determining the volume, route, and pace of rehydration therapy needed.",
"   </p>",
"   <p>",
"    Individual clinical signs and symptoms have important limitations if used as independent predictors of the degree of dehydration. The absence of any particular dehydration sign is not sufficient proof that the patient has been adequately hydrated. For example, a sunken anterior fontanelle is a poor predictor of dehydration in infants, a patient who sheds tears may still be dehydrated, and hypotension is a late finding in dehydrated children (and may be absent even in severe dehydration) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum and urine indices of dehydration provide no additional predictive benefit beyond the clinical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/11,13\">",
"     11,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942404\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent diarrhea in childhood is associated with malnutrition, which contributes to delays or irreversible deficits in physical and cognitive development. Malnutrition is associated with more than 5 million childhood deaths annually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/1,8,14,15\">",
"     1,8,14,15",
"    </a>",
"    ]. Children presenting with diarrhea in developing countries should be assessed for malnutrition according to WHO standards, which are reviewed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=see_link\">",
"     \"Malnutrition in developing countries: Clinical assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with acute diarrhea and malnutrition are at increased risk for developing fluid overload and heart failure during rehydration. The risk of serious bacterial infection is also increased. As a result, such children require an individualized approach to rehydration, nutritional care and antibiotics. (See",
"    <a class=\"local\" href=\"#H2820306\">",
"     'Malnourished children'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942411\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of a child with acute diarrhea should include evaluation of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature &mdash; Fever is common in the setting of diarrheal illness. The presence of fever or hypothermia in a patient with watery diarrhea should also raise clinical suspicion of a comorbid illness. Fever in areas where malaria is endemic should prompt appropriate diagnostic evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"       \"Diagnosis of malaria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory tract &mdash; Tachypnea can be a sign of pneumonia in the setting of cough or difficulty breathing; the WHO uses the following parameters: infants &lt;2 months: &gt;60",
"      <span class=\"nowrap\">",
"       breaths/min;",
"      </span>",
"      infants 2 to 12 months: &gt;50",
"      <span class=\"nowrap\">",
"       breaths/min;",
"      </span>",
"      children 1 to 5 years: &gt;40",
"      <span class=\"nowrap\">",
"       breaths/min;",
"      </span>",
"      children &ge;5 years: &gt;20",
"      <span class=\"nowrap\">",
"       breaths/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/17\">",
"       17",
"      </a>",
"      ]. Children with dehydration should be reassessed for pneumonia following initial rehydration. In some cases a chest radiograph may be required for diagnosis of pneumonia, particularly in severely malnourished and dehydrated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abdomen &mdash; Abdominal pain out of proportion to typical gastroenteritis raises the possibility of a surgical emergency. Among patients with severe dysentery due to Shigella, intestinal obstruction was reported in 2.5 percent of hospitalized cases in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/21\">",
"       21",
"      </a>",
"      ]. Intussusception may present with acute bloody diarrhea and severe intermittent abdominal pain; in some cases a cylindrical abdominal mass is palpable. In young children, appendicitis may also present with diarrhea and abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=see_link\">",
"       \"Emergent evaluation of the child with acute abdominal pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central nervous system &mdash; Moderate dehydration can lead to irritability; severe dehydration can lead to lethargy and coma. Encephalopathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      seizures can occur in the setting of severe disease due to Shigella, and less commonly in systemic Salmonella infection. The differential diagnosis of seizures in a child with diarrhea includes hypoglycemia, hyponatremia, hypernatremia, encephalopathy, meningitis and febrile seizures. Meningeal signs may be absent in infants with meningitis; therefore any abnormal neurologic findings should raise suspicion for meningitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942453\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with acute diarrhea do not require laboratory testing, although in complex cases some laboratory studies may be useful. Patients with seizures or altered consciousness should have glucose and electrolyte assessment if possible. Children with suspected pneumonia, sepsis, meningitis, urinary tract infection, or HIV infection should have the relevant investigations. Imaging studies are warranted for patients with acute abdominal findings on physical examination.",
"   </p>",
"   <p>",
"    Microscopy can be used for presumptive diagnosis of two important causes of gastroenteritis. Cholera may be diagnosed using dark field microscopy to detect motile Vibrios, which appear as \"shooting stars\". In the setting of acute bloody diarrhea, direct microscopic evidence of Entamoeba trophozoites containing red blood cells is a sufficient diagnostic finding warranting treatment for amoebic dysentery (rather than shigellosis) (",
"    <a class=\"graphic graphic_picture graphicRef57615 \" href=\"UTD.htm?22/53/23390\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Microbiology laboratory evaluation, when available, is warranted for patients with invasive diarrhea who do not respond to empiric antibiotic therapy. Other judicious uses of microbiology data include surveillance to detect epidemics and evaluation of antimicrobial susceptibility patterns of selected pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942460\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of correcting fluid and electrolyte losses, administering appropriate nutrition, and managing associated comorbid conditions. In the setting of invasive diarrhea, treatment of the underlying cause of illness is also necessary. The World Health Organization (WHO) provides guidelines for the management of diarrheal illness in developing countries in \"The Treatment of Diarrhea: A Manual for Physicians and Other Senior Health Workers\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2819210\">",
"    <span class=\"h2\">",
"     Acute watery diarrhea",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942469\">",
"    <span class=\"h3\">",
"     Fluid and electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid management consists of two phases: replacement and maintenance. The goal of replacement therapy is to replenish deficits in water and electrolytes lost. The replacement phase is continued until all signs and symptoms of diarrhea are absent and the patient has urinated; ideally this is achieved during the first four hours of therapy. Maintenance therapy counters ongoing losses of water and electrolytes; this phase is continued until all symptoms resolve.",
"   </p>",
"   <p>",
"    Most children with acute diarrhea should be treated with Oral Rehydration Solution (ORS), a mixture of water, salts, and glucose, in both the replacement and maintenance phase. For children with severe dehydration, the replacement phase should begin with intravenous fluids (IVF). The compositions of common oral and intravenous rehydration solutions are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef62757 \" href=\"UTD.htm?37/17/38172\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid loss in acute watery diarrhea can be isonatremic, hyponatremic, or hypernatremic. The advantage of correcting sodium imbalances with ORS is that the correction occurs relatively gradually, reducing the risk of the neurologic complications due to rapid shifts in osmolarity that may occur with intravenous fluids.",
"   </p>",
"   <p>",
"    Stool potassium losses commonly result in hypokalemia. This most often manifests with muscle weakness, though in more severe cases may be complicated by paralytic ileus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrhythmia. Among 140 patients who died following rehydration therapy in Bangladesh, hypokalemia was a proximate cause of death in 9 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/23\">",
"     23",
"    </a>",
"    ]. Potassium losses are generally replaced using ORS, though some isotonic intravenous fluids contain higher amounts of potassium to replace these losses.",
"   </p>",
"   <p>",
"    The approach to fluid and electrolyte management depends on the degree of dehydration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No signs of dehydration &mdash; According to the WHO classification, patients with no overt signs of dehydration are &lt;5 percent dehydrated; they do not require a replacement phase and can begin maintenance therapy (",
"      <a class=\"graphic graphic_table graphicRef68271 \" href=\"UTD.htm?36/63/37883\">",
"       table 3",
"      </a>",
"      ). Such patients usually do not require hospital admission and may be sent home after a brief period of observation to verify that they are tolerating oral maintenance fluids. Ideally ORS is administered for maintenance fluids to counter ongoing fluid and electrolyte losses.",
"      <br/>",
"      <br/>",
"      If the stool output is modest, ORS may not be necessary and ongoing feeding along with supplemental fluids may be sufficient. Acceptable supplemental fluids are listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef82172 \" href=\"UTD.htm?30/54/31595\">",
"       table 5",
"      </a>",
"      ). In general, patient thirst should be sufficient to guide the volume of ORS administered; children under 2 years should receive approximately 50 to 100 mL of ORS for each episode of diarrhea or vomiting and children over 2 years should receive 100 to 200 mL of ORS for each episode. All children over the age of 6 months should also receive zinc therapy. (See",
"      <a class=\"local\" href=\"#H10253534\">",
"       'Vitamins and minerals'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Some dehydration &mdash; According to the WHO classification this category includes children with 5 to 10 percent dehydration (",
"      <a class=\"graphic graphic_table graphicRef68271 \" href=\"UTD.htm?36/63/37883\">",
"       table 3",
"      </a>",
"      ). These children require replacement therapy with ORS in a supervised setting (",
"      <a class=\"graphic graphic_table graphicRef57007 \" href=\"UTD.htm?30/52/31563\">",
"       table 6",
"      </a>",
"      ). If ongoing stool losses are profound, these losses can be added to the initial amount of fluids given over the first four hour period. Ideally stool output is measured by collecting stool using a cholera cot (",
"      <a class=\"graphic graphic_picture graphicRef70839 \" href=\"UTD.htm?26/53/27478\">",
"       picture 4",
"      </a>",
"      ). Alternatively, stool output can estimated as 10 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of body weight for each diarrheal stool.",
"      <br/>",
"      <br/>",
"      Observed fluid replacement and frequent reassessment of hydration status are essential for patients in this category. Replacement fluids should be continued under supervision until all the initial signs of dehydration are absent and the patient has urinated. This may require more fluids than initially estimated. Once dehydration has been corrected, maintenance fluids to counter ongoing losses can be managed as for patients with no signs of dehydration.",
"      <br/>",
"      <br/>",
"      Children with profound ongoing stool losses (such as seen in cholera) or vomiting may fail repeated attempts at oral rehydration or progress to severe dehydration; this occurs in approximately 3 to 5 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/24\">",
"       24",
"      </a>",
"      ]. Such patients require management as outlined for severe dehydration below.",
"     </li>",
"     <li>",
"      Severe dehydration &mdash; According to the WHO classification, this category includes children with &gt;10 percent dehydration (",
"      <a class=\"graphic graphic_table graphicRef68271 \" href=\"UTD.htm?36/63/37883\">",
"       table 3",
"      </a>",
"      ). Severe dehydration is a medical crisis and should be managed urgently with intravenous fluids in a hospital setting. However, patients with severe malnutrition should not receive intravenous fluids, as discussed below. (See",
"      <a class=\"local\" href=\"#H2820306\">",
"       'Malnourished children'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The goal of rehydration with intravenous fluids is to stabilize the circulation immediately. This requires that isotonic fluids be administered as quickly as possible, often through multiple sites of intravenous access. For developing settings the WHO recommends that a bolus of isotonic crystalloid fluid of 30",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      given over 30 minutes (or one hour in infants &lt;12 months), followed by additional isotonic fluids to correct the bulk of the remaining fluid deficit, by giving 70",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic crystalloid over 2.5 hours (or 5 hours for infants). It is critical that isotonic crystalloid fluids such as Ringers&rsquo; Lactate solution or normal saline be used [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/22\">",
"       22",
"      </a>",
"      ]. Colloids, blood products, or hypotonic fluids can be harmful and should NOT be administered since these may cause fluid shifts which exacerbate fluid loss in the cellular compartment.",
"      <br/>",
"      <br/>",
"      ORS should be initiated in addition to intravenous fluids as soon as the patient can drink, since commercial isotonic intravenous fluid solutions primarily replace water and sodium but do not replace glucose, potassium, or other electrolyte losses. If seizures are present (and hypoglycemia is suspected), a rapid bolus of intravenous glucose should be given followed by addition of 5 percent glucose to the intravenous fluid. Some locally prepared isotonic intravenous fluids (termed \"cholera saline\") contain higher amounts of potassium to replace potassium losses, but these fluids are not available in many clinical settings.",
"      <br/>",
"      <br/>",
"      In settings where intravenous fluids are not available or intravenous access cannot be established, patients can be resuscitated by administration of fluids via nasogastric tube; such patients should be monitored for abdominal distension. Intraosseous administration of fluids is also a possible alternative. If neither of these approaches is possible, fluids may be administered by mouth directly at a rate of 20",
"      <span class=\"nowrap\">",
"       mL/kg/hour",
"      </span>",
"      for up to six hours. These are suboptimal therapies due to the risk of aspiration, but are preferable to the alternative of no fluid therapy. Comatose patients receiving oral fluids should be monitored for vomiting and aspiration, in which case the rate of administration should be slowed until fluids are tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2820306\">",
"    <span class=\"h4\">",
"     Malnourished children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality of children with diarrhea and severe malnutrition may exceed 50 percent; this can be reduced to less than 10 percent using a standardized approach incorporating management of dehydration, nutrition, hypoglycemia, and treatment of common concomitant infections [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/8\">",
"     8",
"    </a>",
"    ]. In severely malnourished patients, important clinical signs of dehydration may be masked by kwashiorkor and sepsis.",
"   </p>",
"   <p>",
"    In general, the approach to rehydration in patients with severe malnutrition should be conservative because of the risk of fluid overload, while the approach to possible concomitant infection should be aggressive. Intravenous fluids should be used only in patients with overt shock, and a specialized approach to the composition and administration of ORS is required [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. The WHO recommends the use of reduced osmolality ORS in malnourished children. All patients with severe malnutrition and diarrhea should be started on empiric broad spectrum antibiotics immediately, as well as appropriate nutritional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. These areas are covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9178?source=see_link\">",
"     \"Severe malnutrition in children in developing countries: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2820314\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of nutritional management for patients without malnutrition is to encourage sufficient feeding both during and after the diarrheal illness episode to prevent development of malnutrition and chronic enteropathy.",
"   </p>",
"   <p>",
"    Infants with diarrhea should be encouraged to breastfeed as much as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/22\">",
"     22",
"    </a>",
"    ]. Infants that are not breastfed should be encouraged to continue to take undiluted formula at least every three hours, in addition to ORS. For infants with dehydration, this should start once rehydration is completed. Milk intolerance is a rare cause of diarrhea in developing countries; this diagnosis should not be applied unless milk refeeding causes a prompt increase in stool volume, weight loss, and worsening of dehydration.",
"   </p>",
"   <p>",
"    Children with diarrhea should be encouraged to take solid foods immediately after initial dehydration is corrected; delaying the initiation of a nutrient rich diet may increase the risk of malnutrition. In a review of 12 trials including 1226 children under five years of age (724 given early refeeding; 502 given late refeeding), there was no significant difference between children who received &ldquo;early&rdquo; refeeding (within 12 hours of the start of rehydration) or &ldquo;late&rdquo; refeeding (after 12 hours from the start of rehydration) with respect to the number of participants who needed unscheduled intravenous fluids, experienced episodes of vomiting, or developed persistent diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/25\">",
"     25",
"    </a>",
"    ]. The mean length of hospital stay was also similar. Therefore, early refeeding does not appear to increase the risk of these complications in the setting of acute diarrheal illness; further study is needed for evaluation of other parameters such as duration of diarrhea and effect on weight gain.",
"   </p>",
"   <p>",
"    As long as diarrhea persists, foods high in energy content and micronutrients should be offered at frequent intervals (at least six meals a day). After diarrhea resolves, at least one extra meal per day should be continued for a minimum of two weeks, or until the patient regains normal weight-for-height [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children with severe malnutrition, nutritional therapy is part of a specific and comprehensive management approach. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9178?source=see_link\">",
"     \"Severe malnutrition in children in developing countries: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10253534\">",
"    <span class=\"h3\">",
"     Vitamins and minerals",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9048276\">",
"    <span class=\"h4\">",
"     Zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that zinc supplementation reduces the severity and duration of diarrhea and reduces the incidence of subsequent episodes of diarrhea for several months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Based on these studies, the WHO recommends zinc for children under 5 years of age with diarrhea (10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for under 6 months and 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 10 days for 6 months to 5 years). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link\">",
"     \"Zinc deficiency and supplementation in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9048283\">",
"    <span class=\"h4\">",
"     Vitamin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with diarrhea in developing countries are at high risk of vitamin A deficiency and should receive high dose supplementation with vitamin A. Patients with signs of xerophthalmia, severe malnutrition, or a history of measles should receive a three dose series of repeated treatments for vitamin A deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942539\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are not indicated for most children with acute watery diarrhea; suspected cholera is an important exception in which antibiotic therapy is useful (",
"    <a class=\"graphic graphic_table graphicRef71548 \" href=\"UTD.htm?20/46/21228\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the absence of culture for diagnosis of cholera, a presumptive diagnosis can be made by darkfield microscopy, rapid dipstick, or clinical suspicion (eg, based on history of acute vomiting and voluminous watery diarrhea in the setting of a cholera outbreak). Rehydration therapy is the most critical element in the reducing the mortality; appropriate antibiotics selected based on local resistance patterns are a useful adjunctive therapy and significantly reduce the fluid requirements and duration of illness in severe cases (",
"    <a class=\"graphic graphic_table graphicRef71548 \" href=\"UTD.htm?20/46/21228\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942546\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstays of treatment for children with diarrhea in developing countries are correction of fluid and electrolyte losses, appropriate nutritional care, and treatment of associated comorbid conditions. No additional therapies have well established benefits and some are potentially harmful. Children with acute diarrhea should NOT receive antimotility agents or antiemetics. Antimotility agents (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/31/8692?source=see_link\">",
"     loperamide",
"    </a>",
"    , diphenoxylate-atropine, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/62/16357?source=see_link\">",
"     tincture of opium",
"    </a>",
"    ) prolong some bacterial infections and may cause fatal paralytic ileus in children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/29\">",
"     29",
"    </a>",
"    ]. Antiemetics (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/35/21047?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/14/5351?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"     promethazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ) have sedating effects that can interfere with rehydration and may cause extrapyramidal reactions and respiratory depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942553\">",
"    <span class=\"h2\">",
"     Invasive diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of invasive diarrhea requires correction of fluid and electrolyte losses, appropriate nutritional care, and treatment of the underlying cause of illness. The management of fluids and nutrition is as described in the preceding sections. (See",
"    <a class=\"local\" href=\"#H2819210\">",
"     'Acute watery diarrhea'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Empiric antibiotic therapy for acute bloody diarrhea should be targeted against Shigella species. Antimicrobial treatment of Shigella gastroenteritis reduces the duration of fever and diarrhea, decreases the duration of bacterial shedding, and may reduce the risk of life threatening complications of infection such as bacteremia (",
"    <a class=\"graphic graphic_table graphicRef66147 \" href=\"UTD.htm?0/0/1\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8457?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prevention of Shigella infections in children\", section on 'Antibiotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children with bloody diarrhea that does not remit within two days of starting empiric antibiotics for shigellosis, antibiotic-resistant infection or an alternative infectious etiology should be considered. Amebic dysentery due to the intestinal parasite E. histolytica may be clinically indistinguishable from shigellosis and does not respond to anti-Shigella therapy. Direct stool microscopy can be used for presumptive diagnosis as discussed above.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     Metronidazole",
"    </a>",
"    (35 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses for 7 to 10 days in children to a maximum of 750 mg PO three times daily) is a standard treatment regimen with a cure rate of approximately 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1159942453\">",
"     'Diagnostic studies'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942560\">",
"    <span class=\"h3\">",
"     Hemolytic uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigella dysenteriae serotype 1 produce Shiga toxin, which is associated with hemolytic uremic syndrome. In patients with Shigellosis treated with appropriate antibiotics, there is no increase in toxin production or risk of HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/32\">",
"     32",
"    </a>",
"    ]. This is in contrast to Shiga-toxin producing E. coli, for which retrospective and prospective observational studies have reported an increased risk of HUS with the administration of antibiotics during the bloody diarrhea phase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Hemolytic-uremic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942574\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The institution of the appropriate interventions in childhood diarrhea is aimed at reducing subsequent episodes of diarrhea, malnutrition, and delays in physical and mental development. In addition to the interventions listed above, WHO recommendations to prevent diarrhea include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exclusive breastfeeding until age six months, and continued breastfeeding with complementary foods until 2 years of age. Complementary feeding may be considered in younger infants if growth is inadequate.",
"     </li>",
"     <li>",
"      The consumption of safe food and water. If available, water brought to a rolling boil for at least 5 minutes is optimal for preparing food and drinks for young children.",
"     </li>",
"     <li>",
"      Handwashing after defecating, disposing of a child's stool, and before preparing meals.",
"     </li>",
"     <li>",
"      The use of latrines; these should be located more than 10 meters and downhill from drinking water sources.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159942581\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO Strategic Advisory Group of Experts has recommended that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/29/33237?source=see_link\">",
"     rotavirus vaccine",
"    </a>",
"    for infants be included in all national immunization programs, and strongly recommended the introduction of this vaccine in countries where diarrheal deaths account for &ge;10 percent of mortality among children aged &lt;5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5625/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=see_link\">",
"     \"Rotavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cholera vaccines are commercially available in some countries, but at this time they are not widely utilized in areas where cholera is endemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4266688\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrhea is the passage of loose or watery stools at least three times in a 24 hour period. Diarrheal illness is the second leading cause of child mortality; among children younger than 5 years it causes 1.5 to 2 million deaths annually. Diarrheal illness may consist of acute watery diarrhea, invasive (bloody) diarrhea, or chronic diarrhea (persistent &ge;14 days) (",
"      <a class=\"graphic graphic_table graphicRef50975 \" href=\"UTD.htm?35/51/36668\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1159942320\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to the child with diarrhea includes classification of the type of diarrheal illness, assessing and correcting fluid and electrolyte losses, administering appropriate nutrition and managing associated co-morbid conditions. (See",
"      <a class=\"local\" href=\"#H1159942383\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The degree of dehydration should be assessed at presentation based on physical signs and symptoms (",
"      <a class=\"graphic graphic_table graphicRef68271 \" href=\"UTD.htm?36/63/37883\">",
"       table 3",
"      </a>",
"      ). Fluid management consists of two phases: replacement and maintenance (",
"      <a class=\"graphic graphic_table graphicRef82172 \" href=\"UTD.htm?30/54/31595\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57007 \" href=\"UTD.htm?30/52/31563\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62757 \" href=\"UTD.htm?37/17/38172\">",
"       table 4",
"      </a>",
"      ). The goal of replacement therapy is to replenish deficits in water and electrolytes lost. This phase is continued until all signs and symptoms of diarrhea are absent and the patient has urinated. Maintenance therapy counters ongoing losses of water and electrolytes; this phase is continued until all symptoms resolve. (See",
"      <a class=\"local\" href=\"#H1159942397\">",
"       'Hydration status'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1159942469\">",
"       'Fluid and electrolytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the approach to rehydration in patients with severe malnutrition should be conservative because of the risk of fluid overload; intravenous fluids should be used only in patients with overt shock. All patients with severe malnutrition and diarrhea should be started on empiric broad spectrum antibiotics immediately, as well as appropriate nutritional therapy. (See",
"      <a class=\"local\" href=\"#H2820306\">",
"       'Malnourished children'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9178?source=see_link\">",
"       \"Severe malnutrition in children in developing countries: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The goal of nutrition management for patients without malnutrition is to encourage sufficient feeding both during and after the diarrheal illness episode to prevent development of malnutrition and chronic enteropathy. (See",
"      <a class=\"local\" href=\"#H2820314\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotics are not indicated for most children with acute watery diarrhea; suspected cholera is an important exception in which antibiotic therapy is warranted (",
"      <a class=\"graphic graphic_table graphicRef71548 \" href=\"UTD.htm?20/46/21228\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1159942539\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of invasive diarrhea includes the same approach to fluids, electrolytes and nutrition as in acute watery diarrhea. In addition, empiric antibiotic therapy with activity against Shigella species should be initiated. (See",
"      <a class=\"local\" href=\"#H1159942553\">",
"       'Invasive diarrhea'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8457?source=see_link\">",
"       \"Treatment and prevention of Shigella infections in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preventive measures for acute diarrhea among children in developing settings include breastfeeding, consumption of safe food and water, adherence to hygienic practices and vaccination against rotavirus infection. (See",
"      <a class=\"local\" href=\"#H1159942574\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/1\">",
"      Bryce J, Boschi-Pinto C, Shibuya K, et al. WHO estimates of the causes of death in children. Lancet 2005; 365:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/2\">",
"      Boschi-Pinto C, Velebit L, Shibuya K. Estimating child mortality due to diarrhoea in developing countries. Bull World Health Organ 2008; 86:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/3\">",
"      Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003; 81:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/4\">",
"      Huilan S, Zhen LG, Mathan MM, et al. Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. Bull World Health Organ 1991; 69:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/5\">",
"      Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999; 77:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/6\">",
"      Ryan ET, Dhar U, Khan WA, et al. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am J Trop Med Hyg 2000; 63:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/7\">",
"      Heyman SN, Ginosar Y, Shapiro M, et al. Diarrheal epidemics among Rwandan refugees in 1994. Management and outcome in a field hospital. J Clin Gastroenterol 1997; 25:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/8\">",
"      Ahmed T, Ali M, Ullah MM, et al. Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol. Lancet 1999; 353:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/9\">",
"      Gorelick MH, Shaw KN, Murphy KO. Validity and reliability of clinical signs in the diagnosis of dehydration in children. Pediatrics 1997; 99:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/10\">",
"      Duggan C, Refat M, Hashem M, et al. How valid are clinical signs of dehydration in infants? J Pediatr Gastroenterol Nutr 1996; 22:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/11\">",
"      Steiner MJ, DeWalt DA, Byerley JS. Is this child dehydrated? JAMA 2004; 291:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/12\">",
"      King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/13\">",
"      Steiner MJ, Nager AL, Wang VJ. Urine specific gravity and other urinary indices: inaccurate tests for dehydration. Pediatr Emerg Care 2007; 23:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/14\">",
"      Guerrant RL, Ori&aacute; RB, Moore SR, et al. Malnutrition as an enteric infectious disease with long-term effects on child development. Nutr Rev 2008; 66:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/15\">",
"      Petri WA Jr, Miller M, Binder HJ, et al. Enteric infections, diarrhea, and their impact on function and development. J Clin Invest 2008; 118:1277.",
"     </a>",
"    </li>",
"    <li>",
"     Management of severe malnutrition: a manual for physicians and other senior health workers, WHO, Geneva 1999 www.who.int/nutrition/publications/malnutrition/en/index.html (Accessed on January 10, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. The management of acute respiratory infections in children. In: Practical guidelines for outpatient care. World Health Organization, Geneva, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/18\">",
"      Chisti MJ, Ahmed T, Faruque AS, Abdus Salam M. Clinical and laboratory features of radiologic pneumonia in severely malnourished infants attending an urban diarrhea treatment center in Bangladesh. Pediatr Infect Dis J 2010; 29:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/19\">",
"      Chisti MJ, Tebruegge M, La Vincente S, et al. Pneumonia in severely malnourished children in developing countries - mortality risk, aetiology and validity of WHO clinical signs: a systematic review. Trop Med Int Health 2009; 14:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/20\">",
"      Chisti MJ, Huq S, Das SK, et al. Predictors of severe illness in children under age five with concomitant infection with pneumonia and diarrhea at a large hospital in Dhaka, Bangladesh. Southeast Asian J Trop Med Public Health 2008; 39:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/21\">",
"      Bennish ML, Azad AK, Yousefzadeh D. Intestinal obstruction during shigellosis: incidence, clinical features, risk factors, and outcome. Gastroenterology 1991; 101:626.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. The treatment of diarrhoea, a manual for physicians and other senior health workers. -- 4th revision. WHO/FCH/CAH/05.1. Geneva: World Health Organization, 2005. file://whqlibdoc.who.int/publications/2005/9241593180.pdf (Accessed on January 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/23\">",
"      Butler T, Islam M, Azad AK, et al. Causes of death in diarrhoeal diseases after rehydration therapy: an autopsy study of 140 patients in Bangladesh. Bull World Health Organ 1987; 65:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/24\">",
"      Hartling L, Bellemare S, Wiebe N, et al. Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children. Cochrane Database Syst Rev 2006; :CD004390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/25\">",
"      Gregorio GV, Dans LF, Silvestre MA. Early versus Delayed Refeeding for Children with Acute Diarrhoea. Cochrane Database Syst Rev 2011; :CD007296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/26\">",
"      Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev 2012; 6:CD005436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/27\">",
"      Lukacik M, Thomas RL, Aranda JV. A meta-analysis of the effects of oral zinc in the treatment of acute and persistent diarrhea. Pediatrics 2008; 121:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/28\">",
"      Bhandari N, Mazumder S, Taneja S, et al. Effectiveness of zinc supplementation plus oral rehydration salts compared with oral rehydration salts alone as a treatment for acute diarrhea in a primary care setting: a cluster randomized trial. Pediatrics 2008; 121:e1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/29\">",
"      Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Med 2007; 4:e98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/30\">",
"      Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2009; :CD006784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/31\">",
"      Bercu TE, Petri WA, Behm JW. Amebic colitis: new insights into pathogenesis and treatment. Curr Gastroenterol Rep 2007; 9:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/32\">",
"      Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006; 42:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5625/abstract/33\">",
"      Meeting of the immunization Strategic Advisory Group of Experts, April 2009--conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:220.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13956 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-9B4BA70C19-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5625=[""].join("\n");
var outline_f5_31_5625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4266688\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942320\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942355\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17612372\">",
"      Infectious gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942362\">",
"      - Acute watery diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942369\">",
"      - Invasive (bloody) diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942376\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942383\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942390\">",
"      Classification of diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942397\">",
"      Hydration status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942404\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942411\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942453\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942460\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2819210\">",
"      Acute watery diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942469\">",
"      - Fluid and electrolytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2820306\">",
"      Malnourished children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2820314\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10253534\">",
"      - Vitamins and minerals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9048276\">",
"      Zinc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9048283\">",
"      Vitamin A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942539\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942546\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942553\">",
"      Invasive diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942560\">",
"      - Hemolytic uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942574\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1159942581\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4266688\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13956|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/36/42561\" title=\"picture 1\">",
"      Acute watery diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/47/17137\" title=\"picture 2\">",
"      Invasive diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/53/23390\" title=\"picture 3\">",
"      Entamoeba histolytica trophozoite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/53/27478\" title=\"picture 4\">",
"      Cholera cots",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13956|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/51/36668\" title=\"table 1\">",
"      Childhood diarrhea etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/0/1\" title=\"table 2\">",
"      Antibiotics for suspected shigellosis in developing settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/63/37883\" title=\"table 3\">",
"      Guidelines for assessment of dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/17/38172\" title=\"table 4\">",
"      Common solutions for rehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/54/31595\" title=\"table 5\">",
"      Fluids for patients without dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/52/31563\" title=\"table 6\">",
"      Replacement fluid volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/46/21228\" title=\"table 7\">",
"      Oral antibiotics for suspected cholera",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=related_link\">",
"      Clinical presentation and diagnosis of rotavirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35525?source=related_link\">",
"      Diagnostic testing for HIV infection in infants and children younger than 18 months",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22490?source=related_link\">",
"      Emergent evaluation of the child with acute abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=related_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=related_link\">",
"      Persistent diarrhea in children in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40937?source=related_link\">",
"      Rotavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9178?source=related_link\">",
"      Severe malnutrition in children in developing countries: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/16/8457?source=related_link\">",
"      Treatment and prevention of Shigella infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_31_5626="Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients";
var content_f5_31_5626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5626/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5626/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5626/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5626/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/31/5626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/31/5626/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/31/5626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of chronic kidney disease (CKD) is, in most patients, normocytic and normochromic. It is principally due to reduced renal erythropoietin production (a presumed reflection of the reduction in functioning renal mass) and, to a lesser degree, to shortened red cell survival.",
"   </p>",
"   <p>",
"    Anemia can develop well before the onset of uremic symptoms due to end-stage renal disease (ESRD). Although anemia due to renal dysfunction generally develops when the glomerular filtration rate (GFR) declines to less than 30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    it can also be observed in those with higher GFRs.",
"   </p>",
"   <p>",
"    If left untreated, the anemia of CKD is associated with several abnormalities. These include deterioration in cardiac function, decreased cognition and mental acuity, fatigue, and other signs and symptoms. There are also associations with an increased risk of morbidity and mortality, principally due to cardiac disease and stroke.",
"   </p>",
"   <p>",
"    The primary therapeutic options for the anemia of CKD include red blood cell transfusions, erythropoietin stimulating agents (ESAs), and, to a much lesser degree, androgens.",
"   </p>",
"   <p>",
"    The use of erythropoietin in the treatment of anemia of CKD in hemodialysis patients is discussed in this topic review. The use of erythropoietin in predialysis patients with CKD and peritoneal dialysis patients, overviews of the use of iron or darbepoetin in patients with kidney disease, and target hemoglobin levels in patients with CKD, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     KIDNEY AND ERYTHROPOIETIN PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney is the primary site of erythropoietin production in the adult, with the liver making only a minor contribution [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Erythropoietin enhances the growth and differentiation of erythroid progenitors. With increasing renal dysfunction, decreased levels of erythropoietin are observed, resulting in progressive anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Animal studies suggest that a population of interstitial fibroblasts (also known as the type I interstitial cell) is the major source of renal erythropoietin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/3\">",
"     3",
"    </a>",
"    ]. Interstitial cells positive for erythropoietin mRNA can be found in the deep cortex and outer medulla in the unstimulated kidney. With increasing anemia, the number of positive cells increases in number and spreads into the superficial cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The production of erythropoietin is regulated via feedback mechanisms involving tissue oxygenation. Erythropoietin is not stored within the kidney and is released as it is formed. Transcription of the erythropoietin gene on chromosome 7 is regulated by a hypoxia-inducible factor (HIF) acting on a hypoxia responsive element that is upstream of the gene. The HIF molecules exist as heterodimers composed of alpha and beta subunits. The beta subunit is constitutively present. The abundance of the alpha subunit is regulated by a family of alpha-oxoglutarate-dependent dioxygenases termed HIF proline dehydrogenases.",
"   </p>",
"   <p>",
"    Hydroxylation of a proline residue within the HIF-alpha domain by these specific oxidases inactivates in the oxygen-sensing mechanism and eventual gene transcription of epoetin. Abundance of HIF is determined primarily by degradation rather than production. The ensuing rise in red cell production in response to elevated levels of erythropoietin will tend to return oxygen-carrying capacity toward normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The kidney is well suited to be the site of erythropoietin production because it is able to dissociate changes in blood flow alone from those in oxygenation. The kidney functions as a \"critmeter\" since it senses both oxygen tension and extracellular volume [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/4\">",
"     4",
"    </a>",
"    ]. Through erythropoietin, it regulates red blood cell mass and, through salt and water excretion, it regulates plasma volume. The kidney thus regulates the numerator and denominator of the \"hematocrit.\"",
"   </p>",
"   <p>",
"    Reducing renal blood flow, for example, will also tend to diminish both the glomerular filtration rate and total tubular sodium reabsorption. Since active transport is responsible for most of renal oxygen consumption, the relation between oxygen delivery (reduced by hypoperfusion) and oxygen utilization (reduced by decreased reabsorption) is relatively well maintained, thereby preventing an inappropriate increase in erythropoietin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/3\">",
"     3",
"    </a>",
"    ]. The normal hematocrit of 40 to 50 percent is not random, as this range maximizes delivery of oxygen to the tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the anemia of CKD, if left untreated, can result in deterioration in cardiac function, and decreased cognition and mental acuity. It can also be accompanied by debilitating symptoms, such as fatigue, weakness, lethargy, anorexia, and sleep disturbances. In addition, anemic patients commonly lack the stamina needed to perform normal daily activities or to work.",
"   </p>",
"   <p>",
"    Furthermore, anemia in patients with CKD is also associated with an increased risk of morbidity and mortality principally due to cardiac disease and stroke, and with an increased risk of hospitalization, hospital length of stay, and mortality in patients with predialysis CKD. Associations, however, do not prove causality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary therapeutic options for the anemia of CKD include red blood cell transfusions, erythropoietin stimulating agents (ESAs), and, to a much lesser degree, androgens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Red blood cell transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with CKD, red blood cell transfusions are almost universally successful in raising hemoglobin levels. Transfusions often can ameliorate the patient's symptoms and improve health-related quality of life. However, they may be associated with significant complications that include transfusion-transmitted infection, immunologic sensitization, iron overload syndromes, volume overload,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of erythropoietin-stimulating agents (ESAs), androgens (which may increase endogenous erythropoietin production, sensitivity of erythroid progenitors to the effects of erythropoietin, and red blood cell survival) were used regularly in the treatment of anemia in dialysis patients. However, the role of androgens in this setting was limited, due primarily to the side effects associated with its use. In addition to the need for intramuscular injection, side effects include acne, virilization, priapism, peliosis hepatis, liver function test abnormalities, and risk of hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=see_link&amp;anchor=H9#H9\">",
"     \"Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Erythropoietin stimulating agents (ESAs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical availability of ESAs subsequently provided an additional treatment option. There have been no prospective randomized studies that directly compared outcomes with erythropoietic agents versus red blood cell transfusions in patients with anemia and CKD. Instead, the best data in support of erythropoietic agents versus transfusions were provided by the initial phase III clinical trial showing that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    was effective and eliminated the need for continued transfusions. In this study, 333 dialysis patients with hemoglobin levels less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    received recombinant human erythropoietin to maintain the hematocrit at 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/5\">",
"     5",
"    </a>",
"    ]. Within two months of initiation of therapy, the need for transfusions (1030 within the six months prior to beginning treatment) was eliminated. In addition, there was a 40 percent reduction in ferritin levels after six months among the 68 patients with iron overload.",
"   </p>",
"   <p>",
"    Thus, the administration of these agents was particularly attractive because they substantially reduce the need for red cell transfusions, with an attendant decrease in",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    risk for transfusion-related complications (eg, transfusion-transmitted infection, transfusion reactions, immunologic sensitization, iron overload syndromes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    volume overload). They also help mobilize iron stores, which is particularly beneficial in patients with CKD and iron overload due to previous transfusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the safety of ESAs in treating severe anemia has not been evaluated in large placebo controlled trials. We agree with the 2012 KDIGO guidelines that the potential benefits of reducing blood transfusions and anemia-related symptoms should be balanced against the harm in individual patients (such as stroke, vascular access loss, and hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/6\">",
"     6",
"    </a>",
"    ]. Sections provide additional detail to the use and specific indications for erythropoietin. The use of darbepoetin, a different erythropoietic agent, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1130568215\">",
"    <span class=\"h3\">",
"     Peginesatide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     Peginesatide",
"    </a>",
"    is a synthetic peptide that activates the EPO receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/7\">",
"     7",
"    </a>",
"    ]. Peginesatide stimulates erythroid colony growth, reticulocyte count and hematocrit in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/8\">",
"     8",
"    </a>",
"    ], but, because its amino acid sequence is unrelated to erythropoietin, does not cross react with erythropoietin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     Peginesatide",
"    </a>",
"    appears to be as effective in treating anemia as other erythropoietic agents. Two randomized controlled open-label studies (EMERALD 1 and EMERALD 2) compared the efficacy of peginesatide (dosed monthly) with that of erythropoietin (dosed one to three times per month) among 1418 hemodialysis patients who were previously treated and stabilized on erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/10\">",
"     10",
"    </a>",
"    ]. Dosages were titrated to maintain hemoglobin concentrations between 10.0 and 12.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for 52 weeks or more. Peginesatide was noninferior to erythropoietin in maintaining hemoglobin concentrations (mean between-group difference -0.15",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    95% CI -0.30 to -0.01 in EMERALD 1 [n = 693], and 0.10",
"    <span class=\"nowrap\">",
"     g/dl,",
"    </span>",
"    95% CI -0.05 to 0.26 in EMERALD 2 [n = 725]). The proportion of patients who received at least one transfusion was also the same between groups.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     Peginesatide",
"    </a>",
"    was equivalent to erythropoietin in achieving a composite cardiovascular safety endpoint that included death from any cause, stroke, myocardial infarction, congestive heart failure, unstable angina or arrhythmia in hemodialysis patients (35.7 versus 38.6 percent, respectively, hazard ratio [HR] 0.95, 95% CI 0.77-1.17).",
"   </p>",
"   <p>",
"    However, in two phase 3 studies (PEARL-1 and PEARL-2) that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    to darbepoetin among non-dialysis CKD patients, there was an increase in cardiovascular events associated with peginesatide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/11\">",
"     11",
"    </a>",
"    ]. It is not clear why there was an increase in the risk of cardiovascular endpoints among non-dialysis CKD patients but not dialysis patients. Data in non-dialysis patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link&amp;anchor=H16#H16\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the basis of these trials, the US Food and Drug Administration approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    for intravenous or subcutaneous administration to treat anemia in adult dialysis patients only but not in patients with CKD who are not on dialysis or in patients with cancer-related anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/12\">",
"     12",
"    </a>",
"    ]. However, subsequent to FDA approval, peginesatide was withdrawn from the market due to serious hypersensitivity reactions reported in approximately 0.2 percent of patients following the first dose of intravenous administration with death occurring in 0.02 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    among CKD patients who are not on dialysis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link&amp;anchor=H16#H16\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     USE FOR ANEMIA IN PATIENTS ON CHRONIC HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of chronic renal failure is, in most patients, normocytic and normochromic, and is due to reduced renal erythropoietin production (a presumed reflection of the reduction in functioning renal mass) and, to a lesser degree, to shortened red cell survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/1\">",
"     1",
"    </a>",
"    ]. Other forms of anemia can occur, including blood loss from the gastrointestinal tract or via the technique of hemodialysis, as well as folate and B12 deficiency.",
"   </p>",
"   <p>",
"    In addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (EPO),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    is another ESA that can be used for the treatment of anemia of chronic renal failure. Darbepoetin is a molecule with 165-amino acids that differs from recombinant human EPO in that it contains five N-linked oligosaccharide chains, whereas EPO has only three. The additional N-glycosylation sites result from five amino acid substitutions in the EPO peptide backbone. The additional carbohydrate chains result in a half-life that is longer than that for EPO. A detailed discussion of darbepoetin is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several general principles govern the administration of recombinant human ESAs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The response to EPO is dose-dependent, but varies greatly among patients.",
"     </li>",
"     <li>",
"      The response is dependent on the route of administration (intravenous versus subcutaneous) and the frequency of administration. With subcutaneous administration, frequency is not as important as with the intravenous route. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15412?source=see_link\">",
"       \"Erythropoietin: Subcutaneous administration\"",
"      </a>",
"      .) Response is less dependent on route of administration for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      than for epoetin.",
"     </li>",
"     <li>",
"      The response may be limited by low iron stores, bone marrow fibrosis, infection, inflammation, inadequate dialysis, and other conditions (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Hyporesponsiveness to ESAs'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stroke, mortality, and hypertension may complicate therapy. This is primarily limited to patients undergoing dialysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=see_link\">",
"       \"Hypertension following erythropoietin in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Efficacy and benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of retrospective and prospective studies have noted the ability of ESAs to raise the hemoglobin level in hemodialysis patients. A discussion of the many studies that have examined this issue and evidence reporting the relative efficacy and a discussion of the safety of ESAs versus red blood cell transfusions and androgens can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Overview of treatment options'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of ESAs has essentially eliminated severe anemia as a major cause of morbidity in dialysis patients. In the United States, for example, over 90 percent of chronically dialyzed patients currently receive ESAs and over 80 percent have hemoglobin levels greater than 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have directly compared the relative efficacy and safety of EPO versus darbepoetin. EPO and darbepoetin are similarly effective in achieving and maintaining target hemoglobin levels. The principal difference is that EPO is a relative short-acting agent, while darbepoetin is a relatively long-acting agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Partial correction of severe anemia in dialysis patients can have profound effects on the cardiovascular and hemodynamic abnormalities that accompany end-stage renal disease (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many dialysis patients and patients with CKD not yet on dialysis have left ventricular hypertrophy (LVH); anemia has been identified as a risk factor for development of LVH and heart failure in dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/17\">",
"       17",
"      </a>",
"      ]. ESA therapy and partial correction of severe anemia has been associated with some improvement in LVH, although complete correction of anemia to normal hemoglobin levels with ESA does not lead to significant regression of established LVH or LV dilation beyond that seen with partial correction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=see_link\">",
"       \"Anemia and left ventricular hypertrophy in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with anemia also have a high cardiac output in association with a fall in systemic vascular resistance. These changes return toward normal with partial correction of anemia with ESAs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/18\">",
"       18",
"      </a>",
"      ]. However, these beneficial effects may be negated by worsening blood pressure control. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=see_link\">",
"       \"Hypertension following erythropoietin in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise-mediated cardiac ischemia is also ameliorated with partial correction of severe anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26984?source=see_link\">",
"       \"Treatment of coronary heart disease in end-stage renal disease (dialysis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Through uncertain mechanisms, ESA-improved anemia has been associated with some non-hematologic symptomatic benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relief of a variety of uremic signs and symptoms, such as sexual dysfunction in men, and impaired carbohydrate and cortisol metabolism.",
"     </li>",
"     <li>",
"      Improved quality of life parameters, particularly vitality and sleep [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased cognitive function and cerebral blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to evaluation of efficacy, a number of studies have assessed the optimal target hemoglobin level among patients with CKD treated with erythropoietin-stimulating agents. This subject and a review of the many studies that have examined this issue are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of ESA treatment is generally suggested for use in most hemodialysis patients who have a hemoglobin level of less than 10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    taking into consideration specific patient characteristics such as functional and cognitive status, life-expectancy, and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/6\">",
"     6",
"    </a>",
"    ]. Dialysis patients who have a history of stroke or malignancy, or an active malignancy, are important exceptions to this: we agree with the 2012 KDIGO guidelines that recommend using ESAs with great caution if at all, in CKD patients who have a history of stroke or malignancy, or an active malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of ESAs among dialysis patients is supported by many retrospective population-based studies in a very large number of hemodialysis patients and some prospective controlled studies that have explored outcomes associated with various hemoglobin or Hct levels. Although there is some variability in results among studies, the most consistent observation has been that better outcomes in terms of quality of life without an increase in adverse reactions are associated with hemoglobin values between 10 and 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    compared to values below this level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among such patients, we also recommend an evaluation to help exclude causes of anemia other than erythropoietin deficiency that may also be contributing to the anemia. Any other factors (ie, iron deficiency [see next section], folate or B12 deficiency, and others) should also be treated prior to the administration of EPO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Iron issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESAs should NOT be started until iron status has been evaluated. Among patients with evidence of iron deficiency, iron supplements should be given first and iron deficiency corrected prior to initiating ESAs. A detailed discussion related to assessment of iron stores and initial and maintenance dosing issues for iron therapy can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .) In addition, other causes of anemia should be excluded and hypertension should be corrected before EPO therapy is begun.",
"   </p>",
"   <p>",
"    To ensure effective erythropoiesis with",
"    <strong>",
"     ongoing",
"    </strong>",
"    ESA administration, adequate iron stores must be continually maintained in both chronic kidney disease (CKD) and dialysis patients. As a result, we recommend that iron therapy be administered for maintenance therapy among most patients receiving ESAs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hemoglobin versus hematocrit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reliance upon the hematocrit alone is not the optimal method for assessing the response to ESAs. Laboratory variability in the measurement of hematocrit is greater than for hemoglobin. In addition, since red blood cells swell if blood samples are allowed to sit for prolonged periods prior to analysis, the practice of mailing specimens to central laboratories, as is commonplace in chronic dialysis facilities, may result in additional errors. By comparison, hemoglobin concentrations are less variable.",
"   </p>",
"   <p>",
"    Thus, to circumvent these problems, we and international advisory groups recommend the use of hemoglobin, rather than hematocrit, for evaluating and treating anemia in patients with kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Hematocrit values of 30, 33, and 36 percent correspond to hemoglobin concentrations of approximately 10, 11, and 12",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hemoglobin level",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of ESA treatment should be transfusion avoidance and minimization or avoidance of symptoms due to anemia. The suggested hemoglobin target for dialysis patients is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link&amp;anchor=H2#H2\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\", section on 'Target levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In previous",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    anemia guidelines, the subcutaneous administration of EPO for the treatment of anemia in hemodialysis patients was recommended because of the relatively greater efficacy associated with subcutaneous versus intravenous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/23\">",
"     23",
"    </a>",
"    ]. A large number of studies have shown that the subcutaneous dose of EPO required to achieve a target hemoglobin is approximately 30 percent less than that required with intravenous administration. This was best shown in one of the largest prospective studies in which 208 hemodialysis patients were randomly assigned to either subcutaneous or intravenous EPO [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/24\">",
"     24",
"    </a>",
"    ]. At 26 weeks, the average subcutaneous EPO to achieve target hemoglobin levels was significantly lower than the intravenous dose (95 versus 140",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per week). Despite increased efficacy, subcutaneous administration is associated with significantly greater discomfort.",
"   </p>",
"   <p>",
"    By comparison, the 2006 guidelines do not make a specific recommendation in favor of subcutaneous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/25\">",
"     25",
"    </a>",
"    ]. Instead, the guidelines indicate that the intravenous route, now recommended in the package insert, is more convenient for hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/25\">",
"     25",
"    </a>",
"    ]. The 2012 KDIGO guidelines suggest either intravenous or subcutaneous administration for patients on hemodialysis, hemofiltration, or hemodiafiltration, and subcutaneous administration for nondialysis CKD patients or patients on peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, over 90 percent of hemodialysis patients receive ESAs intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/26\">",
"     26",
"    </a>",
"    ]. In the past, subcutaneous administration of EPO was more common in many other countries. However, as described in detail elsewhere, the association of acquired pure red cell aplasia with various erythropoietic stimulating products led to recommendations and regulations for labeling in some countries in which subcutaneous administration of one particular brand (Eprex) is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients with chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/22\">",
"     22",
"    </a>",
"    ]. Consequently, intravenous administration of ESAs is now more common in most countries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .) Pure red cell aplasia related to EPO administration is exceedingly rare and need not be considered a contra-indication to subcutaneous administration in the US.",
"   </p>",
"   <p>",
"    Among hemodialysis patients, we suggest administering ESAs either intravenously or subcutaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of EPO should vary based upon the baseline hemoglobin level, overall clinical setting, mode of administration, and the target hemoglobin level. A large number of studies have found that there is wide interpatient variability, as the dose of EPO required to reach hemoglobin levels above 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    among hemodialysis patients ranges from less than 50 to more than 300",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    three times per week [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/24,27-29\">",
"     24,27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, at a starting dose of 100",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    given intravenously three times per week, 90 percent of patients will attain a hemoglobin level of 11 to 12",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    compared to 70 percent who will reach this level with 50",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    given intravenously three times per week. The logic of starting with the higher dose and then titrating down is that a month of therapy may be wasted on the nonresponders if the lower dose is used initially. In addition, titrating up from a smaller initial dose allows the hematocrit to rise more smoothly and more economically than with the titrate down approach.",
"   </p>",
"   <p>",
"    However, given concerns about cardiovascular risks of high hemoglobin levels in dialysis and other CKD patients, we favor starting with intravenous doses of about 50",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    three times per week and slowly titrating upwards as clinically indicated.",
"   </p>",
"   <p>",
"    In addition, numerous studies have found that intravenous therapy may also require, on average, approximately 30 percent more EPO than with the subcutaneous route. Thus, if subcutaneous doses are given, an initial dose for adults is 80 to 120",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per week (typically 6000",
"    <span class=\"nowrap\">",
"     U/week)",
"    </span>",
"    given in one to three doses.",
"   </p>",
"   <p>",
"    The FDA-recommended starting dose is 50 to 100",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    three times per week for both intravenous and subcutaneous administration. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO anemia guidelines do not indicate a specifically recommended starting dose but state that the dose should be individualized [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/6,25\">",
"     6,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients respond to the administration of ESA with a marked increase in hemoglobin values. Among those with increases in hemoglobin of greater than 2.5 to 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    per month, the ESA dose should be held or reduced by at least 50 percent. Some clinicians recommend holding ESA for a period of time before resuming treatment at the reduced dosing level if the hemoglobin exceeds the target value, while others recommend that ESA doses not be held but instead be reduced in dose. Support for this approach was provided by a retrospective study which found that, compared to reducing the dose, discontinuing ESA when patients exceeded target hemoglobin levels resulted in significantly fewer hemoglobin levels higher than target, a higher number of hemoglobin levels within the target range, and less erythropoietin used per dialysis session [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/30\">",
"     30",
"    </a>",
"    ]. The 2012 KDIGO guidelines suggest decreasing the ESA dose in preference to withholding when a downward adjustment of hemoglobin concentration is required [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For hemodialysis patients in whom ESA administration has been initiated or the dose has recently changed, the hemoglobin should be measured once per week to adequately assess the response; by comparison, the hemoglobin of patients with stable hemoglobin levels and ESA dose can be assessed every two to four weeks, although in many dialysis facilities weekly hemoglobin levels are commonly obtained. The 2012 KDIGO guidelines suggest that hemoglobin be measured at least monthly during the initiation and maintenance of ESAs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed in detail elsewhere, there is limited evidence suggesting that an increased mortality may be due to high ESA doses. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of ESA treatment, aside from hypertension and its related problems, are headache (which occurs in 15 percent of cases) and an influenza-like syndrome (affecting 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/5,31\">",
"     5,31",
"    </a>",
"    ]. The influenza-like syndrome is of unknown etiology, but is responsive to anti-inflammatory drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=see_link\">",
"     \"Hypertension following erythropoietin in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Adverse cardiovascular effects with high hemoglobin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse cardiovascular effects have been associated with targeting hemoglobin levels that are higher than 11.5 to 13",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pure red cell aplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients administered rHuEPO subcutaneously, the development of pure red cell aplasia has been described in association with the presence of neutralizing anti-erythropoietin antibodies. This is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hyporesponsiveness to ESAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are relatively resistant to ESAs and require large doses. This may be an important clinical observation since a poor response to ESAs therapy may be associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/33\">",
"     33",
"    </a>",
"    ]. Higher doses of ESAs have also been associated with an increased mortality, an effect that persists after adjustment for the usually lower hematocrit in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large ESAs requirement is defined as either the requirement of excessive doses during initiation of therapy, or inability to achieve or maintain target hemoglobin levels despite the large dose in the iron-replete patient. Different guidelines have suggested different definitions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      450",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per week intravenous EPO or 300",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per week subcutaneous EPO, per",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      300",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      per week of EPO (approximately 20,000",
"      <span class=\"nowrap\">",
"       U/week)",
"      </span>",
"      and 1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      (approximately 100",
"      <span class=\"nowrap\">",
"       mcg/week),",
"      </span>",
"      per the revised European Guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      KDIGO defines initial hyporesponsiveness as having no increase in hemoglobin concentration after the first month of appropriate weight-based dosing, and acquired hyporesponsiveness as requiring two increases in ESA doses up to 50 percent beyond the dose at which the patient had originally been stable [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is no universally accepted definition, we use the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    definition of hyporesponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/23\">",
"     23",
"    </a>",
"    ]. Another approach is to define unresponsive patients as those who receive doses greater than 90 percent of patients in a given facility.",
"   </p>",
"   <p>",
"    The most common cause of resistance to ESAs is absolute iron deficiency which may be due to external blood losses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exhaustion of iron stores due to an increase in erythropoiesis caused by ESA treatment. Patients with functional iron deficiency may also respond to supplemental iron administration with an increase in hemoglobin level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction in ESA dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional causes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone disease due to secondary hyperparathyroidism; this should be suspected when ESA resistance occurs in iron replete patients in the setting of severe hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=see_link\">",
"       \"Bone biopsy and the diagnosis of renal osteodystrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Occult malignancy and unsuspected hematologic disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"       \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple",
"      <span class=\"nowrap\">",
"       myeloma/myelofibrosis/myelodysplastic",
"      </span>",
"      syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic inflammation (with inhibition possibly due to enhanced cytokine production) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/38-42\">",
"       38-42",
"      </a>",
"      ]. The presence of a failed kidney transplant or an occult infection of an old nonfunctioning arteriovenous graft may underlie such inflammation in some patients, with removal or resection frequently resolving resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/40,41,43\">",
"       40,41,43",
"      </a>",
"      ]. This is also consistent with the observation that an increased number of vascular access related infections and dialysis catheter insertions is associated with higher ESA requirements [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"       \"Inflammation in renal insufficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41111?source=see_link\">",
"       \"Withdrawal of immunosuppression after renal transplant failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although now rare, the accumulation of aluminum in bone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"       \"Aluminum toxicity in end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemoglobinopathies, as patients with sickle cell disease or trait may have an inadequate response to the administration of ESA [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of angiotensin converting enzyme inhibitors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiotensin II receptor antagonists. Some reports, but not all, suggest that these agents may result in relative ESA resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. A discussion concerning the possible mechanisms of resistance in this setting can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=see_link\">",
"       \"Erythrocytosis following renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Development of pure red cell aplasia associated with the presence of neutralizing anti-erythropoietin antibodies in patients treated with particular brands of ESA by the subcutaneous route [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/48\">",
"       48",
"      </a>",
"      ] or of neutralizing antibodies to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"       peginesatide",
"      </a>",
"      in patient receiving this ESA [",
"      <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"       \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Presence of HIV infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=see_link\">",
"       \"Human immunodeficiency virus and dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lowering EPO requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to lower the dose of ESA in dialysis patients using non-iron pharmacologic adjuvants are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=see_link\">",
"     \"Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Adequacy of dialysis and different dialysis modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis adequacy may affect responsiveness to ESA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. This relationship was suggested in a study of 20 stable patients on maintenance hemodialysis who were being treated with EPO and who were modestly underdialyzed (mean urea reduction ratio [URR] 60.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/49\">",
"     49",
"    </a>",
"    ]. These patients received an increased intensity of dialysis and showed a rise in hematocrit from 28.4 to 32.3 percent despite a constant dose of EPO; the hematocrit did not change in a control group of 20 patients maintained at the same level of dialysis. Since the study group was dialyzed with a polysulfone dialyzer and the control group was dialyzed with a modified cellulose acetate dialyzer, it is also possible that the change in hematocrit was related to differences in the dialyzer membrane rather than a change in URR. However, other studies have not found a difference in achieved hemoglobin level or EPO responsiveness in comparisons of high flux and low flux hemodialysis membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A change in dialysis prescription is not likely to significantly enhance the response to ESAs in patients who are already being adequately dialyzed (ie,",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of at least 1.3) but may have a more important effect in patients who are not receiving adequate dialysis therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/49,54,55\">",
"     49,54,55",
"    </a>",
"    ]. Use of ultrapure dialysate has been associated in some studies with reduced EPO requirements, presumably related to reduced inflammatory responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/31/5626/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of short-daily and long-nocturnal hemodialysis on anemia and ESA requirements has been reported; this is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The kidney is the primary site of erythropoietin production in the adult, with the liver making only a minor contribution. Erythropoietin enhances the growth and differentiation of the erythroid progenitors. With increasing renal dysfunction, decreased levels of erythropoietin are observed, resulting in progressive anemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Kidney and erythropoietin physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anemia of chronic kidney disease (CKD), if severe and left untreated, can result in deterioration in cardiac function, decreased cognition and mental acuity, and a host of debilitating symptoms. There are also associations with an increased risk of morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Red blood cell transfusions, androgens, and erythropoietic stimulating agents are the primary options available for the management of anemia associated with CKD. Erythropoietin-stimulating agents (ESAs) are highly effective in treating the anemia of CKD. They have also reduced the need for red cell transfusions, helped mobilize iron stores, ameliorated anemia-induced symptoms, provided cardiovascular improvement, and perhaps decreased mortality. In the United States, the two principal agents are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      (EPO) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Hemodialysis patients who are being considered for treatment with ESAs should meet the following criteria (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An initial hemoglobin level of 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or less should be present.",
"     </li>",
"     <li>",
"      Iron status has been evaluated and iron deficiency corrected. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Iron issues'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"       \"Use of iron preparations in hemodialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other treatable causes of anemia (eg, hemolysis, nutritional deficiency [eg, B12, folate]) should be excluded or treated if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"       \"Approach to the adult patient with anemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient should not have a history of stroke or malignancy, or an active malignancy without careful consideration of the potential risks and benefits of ESA use in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among hemodialysis patients who meet these criteria, we administer ESAs rather than red blood cell transfusions or androgens. Either EPO or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      can be used, with the choice determined by patient and staff convenience, compliance, availability and cost. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Iron issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EPO may be administered intravenously or subcutaneously. We favor starting with intravenous doses of about 50",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      three times weekly and slowly titrating upwards as clinically indicated. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Route of administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"       Peginesatide",
"      </a>",
"      is a newer agent that had been approved for use in dialysis patients, but was withdrawn from the market due to serious hypersensitivity reactions. It is no longer available for use. (See",
"      <a class=\"local\" href=\"#H1130568215\">",
"       'Peginesatide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hemodialysis patients treated with ESAs, maintenance supplemental iron should be given to maintain a target transferrin saturation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"       \"Use of iron preparations in hemodialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ESAs are associated with a number of significant side effects, including adverse cardiovascular events with higher hemoglobin levels, pure red cell aplasia, and hypertension. A variety of factors may cause patients to be relatively hyporesponsive to ESAs. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Side effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Hyporesponsiveness to ESAs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/1\">",
"      Eschbach JW. Erythropoietin 1991--an overview. Am J Kidney Dis 1991; 18:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/2\">",
"      Ratcliffe PJ, Ebert BL, Ferguson DJ, et al. Regulation of the erythropoietin gene. Nephrol Dial Transplant 1995; 10 Suppl 2:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/3\">",
"      Maxwell PH, Osmond MK, Pugh CW, et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993; 44:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/4\">",
"      Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 2001; 38:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/5\">",
"      Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/6\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/7\">",
"      Macdougall IC. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. Curr Opin Investig Drugs 2008; 9:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/8\">",
"      Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006; 34:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/9\">",
"      Woodburn KW, Fan Q, Winslow S, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/10\">",
"      Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013; 368:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/11\">",
"      Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013; 368:320.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM297628.pdf.",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/14\">",
"      Muirhead N, Bargman J, Burgess E, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/15\">",
"      Ifudu O, Uribarri J, Rajwani I, et al. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis 2000; 36:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/16\">",
"      Centers for Medicare and Medicaid Services, Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/17\">",
"      Harnett JD, Kent GM, Foley RN, Parfrey PS. Cardiac function and hematocrit level. Am J Kidney Dis 1995; 25:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/18\">",
"      Zehnder C, Zuber M, Sulzer M, et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992; 61:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/19\">",
"      Levin NW, Lazarus JM, Nissenson AR. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis 1993; 22:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/20\">",
"      Benz RL, Pressman MR, Hovick ET, Peterson DD. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study). Am J Kidney Dis 1999; 34:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/21\">",
"      Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999; 33:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/22\">",
"      Locatelli F, Aljama P, B&aacute;r&aacute;ny P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/23\">",
"      NKF-DOQI Clinical Practice Guidelines for Anemia of Chronic Renal Failure. IV. Administration of epoetin. Am J Kidney Dis 2001; 37(Suppl 1):S207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/24\">",
"      Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/25\">",
"      NKF-DOQI Clinical Practice Guidelines for Anemia of Chronic Renal Failure. Am J Kidney Dis 2006; 47(Suppl 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/26\">",
"      Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/27\">",
"      Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/28\">",
"      Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/29\">",
"      Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/30\">",
"      Weiner DE, Miskulin DC, Seefeld K, et al. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 2007; 18:3184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/31\">",
"      Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1991; 1:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/32\">",
"      Buur T, Lundberg M. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients. Clin Nephrol 1990; 34:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/33\">",
"      Bradbury BD, Danese MD, Gleeson M, Critchlow CW. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol 2009; 4:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/34\">",
"      Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/35\">",
"      Kausz AT, Solid C, Pereira BJ, et al. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis 2005; 45:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/36\">",
"      Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/37\">",
"      Schiffl H, Lang SM. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients. Nephrol Dial Transplant 2006; 21:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/38\">",
"      Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/39\">",
"      Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/40\">",
"      L&oacute;pez-G&oacute;mez JM, P&eacute;rez-Flores I, Jofr&eacute; R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/41\">",
"      Nassar GM, Fishbane S, Ayus JC. Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int Suppl 2002; :49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/42\">",
"      Roberts TL, Obrador GT, St Peter WL, et al. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 2004; 66:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/43\">",
"      Solid CA, Foley RN, Gill JS, et al. Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants. Kidney Int 2007; 71:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/44\">",
"      Tomson CR, Edmunds ME, Chambers K, et al. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 1992; 7:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/45\">",
"      Albitar S, Genin R, Fen-Chong M, et al. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/46\">",
"      Schwarzbeck A, Wittenmeier KW, H&auml;llfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes. Lancet 1998; 352:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/47\">",
"      Ert&uuml;rk S, Nergizolu G, Ate K, et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/48\">",
"      Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP, et al. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int 2005; 68:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/49\">",
"      Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/50\">",
"      Movilli E, Cancarini GC, Zani R, et al. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 2001; 16:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/51\">",
"      Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000; 15:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/52\">",
"      Opatrn&yacute; K Jr, Reischig T, Vienken J, et al. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artif Organs 2002; 26:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/53\">",
"      Richardson D, Lindley EJ, Bartlett C, Will EJ. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response. Am J Kidney Dis 2003; 42:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/54\">",
"      Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: what is the evidence base? Nephrol Dial Transplant 2003; 18 Suppl 8:viii29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/55\">",
"      Movilli E, Cancarini GC, Vizzardi V, et al. Epoetin requirement does not depend on dialysis dose when Kt/N &gt; 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores. J Nephrol 2003; 16:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/56\">",
"      Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/57\">",
"      Schiffl H, Lang SM, Bergner A. Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999; 83:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/31/5626/abstract/58\">",
"      Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15:1207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1935 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-6ABA7822FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5626=[""].join("\n");
var outline_f5_31_5626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      KIDNEY AND ERYTHROPOIETIN PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Red blood cell transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Erythropoietin stimulating agents (ESAs)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1130568215\">",
"      - Peginesatide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      USE FOR ANEMIA IN PATIENTS ON CHRONIC HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Efficacy and benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Iron issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hemoglobin versus hematocrit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hemoglobin level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Route of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Adverse cardiovascular effects with high hemoglobin levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hyporesponsiveness to ESAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lowering EPO requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Adequacy of dialysis and different dialysis modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6486?source=related_link\">",
"      Anemia and left ventricular hypertrophy in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=related_link\">",
"      Bone biopsy and the diagnosis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=related_link\">",
"      Erythrocytosis following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15412?source=related_link\">",
"      Erythropoietin: Subcutaneous administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34344?source=related_link\">",
"      Human immunodeficiency virus and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=related_link\">",
"      Hypertension following erythropoietin in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=related_link\">",
"      Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=related_link\">",
"      Pure red cell aplasia due to anti-erythropoietin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26984?source=related_link\">",
"      Treatment of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/9/41111?source=related_link\">",
"      Withdrawal of immunosuppression after renal transplant failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_31_5627="Causes of longitudinal melanonychia";
var content_f5_31_5627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of longitudinal melanonychia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Racial background (dark skin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nevi of the nail matrix",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Addison's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory diseases involving the nail",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onychomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laugier-Huntziker syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5627=[""].join("\n");
var outline_f5_31_5627=null;
var title_f5_31_5628="Hypothermia physiology";
var content_f5_31_5628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic changes by stage of hypothermia*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Core temperature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physiologic changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Mild",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         32-35&deg;C",
"        </p>",
"        (90-95&deg;F)",
"       </td>",
"       <td>",
"        Shivering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasoconstriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild tachycardia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Moderate",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         28-32&deg;C",
"        </p>",
"        (82-90&deg;F)",
"       </td>",
"       <td>",
"        Loss of compensatory shivering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreasing metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreasing cerebral blood flow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extravasation of fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypovolemia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        Severe",
"       </td>",
"       <td rowspan=\"8\">",
"        <p>",
"         &lt;28&deg;C",
"        </p>",
"        (82&deg;F)",
"       </td>",
"       <td>",
"        Muscle rigidity without shivering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of thermoregulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasodilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased HR, SV, CO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased cardiac conduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased cardiac irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slowed nerve conduction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspended cerebral activity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HR: heart rate; SV: stroke volume; CO: cardiac output.",
"     <br/>",
"     * Changes are typical of the stage shown, but may vary in temperature of onset.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5628=[""].join("\n");
var outline_f5_31_5628=null;
var title_f5_31_5629="Nocardia treatment regimens";
var content_f5_31_5629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Empiric antibiotic regimens for the treatment of nocardiosis in adults*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Non-severe infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Isolated cutaneous infection",
"       </td>",
"       <td>",
"        TMP-SMX 2.5 to 5 mg/kg orally of the trimethoprim component twice daily (first-line regimen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minocycline 100 mg orally twice daily (alternative regimen)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Non-severe mycetoma",
"       </td>",
"       <td>",
"        TMP-SMX 5 mg/kg of the trimethoprim component orally twice daily",
"        <strong>",
"         +/-",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dapsone 100 mg orally once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Severe infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Severe mycetoma",
"       </td>",
"       <td>",
"        Imipenem 500 mg IV every 6 hours",
"        <strong>",
"         +/-",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin 7.5 mg/kg IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Severe pulmonary or disseminated disease (without CNS involvement)",
"       </td>",
"       <td>",
"        TMP-SMX 15 mg/kg IV of the trimethoprim component per day in two to four divided doses",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin 7.5 mg/kg IV every 12 hours (first-line regimen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem 500 mg IV every 6 hours",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin 7.5 mg/kg IV every 12 hours (alternative regimen)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Involvement of &ge;2 sites in immunocompromised hosts (without CNS involvement)",
"       </td>",
"       <td>",
"        TMP-SMX 15 mg/kg IV of the trimethoprim component per day in two to four divided doses",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin 7.5 mg/kg IV every 12 hours (first-line regimen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem 500 mg IV every 6 hours",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin 7.5 mg/kg IV every 12 hours (alternative regimen)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Isolated CNS disease",
"       </td>",
"       <td>",
"        TMP-SMX 15 mg/kg IV of the trimethoprim component per day in two to four divided doses",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem 500 mg IV every 6 hours",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        CNS disease with multiorgan involvement (ie, at least one other site)",
"       </td>",
"       <td>",
"        TMP-SMX 15 mg/kg IV of the trimethoprim component per day in two to four divided doses",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem 500 mg IV every 6 hours",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin 7.5 mg/kg IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Life-threatening disease",
"       </td>",
"       <td>",
"        TMP-SMX 15 mg/kg IV of the trimethoprim component per day in two to four divided doses",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem 500 mg IV every 6 hours",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin 7.5 mg/kg IV every 12 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; TMP-SMX: trimethoprim-sulfamethoxazole.",
"     <br>",
"      * Antibiotic dosing must be adjusted in patients with impaired renal function.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5629=[""].join("\n");
var outline_f5_31_5629=null;
var title_f5_31_5630="Diabetic neuropathy score";
var content_f5_31_5630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Michigan Diabetic Neuropathy Score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Sensory impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Right",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibration at big toe",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-g filament",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Pin prick on dorsum of great toe",
"       </td>",
"       <td>",
"        Painful",
"       </td>",
"       <td>",
"        Not Painful",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Left",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vibration at big toe",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10-g filament",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Pin prick on dorsum of great toe",
"       </td>",
"       <td>",
"        Painful",
"       </td>",
"       <td>",
"        Not Painful",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Muscle strength testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Right",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Mild to moderate",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Finger spread",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Great toe extension",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ankle dorsiflexion",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Left",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Finger spread",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Great toe extension",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ankle dorsiflexion",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Right",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Present with reinforcement",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biceps brachii",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triceps brachii",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quadriceps femoris",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Achilles",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Left",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Present with reinforcement",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biceps brachii",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triceps brachii",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quadriceps femoris",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Achilles",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\" rowspan=\"1\">",
"        <strong>",
"         Total: 46 points",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The findings from the clinical examination are scored on this form. Nerve conduction studies&nbsp;(of sural, peroneal motor, median sensory and motor, and ulnar sensory nerves) are graded separately. A composite score is then derived,&nbsp;based upon the number of points scored on the clinical examination (this form) and the number of abnormal nerve conductions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17:1281.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5630=[""].join("\n");
var outline_f5_31_5630=null;
var title_f5_31_5631="Bladder diary PI";
var content_f5_31_5631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Bladder diary",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 760px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <ul>",
"     <li>",
"      <strong>",
"       This diary will help us determine why you have trouble holding your urine, or why you go to the bathroom very often.",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Keep this record for at least 2 days.",
"      </strong>",
"     </li>",
"     <li>",
"      Please write down 4 things every time you pass or leak urine:",
"     </li>",
"     <ul>",
"      <li>",
"       The time (for instance, \"10:30 AM\")",
"      </li>",
"      <li>",
"       The amount of urine that you pass",
"      </li>",
"      <li>",
"       Whether you leaked any urine (were \"wet\") or not (were \"dry\")",
"      </li>",
"      <li>",
"       Whether anything special may have caused you to go (for instance, \"just had coffee,\" \"coughed,\" \"was running to the bathroom,\" \"just took my water pill\")",
"      </li>",
"     </ul>",
"     <li>",
"      To measure the amount of urine you pass, we will give you a special receptacle (called a \"hat\"). Place the hat in the toilet to catch the urine every time you go. Look at how high the urine fills the hat, and write down the amount from the numbers on the inside of the hat. Remember to empty the hat after each time you go.",
"     </li>",
"     <li>",
"      If you leak urine and cannot measure the amount that came out, write down your best guess.",
"     </li>",
"     <li>",
"      Start the record in the morning the first time you go to the bathroom after you get up.",
"      <strong>",
"       Please indicate on the form the time you went to bed and the time you got up.",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Thank you for your help!",
"      </strong>",
"     </li>",
"    </ul>",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_31_5631=[""].join("\n");
var outline_f5_31_5631=null;
